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Abbreviations
3TC lamivudine 
ABC abacavir 
ATV atazanavir 
COBI cobicistat
 (used as booster=/c) 
d4T stavudine 
ddI didanosine 
DLV delavirdine 
DRV darunavir 
DTG  dolutegravir
EFV efavirenz 
EVG elvitegravir 
ENF enfuvirtide 
ETV etravirine 
FI fusion inhibitor 
FPV fosamprenavir 
FTC emtricitabine 
IDV indinavir 
INSTI integrase strand  
transfer inhibitor 
Antiretroviral Drug (ARV) Abbreviations Other Abbreviations 
LPV lopinavir 
MVC maraviroc 
NRTI nucleos(t)ide 
reverse transcriptase 
inhibitors 
NNRTI non-nucleoside 
reverse transcriptase 
inhibitors 
NVP nevirapine 
PI protease inhibitors 
PI/r protease inhibitors 
pharmacologically 
boosted with ritonavir 
RAL raltegravir 
RPV rilpivirine 
RTV ritonavir (used as 
booster=/r)
SQV saquinavir 
TDF tenofovir 
TPV tipranavir 
ZDV zidovudine 
ACE angiotensin converting 
enzyme
ALP alkaline phosphatase
ALT alanine aminotransferase
aMDRD abbreviated modification 
of diet in renal disease 
formula
ART antiretroviral therapy
AST aspartate 
aminotransferase
bid twice daily
BMD bone mineral density
BMI body mass index
BP  blood pressure
cART  combination antiretroviral 
treatment
CKD chronic kidney disease
CKD-EPI CKD epidemiology 
collaboration formula
CMV cytomegalovirus
CNS central nervous system
COPD chronic obstructive 
pulmonary disease
CSF cerebrospinal fluid
CVD cardiovascular disease
CXR chest X-ray
DAA direct acting antiviral drug
DXA dual energy X-ray 
absorptiometry
ECG electrocardiogram
eGFR estimated glomerular 
filtration rate
FBC full blood count
FDC fixed dose combination
FRAX fracture risk assessment 
tool
GT   genotype
HAV  hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HDL-c HDL-cholesterol
HIVAN HIV-associated 
nephropathy
HPV human papillomavirus
HSR hypersensitivity reaction
IGRA interferon-gamma release 
assay
IHD ischaemic heart disease
IM  intramuscular
IV intravenous
IVDU intravenous drug use
LDL-c LDL-cholesterol
LGV lymphogranuloma 
venereum
Mg magnesium
MSM men who have sex with 
men
PO  per oral
PAP  papanicolaou test
PEG-IFN pegylated-interferon
PHI primary HIV infection
PRT proximal renal tubulopathy 
PPI   proton pump inhibitor
PPD purified protein derivative
PSA prostate specific antigen
PTH parathyroid hormone
qd once daily
RBV ribavirin
SC  subcutaneous
SVR sustained virological 
response
STI sexually transmitted 
infection
TC total cholesterol
TDM therapeutic drug 
monitoring
TG triglycerides
tid three times daily
UA/C urine albumin/creatinine 
ratio
UP/C urine protein/creatinine 
ratio 
VL viral load (HIV-RNA) 
WB western blot 
Zn zinc 
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Assessment At HIV diagnosis
Prior to  
starting 
ART
Follow-up 
frequency Comment
See 
page
HISTORY
Medical Complete medical history 
including:
+ + First visit On transfer of care repeat assessment
• Family history (e.g. 
premature CVD, diabetes, 
hypertension, CKD)
+ First visit Premature CVD: cardiovascular events in a first 
degree relative (male < 55, female < 65 years)
34-36, 
38
• Concomitant medicines(i) + + Every visit
• Past and current  
co-morbidities
+ + Every visit
• Vaccination history + Annual Measure antibody titres and offer vaccinations 
where indicated, see Vaccination
Psychosocial Current lifestyle (alcohol 
use, smoking, diet, exercise, 
drug use)
+ + 6-12 months Adverse lifestyle habits should be addressed more 
frequently
Provide advice and support if needed
Provide counselling if needed
33
Employment + +
Every visitSocial and welfare + +
Psychological morbidity + +
Partner and children + Test partner and children if at risk
Sexual and  
Reproductive 
Health
Sexual history +
6-12 months
Address issues concerning sexual dysfunction
Risk of sexual transmission should be addressed 
59-61
Safe sex +
Partner status and  
disclosure
+ Recommend starting ART in serodifferent couples
Conception issues + +
HIV DISEASE
Virology Confirmation of HIV Ab pos + More frequent monitoring of HIV-VL at start of ART
Perform genotypic resistance test before starting 
ART if not previously tested or if at risk of  
super-infection
7-11
Plasma HIV-VL + + 3-6 months
At virological 
failure 
Genotypic resistance test 
and sub-type
+ +/-
R5 tropism (if available) +/- Screen if considering R5 antagonist in regimen
Immunology CD4 absolute count and % 
(optional: CD8 and %)
+ + 3-6 months Annual CD4 count if stable on ART and 
CD4 count > 350(ii)
7-11
HLA B5701 (if available) + +/-     Screen before starting ABC containing ART, if not 
previously tested
CO-INFECTIONS
STIs Syphilis serology + Annual/ as 
indicated
Consider more frequent screening if at risk 59
STI screen + Annual/ as 
indicated
Screen if at risk
Viral Hepatitis HAV serology +
Annual/ as 
indicated
Screen at risk; vaccinate if non-immune 58-
59,67HCV screen + Annual screen if ongoing risk
Measure HCV-RNA if HCV Ab pos or if acute 
infection suspected
HBV screen + + Annual screen in susceptible persons; vaccinate if
non-immune 
Tuberculosis CXR + Re-screen if 
exposure
Consider routine CXR in persons, from high TB 
prevalence populations.
Use of PPD/IGRA depending on availability and 
local standard of care. IGRA should, however, be 
tested before PPD if both are to be used, given the 
potential for a false positive IGRA after PPD
See Diagnosis and Treatment of TB in HIV-positive 
persons
88
PPD if CD4 count >400 
cells/µL
+
IGRA in selected high-risk 
populations (if available)
+
Others Varicella zoster virus 
serology
+ Offer vaccination where indicated 58
Measles/Rubella serology + Offer vaccination where indicated 
Toxoplasmosis serology +
CMV serology +
Leishmania serology +/- Screen according to travel history/origin
Tropical screen (e.g. Schis-
tosoma serology)
+/- Screen according to travel history/origin
Influenza virus + Annual In all HIV-positive persons, see Vaccination 58
Streptococcus pneumonia + No recommendations available regarding the need 
for a booster dose, see Vaccination
58
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Assessment At HIV diagnosis
Prior to  
starting 
ART
Follow-up 
frequency Comment
See 
page
CO-MORBIDITIES
Haematology FBC + + 3-12 months
Haemoglobinopathies + Screen at risk persons
G6PD + Screen at risk persons
Body  
Composition
Body-mass index + + Annual 33
Cardiovascular 
Disease
Risk assessment  
(Framingham score(iii))
+ + 2 years Should be performed in all men > 40 years and 
women > 50 years without CVD
34
ECG + +/- As indicated Consider baseline ECG prior to starting ARVs 
associated with potential conduction problems
Hypertension Blood pressure + + Annual 35-36
Lipids TC, HDL-c, LDL-c, TG(iv) + + Annual Repeat in fasting state if used for medical interven-
tion (i.e. ≥ 8h without caloric intake)
40
Glucose Serum glucose + + Annual Consider oral glucose tolerance test / HbA1c if 
fasting glucose levels of 5.7-6.9 mmol/L  
(100-125 mg/dL)
38-39
Pulmonary  
Disease
CXR +/- As indicated Consider CXR if prior history of pulmonary disease
Spirometry As indicated Screen for COPD in at risk persons(xii)
Liver Disease Risk assessment(v) + + Annual 48-50
ALT/AST, ALP, Bilirubin + + 3-12 months More frequent monitoring prior to starting and on 
treatment with hepatotoxic drugs
Staging of liver fibrosis 12 months In HCV and/or HBV co-infected persons (e.g. 
FibroScan, serum fibrosis markers)
67, 71
Hepatic ultrasound 6 months In HCV co-infected persons with liver cirrhosis 
Child Pugh class A or B and Child Pugh class C 
awaiting liver transplantation; and in HBV co-infect-
ed persons irrespective of fibrosis stage
67, 71
Renal Disease Risk assessment(vi) + + Annual More frequent monitoring if eGFR < 90mL/min, 
CKD risk factors present(vi) and/or prior to starting 
and on treatment with nephrotoxic drugs(ix)
44-45
eGFR (CKD-EPI)(vii) + + 3-12 months
Urine dipstick analysis(viii) + + Annual Every 6 months if eGFR < 60 mL/min,
if proteinuria ≥ 1+ and/or eGFR < 60 mL/min per-
form UP/C or UA/C(viii)
Bone Disease Bone profile: calcium, PO4, 
ALP
+ + 6-12 months 41, 43
Risk assessment(x) 
(FRAX®(xi) in persons 
> 40 years)
  +    + 2 years Consider DXA in specific persons (see page 41 for 
details)
Vitamin D 25(OH) vitamin D + As indicated Screen at risk persons 42
Neurocognitive 
Impairment
Screening questionnaire + + As indicated Screen all persons without highly confounding con-
ditions. If abnormal or symptomatic, see algorithm 
page 66 for further assessment.
66
Depression Questionnaire + + As indicated Screen at risk persons 62-64
Cancer Mammography 1-3 years Women 50-70 years 32, 50
Cervical PAP 1-3 years Sexually active women
Rectal exam and anoscopy  
(MSM)
1-3 years Evidence of benefit not known
Ultrasound and alpha-foe-
toprotein
6 months Controversial; persons with cirrhosis and persons 
with HBV irrespective of fibrosis stage
Others Controversial 
i  Review all concomitant medicines which may potentially interact with 
ARVs or increase co-morbidities, see 
 Drug-drug Interactions between DAAs and ARVs
 Drug-drug Interactions between Antidepressants and ARVs                                   
 Drug-drug Interactions between Antihypertensives and ARVs                                
 Drug-drug Interactions between Analgesics and ARVs                                                                        
 Drug-drug Interactions between Antimalarial Drugs and ARVs     
 Drug-drug Interactions between Corticosteroids and ARVs
 Drug-drug Interactions between Contraceptives and ARVs 
 and www.hiv-druginteractions.org
ii  If stable on ART with undetectable HIV-VL and CD4 count > 350 cells/
μL, suggest annual CD4 count.
iii  A risk equation developed from HIV populations is available, see  
http://www.hivpv.org/ Of note, if an individual receives medicines to 
control dyslipidaemia and/or hypertension, the estimation should be 
interpreted with caution.
iv  A calculator for LDL-cholesterol in cases where TG is not high can be 
found at http://www.hivpv.org/.
v  Risk factors for chronic liver disease include alcohol, viral hepatitis, obe-
sity, diabetes, insulin resistance, hyperlipidaemia and hepatotoxic drugs.
vi  Risk factors for CKD: hypertension, diabetes, CVD, family history, black 
African ethnicity, viral hepatitis, low current CD4 count, smoking, older 
age, concomitant nephrotoxic drugs.
vii  eGFR: use CKD-EPI formula based on serum creatinine, gender, age 
and ethnicity because eGFR quantification is validated >60 mL/min. 
The abbreviated modification of diet in renal disease (aMDRD) or the 
Cockroft-Gault (CG) equation may be used as an alternative; see http://
www.hivpv.org
viii  Some experts recommend UA/C (urinary albumin creatinine ratio) or 
UP/C (urinary protein creatinine ratio) as a screening test for proteinuria 
in all persons. UA/C predominantly detects glomerular disease. Use in 
persons with diabetes. UP/C detects total protein secondary to glomeru-
lar and tubular disease.
ix  Different models have been developed for calculating a 5-year CKD risk 
score while using different nephrotoxic ARVs, integrating HIV indepen- 
dent and HIV-related risk factors [4], [5]
x  Classic risk factors: older age, female gender, hypogonadism, family 
history of hip fracture, low BMI (≤ 19 kg/m2), vitamin D deficiency, smo-
king, physical inactivity, history of low impact fracture, alcohol excess (> 
3 units/day), steroid exposure (minimum 5 mg for > 3 months).
xi  WHO fracture risk assessment (FRAX®) tool: www.shef.ac.uk/FRAX
xii  A diagnosis of COPD should be considered in persons over the age of 
35 who have a risk factor (current or ex-smoker) and who present with 
exertional breathlessness, chronic cough, regular sputum production, 
frequent winter ‘bronchitis’ or wheeze.
EACS   European
AIDS Clinical Society
6EACS Guidelines 8.0 PART II
Part II   ART of HIV-positive Persons
Assessing  HIV-positive Persons' Readiness to Start and Maintain ART(x)
Stages of readiness to start ART
Precontemplation: 
“I don’t need it, I feel good.” 
“I don’t want to think about it.”   
Support: Show respect for the person's attitude. / Try to understand the 
person's health and therapy beliefs. / Establish trust. / Provide concise, 
individualised information. / Schedule next appointment.
Contemplation: 
“I am weighing things up and feel  
torn about what to do about it.”  
Support: Allow ambivalence. / Support the person in weighing pros and 
cons. / Assess the person's information needs and support his/her informa-
tion seeking. / Schedule the next appointment.
Preparation: 
“I want to start, I think the drugs  
will allow me to live a normal life.” 
Support: Reinforce the person's decision. / Decide with the person which 
is the most convenient regimen. / Educate the person on adherence, 
resistance and side effects. / Discuss integration into daily life. / Assess  
self-efficacy. Ask: How confident are you that you can take your medicines 
as we discussed (specify) once you have started? Use VAS 0-10(iii) 
Consider skills training: 
• Medicines-taking training, possibly MEMS 
• Directly observed therapy with educational support 
• Use aids: mobile phone alarm, pillboxes 
• Involve supportive tools/persons where appropriate
Action: 
“I will start now.” 
‘Final check’: With a treatment plan established, is the person  
capable of taking ART and is ART available?
Maintenance: 
“I will continue” or ”I have 
difficulties continuing over 
the long run”
Caveat: A person can relapse 
to an earlier stage, even from 
“maintenance” to “precontemplation”
Assess: Adherence every 3-6 months(iv) 
Evaluate adherence: For persons with good adherence: show respect for 
their success. 
Assess: The person's  own perception of ability to adhere to and continue 
treatment. 
Ask: In the next 3-6 months, how confident are you that you can take your 
medicines? Use VAS 0-10(iii)
For a person without sufficient adherence: use mirroring techniques(v) 
on problems, ask open questions to identify dysfunctional beliefs. 
Assess: Stage of readiness and provide stage-based support 
Assess: Barriers and facilitators(vi)
Schedule next appointment and repeat support
ST
A
R
T 
A
R
T
Goal: to help persons start and/or maintain ART
Successful ART requires a person's readiness to start and adhere to the 
regimen over time. The trajectory from problem awareness to maintenance 
on ART can be divided into five stages. Knowing a person's stage, health 
care providers use appropriate techniques to assist them to start and 
maintain ART. 
Identify the person's stage of readiness using WEMS(i) techniques, and 
start discussion with an open question/invitation: 
“I would like to talk about HIV medicines.” <wait> “What do you think about 
them?” 
Based on the person’s response, identify his/her stage of readiness and 
intervene accordingly.(ii)
Several barriers are known to influence ART decision making and 
adherence to ART
Screen for and talk about problems and facilitators
Consider systematic assessment of: 
• Depression(vii), see page 62-63
• Cognitive problems(viii),  
see page 66
• Harmful alcohol(ix) or recreational 
drug use, see page 31, 33
Consider talking about: 
• Social support and disclosure 
• Health insurance and continuity 
of drug supply 
• Therapy-related factors
Recognise, discuss and reduce problems wherever possible in a  
multidisciplinary team approach.
i WEMS: Waiting (> 3 sec), Echoing, Mirroring, Summarising [1]
ii  The person presenting in the clinic may be at different stages of readi-
ness: precontemplation, contemplation or preparation. The first step is to 
assess the stage, and then to support/intervene accordingly. In the case 
of late presentation (< 350 CD4 cells/μL), the initiation of ART should 
not be delayed. The person should be closely followed and optimally 
supported. Schedule the next appointment within a short time,  
i.e. 1-2 weeks. 
iii VAS (= Visual Analogue Scale; range from 0 to 10,  
i.e. 0= I will not manage, 10= I am sure I will manage).
I will not manage I will manage
0 10
iv Suggested adherence questions: “In the past 4 weeks how often have 
you missed a dose of your HIV medicines: every day, more than once a 
week, once a week, once every 2 weeks, once a month, never?” / “Have 
you missed more than one dose in a row?” [2]. 
v Mirroring: reflecting back on what a person has said or non-verbally 
demonstrated (e.g. anger or disappointment) WITHOUT introducing new 
material by asking questions or giving information. 
vi Adherence to long-term therapies [3].
vii PHQ-2 or PHQ-9 [4]. Meta-analysis shows a consistent relationship 
between depression and ART non-adherence that is not limited to those 
with clinical depression. Therefore, assessment and intervention aimed 
at reducing depressive symptom severity, even at subclinical level is 
important. Ask: "Over the last two weeks, how often have you been 
bothered by any of the following problems? 1. Little interest or pleasure 
in doing things; 2. Feeling down, depressed or hopeless." Answers: Not 
at all (0) / Several days (1) / More than half the days (2) / Nearly every 
day (3). If the person scores 2 or more, seven additional questions, see 
[5] 
viii Ask: “Do you feel having problems to concentrate in your daily life?” / 
“Do you feel slowed in your thinking?” / “Do you feel having problems 
with your memory?” / “Did relatives or friends express that they feel you 
have problems with your memory or difficulty concentrating?” [6]. 
ix FAST-alcohol use, ask: How often have you had 6 or more units if 
female, or 8 or more units if male, on a single occasion in the last year? 
Never=0, Less than monthly=1, Monthly=2, Weekly=3, Daily or almost 
daily=4. Stop if the answer is 3 or 4. Ask more questions if the answer is 
0, 1 or 2. See [7].
x   Algorithm adapted from [8].
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Recommendations for Initiation of ART in HIV-positive Persons with Chronic 
Infection without prior ART Exposure(i)  
Recommendations are graded while taking into account the level of evi-
dence, the degree of progression of HIV disease and the presence of, or 
high risk for, developing various types of (co-morbid) conditions.
Symptomatic HIV disease (CDC B or C 
conditions, incl. tuberculosis)
Asymptomatic HIV infection
Any CD4 count
Current CD4 count
< 350  ≥ 350
SR SR R
SR = Strongly Recommended
R = Recommended
i  ART should always be recommended irrespective of the CD4 count with 
the possible exception of elite controllers with high and stable CD4 count.  
Time should always be taken to prepare the person, in order to optimise 
compliance and adherence. Genotypic resistance testing is recommended 
prior to initiation of ART, ideally at the time of HIV diagnosis; otherwise be-
fore initiation of ART. If ART needs to be initiated before genotypic testing 
results are available, it is recommended to include a PI/r in the first-line 
regimen. Ideally, before starting treatment, the HIV-VL level and CD4 count 
should be repeated to obtain a baseline to assess subsequent response. 
Moreover, use of ART should also be recommended with any CD4 count in 
order to reduce sexual transmission, risk of AIDS event and mother-to-child 
transmission of HIV (before third trimester of pregnancy).
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A) Recommended regimens (one of the following to be selected)*,**
Regimen Dosing Food requirement Caution
2 NRTIs + INSTI
ABC/3TC/DTG(i, ii) ABC/3TC/DTG 600/300/50 mg, 1 tablet qd None Al/Ca/Mg-containing antacids 
should be taken well separated 
in time (minimum 2h after or 6h 
before).
TDF/FTC(iii, iv) + DTG TDF/FTC 300(viii)/200 mg, 1 tablet qd + DTG 50 mg, 1 tablet qd None
TDF/FTC/EVG/c(iii, iv, v) TDF/FTC/EVG/c 300(viii)/200/150/150 mg, 1 tablet qd With food Al/Ca/Mg-containing antacids 
should be taken well separated 
in time (minimum 2h after or 6h 
before).
TDF/FTC(iii, iv) + RAL TDF/FTC 300(viii)/200 mg, 1 tablet qd + RAL 400 mg, 1 tablet 
bid
None Al/Ca/Mg-containing antacids 
should be taken well separated 
in time (minimum 2h after or 6h 
before).
2 NRTIs + NNRTI
TDF/FTC/RPV(iii) TDF/FTC/RPV 300(viii)/200/25 mg, 1 tablet qd With food (min 390 Kcal 
required)
Only if CD4 count >200 cells/µL 
and HIV VL <100,000 copies/mL. 
PPI contraindicated; H2 antago-
nists to be taken 12h before or 4h 
after RPV. 
2 NRTIs + PI/r
TDF/FTC(iii, iv) + DRV/r TDF/FTC 300(viii)/200 mg, 1 tablet qd + DRV 800 mg, 1 tablet 
qd + RTV 100 mg, 1 tablet qd
With food Monitor in persons with a known 
sulfonamide allergy.
B) Alternative regimens (to be used when none of the preferred regimens are feasible or available, whatever the reason)
Regimen Dosing Food requirement Caution
2 NRTIs + INSTI
ABC/3TC(i, ii) + RAL ABC/3TC 600/300 mg, 1 tablet qd + RAL 400 mg, 1 tablet bid None Al/Ca/Mg-containing antacids 
should be taken well separated 
in time (minimum 2h after or 6h 
before)
2 NRTIs + NNRTI
ABC/3TC(i, ii) + EFV (vi) ABC/3TC 600/300 mg, 1 tablet qd + EFV 600 mg, 1 tablet qd At bed time or 2 hours 
before dinner
TDF/FTC/EFV(iii, iv) TDF/FTC/EFV 300(viii)/200/600 mg, 1 tablet qd At bed time or 2 hours 
before dinner
2 NRTIs + PI/r or PI/c
ABC/3TC(i, ii) + ATV/r ABC/3TC 600/300 mg, 1 tablet qd + ATV 300 mg, 1 tablet qd + 
RTV 100 mg, 1 tablet qd
With food
Co-administration with PPI is con-
traindicated.(vii)
TDF/FTC(iii, iv) + ATV/r TDF/FTC 300(viii)/200 mg, 1 tablet qd + ATV 300 mg, 1 tablet 
qd + RTV 1 tablet 100 mg qd
With food
ABC/3TC(i, ii) + ATV/c ABC/3TC 600/300 mg, 1 tablet qd + ATV 300 mg, 1 tablet qd + 
COBI 150 mg, 1 tablet qd
With food
TDF/FTC(iii, iv) + ATV/c TDF/FTC 300(viii)/200 mg, 1 tablet qd + ATV 300 mg, 1 tablet 
qd + COBI 150 mg, 1 tablet qd
With food Co-administration with PPI is con-
traindicated.(vii)
eGFR <70 mL/min: combination not 
recommended.
ABC/3TC(i, ii) + DRV/r ABC/3TC 600/300 mg, 1 tablet qd + DRV 800 mg, 1 tablet qd 
+ RTV 1 tablet 100 mg qd
With food
Monitor in persons with a known 
sulfonamide allergy.ABC/3TC(i, ii) + DRV/c ABC/3TC 600/300 mg, 1 tablet qd + DRV 800 mg, 1 tablet qd 
+ COBI 150 mg, 1 tablet qd
With food
TDF/FTC(iii, iv) + DRV/c TDF/FTC 300(viii)/200 mg, 1 tablet qd + DRV 800 mg, 1 tablet 
qd + COBI 150 mg, 1 tablet qd
With food Monitor in persons with a known 
sulfonamide allergy.
eGFR <70 mL/min: combination not 
recommended.
TDF/FTC(iii, iv) + LPV/r TDF/FTC 300(viii)/200 mg, 1 tablet qd + LPV 200 mg, 2 tablets 
bid + RTV 50 mg, 2 tablets bid 
With food Use with caution in persons with 
high cardiovascular risk
Other combinations
3TC(ii) + LPV/r 3TC 300 mg, 1 tablet qd + LPV 200 mg, 2 tablets bid + RTV 
50 mg, 2 tablets bid
With food
RAL(ii) + DRV/r RAL 400 mg, 1 tablet bid +DRV 800 mg, 1 tablet qd + RTV 
100 mg, 1 tablet qd 
With food Only if CD4 count > 200 cells/µL 
and HIV-VL < 100,000 copies/mL. 
Co-administration of antacids con-
taining Al or Mg not recommended.
* Only drugs currently licensed for initiation of therapy by the EMA are taken into consideration (in alphabetical order). 
** Generic HIV drugs are becoming more available and can be used as long as they replace the same drug and do not break recommended fixed dose combinations. 
i  ABC contra-indicated if HLA B*5701 positive. Even if HLA B*5701 negative, counselling on HSR risk still mandatory. ABC should be used with caution in persons with a high CVD risk (>20%). 
ii  Use this combination only if HBs Ag negative.
iii  Avoid TDF if osteoporosis, renal monitoring required, see page 45
iv  If TDF/FTC is not available, one  alternative could be TDF+3TC as separate entities.
v  TDF/FTC/EVG/c use only if eGFR ≥ 70 mL/min. It is recommended that TDF/FTC/EVG/c is not initiated in persons with eGFR < 90 mL/min unless this is the preferred treatment. 
vi  EFV: not to be given if history of suicide attempts or mental illness; not active against HIV-2 and HIV-1 group O strains. 
vii  If PPI co-administration is judged unavoidable, consider an alternative regimen; if given, dose increase of ATV to 400 mg qd may be considered, close clinical monitoring is recommended and doses of PPI 
 comparable to omeprazole 20 mg should not be exceeded and must be taken approximately 12 hours prior to the ATV/r. H2 antagonists to be taken 12 hours before or 4 hours after ATV.
viii In certain countries TDF is labelled as 245 mg rather than 300 mg to reflect the concentration of the active metabolite.
Initial Combination Regimen for ART-naïve Adult HIV-positive Persons                  
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Definition of Acute primary HIV infection (PHI)(i-v)
• High-risk exposure within previous 6 months, and
• Detectable virus in plasma (p24 Ag and/or HIV-RNA) and/or
• Evolving anti-HIV antibody reactivity (negative or indeterminate to positive).
• With (40-90%) or without clinical symptoms.
Resistance testing
• Recommended in all cases, even if treatment not initiated. 
• In cases when resistance testing cannot be performed immediately and 
treatment initiation is deferred, a plasma sample should be stored for sub-
sequent testing prior to starting ART.
• A genotypic test is recommended due to increased sensitivity and wide 
availability.
Treatment of PHI(vi-viii)
Circumstances
Severe or prolonged symptoms SR
Neurological disease SR
Age ≥ 50 years SR
CD4 count < 350 cells/µL SR
Asymptomatic CD4 count > 350 cells/µL R
SR=Strongly Recommended
R=Recommended
• Evidence of a long-term clinical benefit of treatment of primary infection is 
currently lacking.
• Evidence in favour of starting treatment is mostly derived from subjects with 
symptomatic PHI.
• The recommendation to start ART is based on: a) demonstrated virolog-
ical and immunological benefits and anticipated clinical benefits of early 
therapy, b) a reduced risk of transmission, and c) the usually short interval 
between identification of PHI and a CD4 count < 500 cells/µL.
• If treatment is started, the HIV-positive person should preferably be recruit-
ed into a clinical trial, if available. Treatment selection should otherwise 
follow recommendations made for chronic infection see page 8. However, if 
treatment is started before the results of resistance testing become availa-
ble; preference should be given to starting a PI/r-based regimen. 
• If treatment is started, subsequent interruption (non-earlier than 36-48 
weeks) is generally not recommended.
• Following appropriate counselling persons who are asymptomatic, have a 
CD4 count > 350 cells/µL, and wish to defer treatment may be followed up 
for evidence of a CD4 count increase prior to treatment decision.  
Other considerations
• Examine the HIV-positive person for STIs, including syphilis, gonorrhoea, 
chlamydia (urethritis and LGV), HPV, HBV and HCV.
• Counsel on the high risk of transmission and preventive measures (con-
doms), and about notifying and testing partners.
Primary HIV Infection (PHI)     
i Acute infection is defined by HIV detection (p24 Ag and/or HIV-RNA) in 
the absence of HIV antibodies. After antibody seroconversion and for up 
to 6 months the infection is defined as recent.
ii HIV-1 RNA becomes detectable in plasma around day 11 after expo-
sure, approximately 7 days before p24 Ag and 12 days before anti-HIV 
antibodies.
iii Where available, Western Blot (WB) or Immunoblot patterns of reactivity 
can be used to stage the infection as follows [11]: Stage I: HIV- RNA 
positive only (average duration 5 days).  HIV-VL levels are median 
2000 copies/ml (IQR 300-20000 copies/mL), and are <100 copies/ml in 
approximately 10% of subjects. Low HIV-VL levels should be interpreted 
with caution due to the risk of false positivity (e.g., due to contamination); 
Stage II: HIV-RNA and p24 Ag positive only (5.3 days on average). NB: 
HIV-VL levels are usually >10000 copies/ml; Stage III: HIV-RNA, p24 
Ag and anti-HIV antibody positive by immune-assay, no specific WB 
bands (3.2 days on average); Stage IV: as Stage III but indeterminate 
WB pattern (5.6 days on average); Stage V: as Stage III, but reactive WB 
pattern lacking p31 reactivity (69.5 days on average); Stage VI: as stage 
III but full WB reactivity including a p31 band.
iv All persons with detectable HIV-VL and negative or indeterminate se-
rology must receive confirmation of anti-HIV antibody seroconversion in 
follow-up testing. The interval of testing (up to stage V) is one week.
v Some centres may have access to sero-incidence markers (e.g., anti-
body avidity testing) that identify an infection acquired within the previous 
3-6 months. Assay reliability varies and results should be interpreted with 
caution when they are the sole indicators of a recent infection.
vi Potential advantages of starting therapy in PHI: reduce severity of acute 
symptoms; lower the HIV-VL set-point and size of the HIV reservoir; re-
duce viral genetic evolution; reduce immune activation, inflammation and 
markers of disease progression; preserve immune function and integrity 
of lymphoid tissue; possibly exert neurological and gut protection; pos-
sibly enhance post-treatment control and response to future eradication 
strategies. These effects are more likely if treatment is started in the 
acute phase of PHI. Other benefits include a reduced risk of transmis-
sion, reduced anxiety, and facilitated disclosure to contacts.
vii Potential disadvantages of starting therapy in PHI: uncertain long-term 
clinical benefit; low likelihood of post-treatment control; treatment inter-
ruption leads to rebound of HIV-VL and inflammation markers; possible 
adverse consequences of long-term ART (toxicity, drug resistance). 
viii Persons with neurological involvement should be treated without delay.
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Definition of virologically suppressed
Clinical trials exploring switching strategies have defined suppression as a 
HIV-VL < 50 copies/mL for at least 6 months. 
Indications
1. Documented toxicity caused by one or more of the antiretrovirals includ-
ed in the regimen. Examples of these reactive switches: lipoatrophy (d4T, 
AZT), central nervous system adverse events (EFV), diarrhoea (PI/r) and 
jaundice (ATV).
2. Prevention of long-term toxicity. Example of this proactive switch: 
prevention of lipoatrophy in patients receiving d4T or AZT.
3. Avoid serious drug-drug interactions
4. Planned pregnancy
5. Ageing and/or co-morbidity with a possible negative impact of drug(s) in 
current regimen, e.g. on CVD risk, metabolic parameters
6. Simplification: to reduce pill burden, adjust food restrictions and improve 
adherence.
Principles
1. Clinicians should always review possible adverse events or tolerability 
issues with current antiretroviral regimens. Just because the HIV-VL is 
suppressed it should not be assumed that the HIV-positive person is well 
adapted and tolerating the current regimen. 
2. The objectives of treatment modification should be to eliminate or improve 
adverse events, facilitate adequate treatment of co-morbid conditions, and 
improve quality of life.
3. The primary concern when switching should be not to jeopardize viro-
logical suppression. In persons without prior virological failures and no 
archived resistance, switching regimens entail a low risk of subsequent 
failure if clinicians select one of the recommended combinations for first-
line therapy. The majority of clinical trials showing non-inferiority of the 
new regimen after the switch have actively excluded patients with prior 
virological failures. 
4. A PI/r may be switched to unboosted ATV, an NNRTI, or an INSTI only if 
full activity of the 2 NRTIs remaining in the regimen can be guaranteed. 
Switches have to be planned especially carefully when they result in a 
decrease in the genetic barrier of the regimen in case of prior virologic 
failures. Clinicians should review the complete ARV history and available 
resistance test and HIV-VL results before switching. 
Switch Strategies for Virologically Suppressed Persons   
5. Switches of single drugs with the same genetic barrier (for example T-20 
for RAL) is usually virologically safe in the absence of resistance to the 
new compound.
6. Clinicians should carefully review the possibility of drug-drug interactions 
with the new regimen.
7. If the switch implies discontinuing TDF, clinicians should check the HBV 
status (avoid discontinuation of TDF in persons with chronic HBV and 
assess HBV vaccination status).
8. HIV-positive persons should be seen soon (e.g. 4 weeks) after treatment 
switches to check for maintenance of suppression and possible toxicity of 
the new regimen. 
9. If a HIV-positive person receives and tolerates a regimen that is no longer 
a preferred option, there is no need to change. Example: persons tolerat-
ing EFV-containing regimens.
Strategies not recommended
a. Intermittent therapy, sequential or prolonged treatment interruptions 
b. Two-drug combination, i.e. 1 NRTI + 1 NNRTI or 1 NRTI + 1 PI without 
RTV or 1 NRTI + RAL, or 2 NRTIs or MVC + RAL
c. Triple NRTIs combinations
Other strategies
PI/r monotherapy and dual therapy  with 3TC+ PI/r  may only be given to 
persons without a) resistance to the PI, b) suppression of HIV-VL to < 50 
copies/mL for at least the past 6 months and c) absence of chronic HBV 
co-infection. 
PI/r monotherapy with DRV/r qd or LPV/r bid might represent an option in 
persons with intolerance to NRTIs or for treatment simplification or in illicit 
drug users with documented frequent interruption of cART. This strategy is 
associated with more virological rebounds than continuing triple therapy. 
However, resistance occurs rarely, and suppression can be regained with 
nucleoside reintroduction. 
Dual therapy: 3TC + LPV/r or 3TC+ ATV/r. In clinical trials this strategy has 
not been associated with more virological rebounds than triple therapy. It 
might therefore be a better option than PI/r monotherapy. 
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Definition Confirmed HIV-VL > 50 copies/mL 6 months after starting
therapy (initiation or modification) in persons that remain
on ART. Depending on the HIV-VL assay, this limit could 
be higher or lower.
General 
measures
Review expected potency of the regimen
Evaluate adherence, compliance, tolerability, drug-drug 
interactions, drug-food interactions, psychosocial issues
Perform resistance testing on failing therapy (usually 
routinely available for HIV-VL levels > 350-500 copies/
mL and in specialised laboratories for lower levels of 
viraemia) and obtain historical resistance testing for 
archived mutations
Tropism testing
Consider TDM
Review ART history
Identify treatment options, active and potentially active 
drugs/combinations
Management 
of virological 
failure (VF)
If HIV-VL > 50 and < 500-1000 copies/mL:
Check for adherence
Check HIV-VL 1 to 2 months later
If genotype not possible, consider changing regimen 
based on past treatment and resistance history
If HIV-VL confirmed > 500 copies/mL: 
Change regimen as soon as possible. What to change will 
depend on the resistance testing results:
If no resistance mutations found: re-check for adherence, 
perform TDM
If resistance mutations found: switch to a suppressive 
regimen based on drug history; multidisciplinary expert 
discussion advised
Goal of new regimen: HIV-VL < 400 copies/mL after 3 
months, HIV-VL < 50 copies/mL after 6 months
 Virological Failure                                                                 
In case of 
demonstrated 
resistance 
mutations
General recommendations:
Use at least 2 and preferably 3 active drugs in the new 
regimen (including active drugs from previously used 
classes)
Any regimen should use at least 1 fully active PI/r (e.g. 
DRV/r) plus 1 drug from a class not used previously e.g. 
fusion, integrase or CCR5 antagonist (if tropism test 
shows R5 virus only), or 1 NNRTI (e.g. ETV), assessed 
by genotypic testing
Defer change if < 2 active drugs available, based on 
resistance data, except in persons with low CD4 count 
(< 100 cells/μL) or with high risk of clinical deterioration 
for whom the goal is the preservation of immune function 
through partial reduction of HIV-VL (> 1*log10 reduction) 
by recycling 
If limited options, consider experimental and new drugs, 
favouring clinical trials (but avoid functional monotherapy)
Treatment interruption is not recommended
Consider continuation of 3TC or FTC in particular 
situations even if documented resistance mutation 
(M184V/I)
If many options are available, criteria of preferred choice 
include: simplicity of the regimen, toxicity risks evaluation, 
drug-drug interactions, and future salvage therapy
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Criteria for starting ART in pregnant women (see different scenarios) Same as for non pregnant
Objective of treatment in pregnant women Full plasma HIV-VL suppression at least by third trimester and specifically 
at time of delivery
Resistance testing Same as for non pregnant women, i.e. before starting ART and in case of 
virological failure
SCENARIO
1. Women planning to be pregnant while already on ART 1.  Maintain ART, unless taking some contra-indicated regimen during 
    pregnancy (ddI + d4T, triple NRTI combinations)
2.  Women becoming pregnant while already on ART 2. Maintain ART, unless taking some contra-indicated regimen during 
    pregnancy (ddI + d4T, triple NRTI combinations)
3.  Women becoming pregnant while treatment-naïve 3. Starting ART as soon as possible and not later than beginning of 2nd          
trimester is highly recommended
4.  Women whose follow-up starts after week 28 of pregnancy 4.  Start ART immediately and consider adding INSTI to obtain rapid  
 HIV-VL decline in case of high HIV-VL
5.  Women whose HIV-VL is not undetectable at third trimester 5.  Perform resistance testing and consider adding INSTI to obtain 
 rapid HIV-VL decline
Antiretroviral regimen in pregnancy
Same as non pregnant
NVP not to be initiated but continuation is possible if started before 
pregnancy
EFV can be started if other options are not available or suitable.
Continuation of EFV is possible if already started before pregnancy
Among PI/r, prefer LPV/r or ATV/r
If RAL, DRV/r: could be continued
Drugs contra-indicated during pregnancy ddI + d4T, triple NRTI combinations
iv ZDV during labour Not necessary if HIV-VL < 50 copies/mL
Single dose NVP during labour Not recommended
Caesarean section Only if HIV-VL > 50 copies/mL at week 34-36 
Treatment of HIV-positive Pregnant Women                                                                                         
Pregnant women should be monitored every month and as close as  
possible to the predicted delivery date
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Important Drug-Drug Interactions between ART and  
rifampicin / rifabutin
ARV drug 
class
Specific ARVs Drug-drug interactions and recom-
mended adjustment of dose of either 
or both drugs
NRTIs Rifampicin: standard dose of all drugs 
Rifabutin: standard dose of all drugs
PI/r and 
PI/c
Rifampicin: not recommended
PI/r Monitor liver 
enzymes and, 
whenever possible, 
perform TDM for PI
Rifabutin: dose as 150 mg qd(i). PI/r at 
standard dose
PI/c Rifabutin: not recommended. If needed 
recommended dose of rifabutin: 150 mg 
qd(ii)
NNRTIs EFV Rifampicin: No dose change required. 
EFV: standard dose ARV TDM recom-
mended after 2 weeks
Rifabutin: 450 mg qd. EFV: standard 
dose 
NVP Neither rifampicin nor rifabutin recom-
mended 
RPV Rifampicin: not recommended
Rifabutin: standard dose. RPV dose 
should be increased (use with caution)
ETV Rifampicin: not recommended
Rifabutin: standard dose of both drugs 
(few data – use with caution)
INSTI EVG/c Rifampicin: not recommended
Rifabutin: 150 mg qd. EVG: standard 
dose. Use with caution.
RAL Rifampicin: standard dose. RAL 400 or 
800 mg bid and perform TDM for RAL
Rifabutin: standard dose of both drugs
DTG Rifampicin: standard dose. DTG 50 
mg bid (use only in absence of INSTI 
resistance)
Rifabutin: standard dose of both drugs
Other 
ART
MVC Rifampicin: MVC 600 mg bid
Rifabutin: Standard dose of MVC (300 
mg bid in absence of a PI, 150 mg bid in 
presence of a PI)
i Initial pharmacokinetic studies in healthy volunteers showed that 
concentrations of rifabutin and its active metabolite were significantly in-
creased when combined with PI/r. Thus, a reduction of rifabutin dosage 
to 150 mg x3/week was recommended to reduce the risk of rifabutin 
related toxicity. However, more recent pharmacokinetic data derived 
from HIV/TB co-infected persons have shown that the co-administration 
of LPV/r or ATV/r with rifabutin (150 mg x3/week) resulted in rifabutin 
concentrations that were lower than those observed with rifabutin 300 
mg x1/day without PI/r suggesting that rifabutin dosage may be inade-
quate. Cases of relapses with acquired rifamycin-resistant TB have been 
described in co-infected persons treated with rifabutin 150 mg x3/week 
and LPV/r or ATV/r. The US guidelines for HIV treatment recommend the 
administration of rifabutin at 150 mg qd with PI/r. Due to the limited safe-
ty data with this dose and combination, persons receiving rifabutin 150 
mg qd with PI/r should be closely monitored for rifabutin related toxicities 
(i.e. uveitis or neutropenia). 
ii     Few data are available. Use with caution and always seek the advise 
of an HIV specialist. Some experts advise that, in presence of COBI a 
rifabutin dose of 150 mg x3/week may be used in order to reduce the 
risk of toxicity. If used at 150 mg qd, enhanced monitoring of rifabutin 
toxicity is needed.       
ART in TB/HIV Co-infection           
Principles
Persons with TB should be started on standard TB therapy with 2 months 
rifampicin/isoniazid/pyrazinamide/ethambutol followed by 4 months  
rifampicin/isoniazid (choice of drugs and length of treatment depends on 
drug susceptibility and site of disease), see Diagnosis and Treatment of TB 
in HIV-positive persons
All persons with TB/HIV co-infection should start ART irrespective of CD4 
count. Treatment supervision and adherence evaluation are very important. 
Suggested timing of ART initiation in TB/HIV co-infection  
according to CD4 count 
< 50 cells/µL* : As soon as TB treatment is tolerated and wherever possible 
within 2 weeks 
≥ 50 cells/µL** :Can be deferred until between 8 and 12 weeks of TB 
treatment, especially when there are difficulties with drug-drug interactions, 
adherence and toxicities
Although a RCT showed that early ART (within 2 weeks) did not reduce mor-
tality in TB meningitis, recommendations on ART initiations should be based 
on the CD4 count in HIV-positive persons with TB co-infection.
*  Be aware of IRIS reaction in persons starting ART at low CD4 count lev-
els and with early initiation of ART. Corticosteroids should be considered 
for treatment of symptomatic IRIS, with dosages and duration tailored 
according to response.
**  Although the data suggests a cut-off of 50 cells/µL, because of the daily 
variability in CD4 count, a cut-off of 100 cells/µL may be more appropri-
ate.
Recommended 1st line ARV combination with anti-TB medicines
TDF/FTC + RAL or TDF/FTC/EFV (see table for dose adjustment with 
rifamycins).
Alternatives
Where combinations are not recommended or to be used with caution or 
because of resistance/intolerance, specialist HIV treatment advice should be 
sought.
• TDF/FTC + PI/r, using rifabutin instead of rifampicin (see table for dose 
adjustment of rifabutin). Use with caution. 
• TDF/FTC + DTG bid*** with rifampin. 
In countries where neither DTG nor rifabutin are available, following combi-
nations could also represent a short-term alternative until anti-TB treatment 
has been completed.
• Rifampin plus fixed-dose combination of ABC/3TC/ZDV bid + TDF qd (if 
HIV-VL < 100,000 copies/mL).
• Rifampin plus double dose LPV/r or with RTV super boosted (400 mg bid) 
+ LPV.
• For other regimens based on 2NRTIs plus NVP, RPV, ETV or MVC, consul-
tation with an HIV specialist is recommended. 
*** Only pharmacokinetic and not clinical data are available, use with cauti-
on. 
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Post-exposure Prophylaxis (PEP)                                       
PEP recommended in case of:
Risk Nature of exposure                            Status of source person
Blood Subcutaneous or 
intramuscular penetration 
with iv or im needle, or 
intravascular device
HIV-positive or serostatus 
unknown, but presence of 
HIV risk factors
Percutaneous injury with 
sharp instrument (lancet), 
im or sc needle, suture 
needle
Contact > 15 min of 
mucous membrane or non 
intact skin
HIV-positive
Genital 
secretions
Anal or vaginal sex Viraemic HIV-positive 
or serostatus unknown 
but presence of HIV risk 
factors
Receptive oral sex with 
ejaculation
Viraemic HIV-positive
iv drug use Exchange of syringe, 
needle, preparation 
material or any other 
material
HIV-positive
• Rapid testing of the source person for HCV and HIV  
(if HIV-status unknown) recommended
• If source person HIV-positive on ART, order resistance testing  
if HIV-VL detectable
• Individualise PEP according to the source’s treatment history and  
previous resistance tests
• For sexual exposure, if HIV-positive source has documented undetectable 
HIV-VL, PEP is no longer recommended.
• PEP to be started ideally < 4 hours after the exposure,  
and no later than 48/72 hours
• Duration of PEP: 4 weeks
• PEP regimens: TDF/FTC (alternative: ZDV/3TC) + RAL bid, or + DRV/r 
qd or + LPV/r bid. TDF/FTC + DTG qd may be also considered as an 
alternative. 
• Full sexual health screen in case of sexual exposure
• Follow-up:
– HIV serology + HBV and HCV, pregnancy test (women)  
within 48 hours of exposure
– Re-evaluation of PEP indication by HIV expert within 48-72 hours
– Assess tolerability of PEP regimen
– Transaminases, HCV-PCR and HCV serology at month 1 if source 
person HCV-positive (observed or suspected)
– Repeat HIV serology after 2 and 4 months, syphilis serology  
after 1 month if sexual exposure
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Pre-exposure Prophylaxis (PrEP)                                       
1. PrEP can be used in adults at high-risk of acquiring HIV infection.  • Before PrEP is initiated, HBV serology status should be documented. 
If HBsAg positive see Clinlical Management and Treatment of HBV 
and HCV Co-infection in HIV-positive Persons.
• Counsel that PrEP does not prevent other types of STD; screen for 
STD (including HCV) when starting PrEP and regularly during use of 
PrEP.
• Counsel that PrEP may impact renal and bone health (see page 45 
and 41). Check renal function and bone mineral density according to 
guidelines on TDF use. 
• Counsel that PrEP, like other prevention methods, only works when it 
is taken. Adherence counselling is recommended.
• Counsel that PrEP can be prescribed long term but that each 
consecutive PrEP prescription should be for a period of maximum 3 
months (90 tablets) to ensure appropriate monitoring.
3.     PrEP regimen
TDF/FTC 300*/200 mg 1 tablet qd. For MSM with high-risk sexual 
behavior PrEP may be dosed ‘on demand’ (double dose of drug 2-24 
hours before each sexual intercourse, followed by two single doses of 
drug, 24 and 48 hours after the first drug intake).  If dosed ‘on demand’, 
the total dose per week should not exceed 7 tablets. 
* In certain countries TDF is labelled as 245 mg rather than 300 mg to
reflect the concentration of the active metabolite.
• Recommended in HIV-negative men who have sex with men (MSM) 
and transgender individuals who are inconsistent in their use of 
condoms with casual partners or with HIV-positive partners who are 
not on treatment. A recent STD or use of post-exposure prophylaxis 
may be markers of increased risk for HIV acquisition.
• May be considered in HIV-negative heterosexual women and men 
who are inconsistent in their use of condoms and likely to have HIV 
positive partners who are not on treatment.
2. PrEP is a medical intervention that may not provide full protection 
against acquiring HIV, does not protect against other STDs and should 
be used in combination with other preventive interventions, including 
the use of condoms.
 PrEP should be supervised by a doctor, experienced with sexual health 
and use of HIV medicines, possibly as part of a shared care arrange-
ment. 
The following procedures are recommended: 
• Documented negative fourth generation HIV test prior to starting PrEP. 
During PrEP, this test should be repeated every 3 months, and PrEP 
should be stopped immediately in case of early clinical signs of HIV se-
roconversion or a positive HIV diagnostic test and the person referred 
for evaluation to an HIV unit.
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Adverse Effects of ARVs & Drug Classes Bold: Frequent effectsRed: Severe effects 
Black: Neither Frequent nor Severe(i)
Skin Digestive Liver CV Musculo-skeletal
Genito-
urinary Nervous Body fat Metabolic Other
NRTIs
ABC Rash* Nausea*
Diarrhoea*
IHD *Systemic 
hyper- 
sensitivity 
syndrome
(HLA 
B*5701 
dependent)
ZDV Nail pigmen-
tation
Nausea Steatosis Myopathy,
Rhabdo- 
myolysis
Lipoatrophy
Dyslipi-
daemia,
Hyperlacta- 
taemia
Anaemia
d4T
Pancreatitis
Steatosis
Peripheral 
neuropathy
Dyslipi-
daemia,
Hyperlacta- 
taemia
ddI Steatosis, 
Liver fibrosis
IHD Hyperlacta- 
taemia
3TC
FTC
TDF(iii) ↓ BMD,  
Osteomalacia
↑ Fractures 
risk
↓ eGFR,
Fanconi  
syndrome
NNRTIs
EFV Rash Hepatitis Depression, 
Sleep  
disturbanc-
es,  
Headache,
Suicidal 
ideation
Dyslipi-
daemia,
Gynaeco-
mastia
↓ plasma 
25(OH) 
vitamin D,  
Teratogen-
esis
ETV Rash
NVP Rash* Hepatitis* *Systemic 
hypersen- 
sitivity (CD4 
count-and 
gender-de-
pendent)
RPV Rash Hepatitis ↓ eGFR(iv) Depression,  
Sleep  
disturbances, 
Headache
PIs
ATV(v)
Nausea
and
Diarrhoea(ii)
Hyperbiliru-
binaemia,
Jaundice,
Cholelithiasis
↓ eGFR, 
Nephrolith-
iasis
Dyslipi-
daemia
DRV(v) Rash Nephrolith-
iasis
Dyslipi-
daemia
FPV(vi) Rash IHD Dyslipi-
daemia
IDV(vi) Dry skin, 
Nail 
dystrophy
Jaundice IHD Nephrolith-
iasis
 ↑ Abdominal 
fat
Dyslipi-
daemia,
Diabetes 
mellitus
LPV IHD ↓ eGFR Dyslipi-
daemia
SQV(vi) Dyslipi-
daemia
TPV(vi) Hepatitis Intracranial 
haemorrhage
Dyslipi-
daemia
Boosting
RTV ↓ eGFR(iv)
COBI ↓ eGFR(iv)
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FI
ENF Injection 
nodules
Hypersensi-
tivity
INSTI
RAL Nausea Myopathy,
Rhabdomy-
olysis
Mood  
changes
DTG Rash Nausea ↓ eGFR(iv) Headache Systemic
hyper-
sensitivity 
syndrome
(<1%)
EVG/c Nausea, 
Diarrhoea
Hyperbiliru-
binemia
↓ eGFR(iv) Headache
CCR5 inhibitor
MVC Hepatitis IHD ↑ Infections 
risk 
i  "Frequent effects" (events expected in at least 10% of treated 
HIV-positive persons), in bold 
 "Severe effects" (events that can put a person's life at risk and represent a 
medical emergency), in red 
 "Neither frequent nor severe effects", in black 
ii  Frequency and severity differs between individual ARVs. 
iii  Tenofovir Disoproxil Fumarate (TDF) has been the classical prodrug of 
tenofovir. A new prodrug named Tenofovir Alafenamide Fumarate (TAF) 
may have a lower risk of tenofovir-related kidney and bone adverse 
effects but long-term experience is lacking. 
iv Due to inhibition of renal tubular creatinine secretion without affecting 
glomerular filtration itself. 
v  ATV can be used unboosted, or boosted with low-dose RTV or COBI. 
ATV-related adverse effects are more common with boosting. DRV can be 
used boosted with low-dose RTV or COBI. Both low-dose RTV and COBI 
as boosters may cause similar minor digestive problems. 
vi Currently available but seldom used. Requires RTV-boosting.
* Refers to effects seen in relation to hypersensitivity reactions.
Note: the adverse effects included in the table above are not exhaustive, but 
represent the most important effects with a likely causal relation. Nausea, 
diarrhoea and rash are frequently observed in persons on ART, and these 
symptoms are indicated in the table for drugs where clinical experience 
suggests a possible causal link. 
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Drug-drug Interactions between ARVs and Non-ARVs(i)
Non-ARV drugs ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL ABC FTC 3TC TDF ZDV
C
ar
di
ov
as
cu
la
r d
ru
gs
atorvastatin ↑ ↑ ↑ ↑490% ↓43% ↓37% ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
fluvastatin ↔ ↑ ↔ ↔ ↑ ↑ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
pravastatin ↔ ↑ ↑81% ↔ ↓44% ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
rosuvastatin ↑213% ↑ ↑48% ↑107% ↔ ↑ ↔ ↔ ↔ ↔ ↑38% ↔ ↔ ↔ ↔ ↔ ↔
simvastatin ↑ ↑ ↑ ↑ ↓68% ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
amlodipine ↑iii ↑ ↑ ↑iii ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
diltiazem ↑iii ↑ ↑ ↑iii ↓69% ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
metoprolol ↑iii ↑ ↑ ↑iii ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
verapamil ↑iii ↑ ↑ ↑iii ↓ ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
warfarin ↑ or ↓ ↑ ↓ ↓ ↑ or ↓ ↑ ↑ or ↓ ↔ ↔ ↔ ↑ or ↓ ↔ ↔ ↔ ↔ ↔ ↔
C
N
S 
dr
ug
s
diazepam ↑ ↑ ↑ ↑ ↓ ↑ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
midazolam (oral) ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
triazolam ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
citalopram ↑iii ↑ ↑ ↑iii ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
mirtazapine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
paroxetine ↑↓? ↑↓? ↓39% ↑↓? ↔ ↔ ↔ ↔ ↔ ↔ ↑↓? ↔ ↔ ↔ ↔ ↔ ↔
sertraline ↓ ↑ ↓49% ↓ ↓39% ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
bupropion ↓ ↔ ↓ ↓57% ↓55% ↔ ↓ ↔ ↔ ↔ ↑? ↔ ↔ ↔ ↔ ↔ ↔
pimozide ↑iii ↑ ↑ ↑iii ↑ ↓ ↓ ↔iv ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
carbamazepine ↑D ↑D ↑ ↑D ↓27%D36% D ↓D D D D D D ↑ ↔ ↔ ↔ ↑ix
lamotrigine ↓32%ii ↔ ↓ii ↓50% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
phenytoin ↓D D ↓D ↓D ↓D D ↓D D D D D D D ↔ ↔ ↔ ↓
A
nt
i-i
nf
ec
tiv
es
clarithromycin ↑iii ↑ ↑ ↑iii ↓ ↓E ↓ E E ↔ ↑E ↔ ↔ ↔ ↔ ↔ D
fluconazole ↔ ↑? ↔ ↔ ↔ E86% E100% E ↔ ↔ ↑? ↔ ↔ ↔ ↔ ↔ E74%
itraconazole ↑E ↑E ↑E ↑E ↓ ↓E ↓61% E E ↔ ↑E ↔ ↔ ↔ ↔ ↔ ↔
rifabutin ↑ ↑D ↑E50% ↑ ↓38% D37% ↑17% D * ↔ ↑D ↔ ↔ ↔ ↔ ↔ ↔
rifampicin D72% D D D D26% D D58% D80% D D54%x D D40% D ↔ ↔ ↔ D47%
voriconazole ↓ ↑E ↓ ↓ ↓E ↑E ↓E E E ↔ ↑E ↔ ↔ ↔ ↔ ↔ ↔
M
is
ce
lla
ne
ou
s
antacids D ↔ ↔ ↔ ↔ ↔ ↔ D ↔ D D D ↔ ↔ ↔ ↔ ↔
PPIs D ↔ ↔ ↔ ↔ ↔ ↔ D ↔ ↔ ↔ E ↔ ↔ ↔ ↔ ↔
H2 blockers D ↔ ↔ ↔ ↔ ↔ ↔ D ↔ ↔ ↔ E ↔ ↔ ↔ ↔ ↔
alfuzosin ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
beclometasone 
inhal.
↑?v ↑?v ↓11% ↑?v ↔ ↔ ↔ ↔ ↔ ↔ ↑v ↔ ↔ ↔ ↔ ↔ ↔
buprenorphine ↑67% ↑ ↑vi ↔ ↓50% ↓25% ↔ ↔ ↔ ↔ ↑35% ↔ ↔ ↔ ↔ ↔ ↔
budesonide inhal. ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
ergot derivatives ↑ ↑ ↑ ↑ ↑ ↑ ↓ E ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
ethinylestradiol ↓vii ↑ ↓ ↓ ↔viii ↔ ↓ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
fluticasone inhal. ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
methadone ↓ii, iii ↑? ↓16% ↓53%iii ↓52% ↑6% ↓≈50% ↓16% ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ E29-
43%
salmeterol inhal. ↑iii ↑ ↑ ↑iii ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sildenafil (erec. 
dys.)
↑ ↑ ↑ ↑ ↓ ↓37% ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
St John's wort D D D D D D D D D D D ↔ ↔ ↔ ↔ ↔ ↔
varenicline ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Comments      
i This table summarizes the drug-drug interactions between HIV therapy and some commonly 
prescribed co-medications as well as the drug-drug interactions of particular clinical relevance. 
This table is not exhaustive. For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, see www.hiv-druginteractions.org 
(University of Liverpool).
Legend      
↑  potential elevated exposure of non-ARV drug
↓  potential decreased exposure of non-ARV drug
↔ no significant effect     
E potential elevated exposure of ARV
D potential decreased exposure of ARV      
 Numbers refer to decreased/increased AUC of non-ARV/ARV drugs as observed in drug 
interactions studies  
ii no PK changes with unboosted PI
iii  ECG monitoring is recommended
iv RPV manufacturer recommends caution when coadministering with another drug susceptible 
to prolong QT interval
v increase in concentration of active metabolite observed with RTV 100 mg bid alone but with-
out significant effect on adrenal function 
  
        
 
vi concentration of parent drug unchanged but concentration of metabolite increased 
vii  increase in ethinylestradiol with unboosted ATV 
viii  no effect on ethinylestradiol but ↓ progestin 
ix  potential haematological toxicity
x   administer DTG at a dose of 50 mg bid in treatment naïve or INSTI naïve  HIV-positive 
persons.  Alternative to rifampicin should be used where possible for INSTI-experienced 
HIV-positive persons with certain INSTI-associated resistance substitutions or clinically 
suspected INSTI resistance
*  no dose adjustment for MVC in absence of PI. With PI (except TPV/r; FPV/r), give MVC 
150 mg bid       
Colour legend 
 no clinically significant interaction expected.
 these drugs should not be co-administered.
 potential interaction which may require a dosage adjustment or close monitoring. 
 potential interaction predicted to be of weak intensity (< 2 fold ↑AUC or < 50% ↓AUC). 
A dosage adjustment is a priori not recommended unless the drug has a narrow 
therapeutic index.  
Note: the symbol (green, amber, red) used to rank the clinical significance of the drug interaction 
is based on www.hiv-druginteractions.org.     
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Antidepressants ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL
SSRI citalopram ↑ a ↑ ↑ ↑ a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
escitalopram ↑ a ↑ ↑ ↑ a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
fluvoxamine ↑ ↑ ↑ ↑ ↔ ↔ E ↔ ↔ ↔ ↑ ↔
fluoxetine ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
paroxetine ↑↓? ↑↓? ↓39% ↑↓? ↔ ↔ ↔ ↔ ↔ ↔ ↑↓? ↔
sertraline ↓ ↑ ↓49% ↓ ↓39% ↓ ↓ ↔ ↔ ↔ ↑ ↔
SNRI duloxetine ↑↓ ↑ ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
venlafaxine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ D ↔ ↑ ↔
TCA amitriptyline ↑a ↑ ↑ ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
clomipramine ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
desipramine ↑a ↑ ↑ ↑5%a ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
doxepin ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
imipramine ↑ a ↑ ↑ ↑ a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
nortriptyline ↑ a ↑ ↑ ↑ a ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
trimipramine ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
TeCA maprotiline ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
mianserine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
mirtazapine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
Others bupropion ↓ ↔ ↓ ↓57% ↓55% ↔ ↓ ↔ ↔ ↔ ↑? ↔
lamotrigine ↓32% ↔ ↓ ↓50% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔
nefazodone ↑ ↑ ↑ ↑ ↓E ↓ E ↓E E E ↔ ↑ ↔
St John's wort D D D D D D D D D Db D ↔
trazodone ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
Legend
↑  potential elevated exposure of the antidepressant       
↓  potential decreased exposure of the antidepressant
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
a  ECG monitoring is recommended       
b  the US Prescribing Information recommends that co-administration 
should be avoided as there are insufficient data to make dosing 
recommendations.
 Numbers refer to decreased AUC of the antidepressant as observed 
in drug-drug interactions studies.
SSRI  selective serotonin reuptake inhibitors 
SNRI serotonin and norepinephrine reuptake inhibitors
TCA  tricyclic antidepressants    
TeCA  tetracyclic antidepressants
Colour legend
 no clinically significant interaction expected.  
 these drugs should not be co-administered. 
 potential interaction, which may require a dosage adjustment or 
close monitoring.  
 potential interaction predicted to be of weak intensity (< 2 fold ↑AUC 
or < 50% ↓AUC).  A dosage adjustment is a priori not recommended. 
Comment
The symbol (red, amber, green) used to rank the clinical significance of the 
drug interaction is based on www.hiv-druginteractions.org (University of 
Liverpool). For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, refer to the above 
mentioned website.       
    
Drug-drug Interactions between Antidepressants and ARVs
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Antihypertensives ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL ABC FTC 3TC TDF ZDV
A
C
E 
in
hi
bi
to
rs
cilazapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
enalapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
lisinopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
perindopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
quinapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
ramipril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
trandolapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
A
ng
io
te
ns
in
 
an
ta
go
ni
st
s
candesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
irbesartan ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
losartan ↓a ↔ ↓a ↓a ↑b ↑b ↔ ↔ ↔ ↔ ↓a ↔ ↔ ↔ ↔ ↔ ↔
olmesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
telmisartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
valsartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
β 
bl
oc
ke
rs
atenolol ↔d ↔ ↔ ↔d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bisoprolol ↑d ↑ ↑ ↑d ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
carvedilol ↑↓d ↑ ↑↓ ↑↓d ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
metoprolol ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
propranolol ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
C
al
ci
um
 c
ha
nn
el
 b
lo
ck
er
s amlodipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
diltiazem ↑c ↑ ↑ ↑e ↓69% ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
felodipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lacidipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lercanidipine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nicardipine ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nifedipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nisoldipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
verapamil ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
D
iu
re
tic
s
amiloride ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bendroflumethiazide ? ? ? ? ? ? ? ↔ ↔ ↔ ? ↔ ↔ ↔ ↔ ↔ ↔
chlortalidone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
furosemide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E ↔
indapamide ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
torasemide ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
O
th
er
s doxazosin ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
spironolactone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Drug-drug Interactions between Antihypertensives and ARVs
Legend
↑  potential elevated exposure of the antihypertensive     
↓  potential decreased exposure of the antihypertensive
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
a  [parent drug] decreased but [active metabolite] increased    
b  [parent drug] increased but [active metabolite] decreased
c  ECG monitoring recommended   
d  risk of PR interval prolongation
e use with caution as both LPV and calcium channel blockers prolong 
the PR interval. Clinical monitoring is recommended.
Numbers refer to decreased AUC of the antihypertensive as observed in 
drug-drug interactions studies.
Colour legend
 no clinically significant interaction expected.  
 these drugs should not be co-administered. 
 potential interaction, which may require a dosage adjustment or 
close monitoring.  
 potential interaction predicted to be of weak intensity (< 2 fold ↑AUC 
or < 50% ↓AUC).  A dosage adjustment is a priori not recommended.
 
Note: although some drug interactions are predicted to potentially require a 
dosage adjustment based on the drug's metabolic pathway, clinical 
experience with a particular antihypertensive and ARV drug may indicate 
that dosage adjustments are not an a priori requirement.    
Comment
The symbol (red, amber, green) used to rank the clinical significance of the 
drug interaction is based on www.hiv-druginteractions.org (University     
of Liverpool). For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, refer to the
above mentioned website.       
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Analgesics ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL ABC FTC 3TC TDF ZDV
N
on
-o
pi
oi
d 
an
al
ge
si
cs
aspirin ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ h ↔
celecoxib ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ h ↔
diclofenac ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eh ↔
ibuprofen ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eh ↔b
mefenamic acid ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eh ↔
naproxen ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eh ↔b
nimesulide ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ h ↔
paracetamol ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
piroxicam ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ h ↔
O
pi
oi
d 
an
al
ge
si
cs
alfentanil ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
buprenorphine ↑67% ↑ ↑c ↔ ↓50% ↓25% ↔ ↔ ↔ ↔ ↑35% ↔ ↔ ↔ ↔ ↔ ↔
codeine ↑e ↑e ↑e ↑e ↓ e ↓ e ↓ e ↔ ↔ ↔ ↑e ↔ ↔ ↔ ↔ ↔ ↔
dihydrocodeine ↓↑ ↑ ↓↑ ↓↑ ↓↑ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
fentanyl ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
methadone ↓d ↑? ↓16% ↓53%d ↓52% ↑6% ↓≈50% ↓16%d ↔ ↔ ↑7% ↔ ↓ ↔ ↔ ↔ E
morphine ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
oxycodone ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
pethidine ↓f ↑ ↓f ↓f ↓f ↓f ↓f ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sufentanil ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
tramadol ↑e ↑e ↑e ↑e ↓g ↔ ↔ ↔ ↔ ↔ ↑e ↔ ↔ ↔ ↔ ↔ ↔
Drug-drug Interactions between Analgesics and ARVs
Legend
↑  potential elevated exposure of the analgesic   
↓  potential decreased exposure of the analgesic
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
a     clinical significance unknown. Use the lowest recommended dose 
particularly in HIV-positive persons with risk factors for cardiovascular 
disease, those HIV-positive persons at risk of developing gastrointestinal 
complications, HIV-positive persons with hepatic or renal impairment, 
and in elderly HIV-positive persons.
b  potential additive haematological toxicity
c  [parent drug] unchanged but [metabolite] increased
d  both drugs can potentially prolong the QT interval, ECG monitoring 
recommended
e  potential decrease of the analgesic effect due to the reduced conversion 
to the active metabolite
f  [parent drug] decreased and increase [neurotoxic metabolite];
g  [parent drug] decreased but no change [more active metabolite]. 
h    potential risk of nephrotoxicity which is increased if NSAID is used for 
a long duration, if the HIV-positive person has a pre-existing renal 
dysfunction, has a low body weight or receives other drugs that may 
increase TDF exposure. Concurrent use of NSAIDs with TDF warrants 
monitoring of renal function. Numbers refer to increased or decreased 
AUC of the analgesic as observed in drug-drug interactions studies.
 
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential interaction which may require a dosage adjustment or close 
monitoring  
 potential interaction predicted to be of weak intensity (< 2 fold ↑AUC 
or < 50% ↓AUC).  A dosage adjustment is a priori not recommended
Comment             
The symbol (red, amber, green) used to rank the clinical significance of 
the drug interaction is based on www.hiv-druginteractions.org (University 
of Liverpool). For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, refer to the above 
mentioned website.
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Drug-drug Interactions between Contraceptives/Hormone Therapy Replacement 
Treatment and ARVs  
ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL ABC FTC 3TC TDF ZDV
Es
tr
o-
ge
ns
ethinylestradiol ↓19%a ↑ ↓44%b ↓42%b ↔d ↑22% ↓20%b ↑14% ↔ ↑3% ↓25%e ↔ ↔ ↔ ↔ ↔ ↔
estradiol ↓f ↑ ↓f ↓f ↓f ↓f ↓f ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
Pr
og
es
tin
s
desogestrel ↑g,h ↑g,n ↑g,h ↑g,h ↓i ↓i ↓i ↔ ↔ ↔ ↑g,h ↔ ↔ ↔ ↔ ↔ ↔
drospirenone ↑h ↑h,n ↑h ↑h ↓i ↓i ↓i ↔ ↔ ↔ ↑h ↔ ↔ ↔ ↔ ↔ ↔
dydrogesterone ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
etonogestrel ↑h ↑n ↑h ↑52%h ↓63%c ↓c ↓c ↔ ↔ ↔ ↑h ↔ ↔ ↔ ↔ ↔ ↔
gestodene ↑h ↑n ↑h ↑h ↓i ↓i ↓i ↔ ↔ ↔ ↑h ↔ ↔ ↔ ↔ ↔ ↔
levonorgestrel ↑h ↑n ↑h ↑h ↓c ↓c ↓c ↔ ↔ ↔ ↑h ↔ ↔ ↔ ↔ ↔ ↔
medroxypro-
gesterone (IM)
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
medroxypro-
gesterone (oral)
↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
norelgestromin ↑j ↑n ↑j ↑83%j ↓i ↓i ↓i ↔ ↔ ↔ ↑j ↔ ↔ ↔ ↔ ↔ ↔
norethisterone ↓i,k ↑n ↓14%i ↓17%i ↓i ↓5% ↓19%i ↓ 11% ↔ ↔ ↑h ↔ ↔ ↔ ↔ ↔ ↔
norgestimate ↑85%h ↑n ↑h ↑h ↓i ↓i ↓i ↔ ↔ ↔ ↑126%h ↑14% ↔ ↔ ↔ ↔ ↔
norgestrel ↑h ↑n ↑h ↑h ↓i ↓i ↓i ↔ ↔ ↔ ↑h ↔ ↔ ↔ ↔ ↔ ↔
O
th
er
levonorgestrel 
(EC)
↑ ↑ ↑ ↑ ↓58%l ↓l ↓l ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
mifepristone ↑ ↑ ↑ ↑ ↓ ↓ ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
ulipristal ↑ ↑ ↑ ↑ ↓m ↓m ↓m ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑  potential increased exposure of the hormone  
↓  potential decreased exposure of the hormone
↔  no significant effect    
D  potential decreased exposure of HIV drug
E  potential elevated exposure of HIV drug
a     unboosted ATV increased ethinylestradiol AUC by 48%. Use no more 
than 30 microgram of ethinylestradiol if co-administered with unboosted 
ATV and at least 35 microgram of ethinylestradiol if co-administered with 
ATV/r
b  alternative or additional contraceptive measures are recommended or, 
if used for hormone replacement therapy, monitor for signs of oestrogen 
deficiency
c  the use of implants or vaginal rings is not recommended in women on 
long-term treatment with hepatic enzyme inducing drugs
d  no effect on ethinylestradiol exposure, however levels of co-adminis-
tered progestin were markedly decreased. A reliable method of barrier 
contraception must be used in addition to oral contraception
e  European SPC states a hormonal contraceptive should contain at least 
30 microgram ethinylestradiol
f  monitor for signs of oestrogen deficiency  
g  increased conversion to active metabolite etonogestrel 
h     when used in combined pill, oestrogen component is reduced. Given the 
lack of clinical data on the contraceptive efficacy, caution is recommend-
ed and additional contraceptive measures should be used
i      a reliable method of barrier contraception should be used in addition to 
oral contraception
j      norelgestromin is combined with ethinylestradiol and administered as 
transdermal patch. Ethinylestradiol was shown to be reduced which may 
compromise the contraceptive efficacy, caution is recommended and  
additional contraceptive measures should be used;  
k  unboosted ATV increased norethisterone AUC by 2.1 fold
l      use 3 mg as single dose for emergency contraception. Of note: the 
doubling of the standard dose is outside the product licence and there is 
limited evidence in relation to efficacy
m    may reduce the efficacy of the emergency contraceptive pill
n     since no data are available to make recommendations on the use of 
DRV/c with combined or progestagen only oral or implanted contracep-
tives, alternative forms of contraception should be used.
       Numbers refer to increased or decreased AUC of the non HIV drug as 
observed in drug-drug interaction studies
 Comment: transdermal application: first-pass metabolism avoided how-
ever hepatic metabolism still occurs and therefore there is a risk of DDI.
       Intrauterine administration: hormone (i.e. levonorgestrel)  is released 
directly to the target organ before it is absorbed into the systemic circu-
lation and therefore less likely to be affected by ARVs.
Colour legend
 no clinically significant interaction expected.  
 these drugs should not be co-administered. 
 potential interaction which may require a dosage adjustment or close 
monitoring.  
 potential interaction predicted to be of weak intensity (< 2 fold ↑ AUC 
or < 50% ↓ AUC). No a priori dosage adjustment is recommended. 
Comment             
The symbol (red, amber, green) used to rank the clinical significance of 
the drug interaction is based on www.hiv-druginteractions.org (University 
of Liverpool). For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, refer to the above 
mentioned website.
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Drug-drug Interactions between Corticosteroids and ARVs 
Corticosteroids ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL ABC FTC 3TC TDF ZDV
In
ha
le
d,
 o
ra
l, 
to
pi
c 
an
d/
or
 in
je
ct
ed
 c
or
tic
os
te
ro
id
s
beclometasone 
(inhalation)
↑a ↑?a ↓b ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↑a ↔ ↔ ↔ ↔ ↔ ↔
betamethasone ↑c ↑c ↑c ↑c ↓ ↓ ↓ D D ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
budenoside 
(inhalation)
↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
clobetasol 
(topical)
↑c,d ↑c,d ↑c,d ↑c,d ↔ ↔ ↔ ↔ ↔ ↔ ↑c,d ↔ ↔ ↔ ↔ ↔ ↔
dexamethasone ↑c D ↑c D ↑c D ↑c D ↓ D ↓ D ↓ D D D ↔ ↑c D ↔ ↔ ↔ ↔ ↔ ↔
fluocinolone 
(topical)
↑c,d ↑c,d ↑c,d ↑c,d ↔ ↔ ↔ ↔ ↔ ↔ ↑c,d ↔ ↔ ↔ ↔ ↔ ↔
fluticasone 
(inhalation)
↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
hydrocortisone 
(oral)
↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
hydrocortisone 
(topical)
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
methylpredni-
solone
↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
mometasone 
(inhalation)
↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
prednisolone 
(oral)
↑c ↑c ↑c ↑c ↓ 40% ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
prednisone ↑c ↑c ↑c ↑c ↓ 40% ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
triamcinolone ↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑  potential increased exposure of the corticosteroid 
↓  potential decreased exposure of the corticosteroid
↔  no significant effect    
D  potential decreased exposure of HIV drug
E  potential elevated exposure of HIV drug
a     co-administration of RTV (100 mg bid) increased the concentrations of 
the active metabolite (beclometasone-17-monopropionate) but no signifi-
cant effect on adrenal function was seen. Caution is still warrented, use 
the lowest possible corticosteroid dose and monitor for corticosteroid 
side effects
b  DRV/r decreased the exposure of active metabolite (beclometa-
sone-17-monopropionate), no significant effect on adrenal function was 
seen
c  risk of having elevated corticosteroid levels, Cushing's syndrome and 
adrenal suppression. This risk is present for oral, injected but also for 
topical, inhaled or eye drops corticosteroid
d  the extent of percutaneous absorption is determined by many factors 
such as degree of inflammation and alteration of the skin, duration, 
frequency and surface of application, use of occlusive dressings
 
Colour legend
 no clinically significant interaction expected. 
 these drugs should not be co-administered. 
 potential interaction which may require a dosage adjustment or close 
monitoring. 
Comment             
The symbol (red, amber, green) used to rank the clinical significance of the 
drug interaction is based on www.hiv-druginteractions.org (University     
of Liverpool). For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, refer to the   
above mentioned website.           
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Drug-drug Interactions between Antimalarial Drugs and ARVs
Mefloquine (M)
Metabolism CYP 3A4
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ No
RPV, RAL, MVC, DTG → No
PI, COBI ↑ M may reduce PI/c (RTV ca. 35%) Potential
Artemisinins (A)
Artemisinins and its key metabolite, dihydroartemisinin, are active compounds
Metabolism CYP 2B6, 3A4, 2C19
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ A & dihydroartemisinin; 
A & metabolites reduce NVP, but not EFV/ETR
Do not use or 
use with caution
RPV, RAL, MVC, DTG → A may reduce RPV, MVC Potential
PI, COBI ↑ Increase A: monitor toxicity (liver) Potential
Lumefantrin (L)
Metabolism CYP 3A4
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ Potential
RPV, RAL, MVC, DTG → No
PI, COBI ↑ LPV increases L 2-3x Do not use or
use with caution
Atovaquone (At), Proguanil (P)
• Atovaquone increases ZDV levels by 35%
• Synergy with atovaquone is related to proguanil, not its active metabolite; therefore presumably no net  
effect of induction/inhibition
Metabolism CYP 2C19
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ ETV is increased Potential  
RPV, RAL, MVC, DTG → No
PI, COBI ↓ At & P 
take with fat meal, consider dose increase
Potential
Doxycycline
Metabolism NA
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) possibly ↓ Potential
RPV, RAL, MVC, DTG → No
PI, COBI → No
Chloroquine
Metabolism CYP 3A4, 2D6
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) → No
RPV, RAL, MVC, DTG → No
PI, COBI → No
Effect of ARVs on antimalarial drugs and key metabolite
Legend: 
Arrows indicate effect of antiretrovirals on antimalarial drug/key metabolite
Green no clinically significant interaction expected
Orange potential interaction (consider treatment ahead of travel and therapeutic drug monitoring)
Red clinically relevant interaction, do not use or use with caution
EACS   European
AIDS Clinical Society
25EACS Guidelines 8.0 PART II
Quinine (Q)
Metabolism CYP 3A4, 2D6
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ Consider dose increase Potential
RPV, RAL, MVC, DTG → No
PI, COBI ↑ RTV increases Q 4x: consider
dose reduction, monitor toxicity
(tinnitus). CAVE: PI & Q prolong QT
Potential
Primaquine
Metabolism CYP 1A2, 2D6, 3A4
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) N/A Potential
RPV, RAL, MVC, DTG → No
PI, COBI N/A
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NRTIs
ABC Child-Pugh Class A: 200 mg bid (use oral solution)
Child-Pugh Class B or C: Contraindicated
ddI Contraindicated
If used no dosage adjustment
d4T Contraindicated
If used no dosage adjustment
FTC No dosage adjustment
3TC No dosage adjustment
TDF No dosage adjustment
TDF/FTC No dosage adjustment
ZDV Reduce dose by 50% or double the interval between
doses if Child-Pugh Class C
NNRTIs
EFV No dosage adjustment; use with caution in persons 
with hepatic impairmentTDF/FTC/EFV
ETV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
NVP Child-Pugh Class B or C: contraindicated
RPV Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data
PIs
ATV Child-Pugh Class B: 300 mg qd
Child-Pugh Class C: not recommended
RTV boosting is not recommended in persons with
hepatic impairment (Child-Pugh Class B or C)
DRV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
FPV PI-naïve persons:
Child-Pugh Class A or B: 700 mg bid
Child-Pugh Class C: 350 mg bid
PI-experienced persons:
Child-Pugh Class A: 700 mg bid + RTV 100 mg qd
Child-Pugh Class B: 450 mg bid + RTV 100 mg qd
Child-Pugh Class C: 300 mg bid + RTV 100 mg qd
IDV Child-Pugh Class A or B: 600 mg q8h
Child-Pugh Class C: no data
LPV/r No dosage recommendation; use with caution in
persons with hepatic impairment
RTV Refer to recommendations for the primary PI
SQV Child-Pugh Class A or B: use with caution
Child-Pugh Class C: contraindicated
TPV Child-Pugh Class A: use with caution
Child-Pugh Class B or C: contraindicated
FI
ENF No dosage adjustment
CCR5 Inhibitor
MVC No dosage recommendations. Concentrations will
likely be increased in persons with hepatic impairment
INSTI
RAL No dosage adjustment
EVG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
DTG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TDF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
ABC/3TC/DTG Use separate compounds and refer to those adjust-
ments 
Note: Hepatic dysfunction is a good indication for TDM as clinical experience 
with these dose adjustments is very limited.
Dose Adjustment of ARVs for Impaired Hepatic Function
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Dose Adjustment of ARVs for Impaired Renal Function
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
NRTIs
ABC  300 mg q12h
No dose adjustment required
 
 
ddI(ii) ≥ 60 kg 400 mg q24h 200 mg q24h 150 mg q24h 100 mg q24h 100 mg q24h(iv)
< 60 kg 250 mg q24h 125 mg q24h 100 mg q24h 75 mg q24h 75 mg q24h(iv)
d4T                   ≥ 60 kg 30 mg q12h 15 mg q12h 15 mg q24h 15 mg q24h 15 mg q24h(iv)
< 60 kg 40 mg q12h 20 mg q12h 20 mg q24h 20 mg q24h 20 mg q24h(iv)
FTC 200 mg q24h 200 mg q48h 200 mg q72h 200 mg q96h 200 mg q96h(iv)
3TC 300 mg q24h 150 mg q24h 100 mg q24h(iii) 50-25 mg q24h(iii) 50-25 mg q24h(iii), (iv)
TDF(v)
300(viii) mg q24h 300(viii) mg q48h
Not recommended Not recommended
300(viii) mg q7d(iv)(300(viii) mg q72-96h, 
if no alternative)
(300(viii) mg q7d, if 
no alternative)
ZDV 300 mg q12h No dose adjustment 
required
100 mg q8h 100 mg q8h(iv)
ABC/3TC 600/300 mg q24h
Use individual drugsZDV/3TC 300/150 mg q12h
ABC/3TC/ZDV 300/150/300 mg 
q12h
TDF/FTC 300(viii)/200 mg q24h 300(viii)/200 mg q48h Use individual drugs
NNRTIs
EFV 600 mg q24h              No dose adjustment required
ETV 200 mg q12h              No dose adjustment required
NVP 200 mg q12h              No dose adjustment required
TDF/FTC/RPV 300(viii)/200/25 mg 
q24h
Do not use
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
PIs(v)
ATV/r 300/100 mg q24h No dose adjustment required(vi)
DRV/r 800/100 mg q24h
600/100 mg q12h No dose adjustment required
(vi)
DRV/c 800/150 mg q24h No dose adjustment required(vi)
FPV/r 700/100 mg q12h No dose adjustment required(vi)
LPV/r 400/100 mg q12h No dose adjustment required(vi)
SQV/r 1000/100 mg q12h No dose adjustment required(vi)
TPV/r 500/200 mg q12h No dose adjustment required(vi)
Other ART
RAL 400 mg q12h No dose adjustment required(vi)
DTG 50 mg q24h No dose adjustment No clinical data; PK 
data suggest safety
ABC/3TC/DTG 600/300/50 mg q24h Use individual drugs
TDF/FTC/EVG/c Do not initiate if eGFR < 70 mL/min Discontinue if eGFR < 50 mL/min
MVC: co-administered
without CYP3A4
inhibitors(vii)
300 mg q12h No dose adjustment required
MVC: co-administered 
with CYP3A4 inhibitors(vii)
If eGFR < 80 mL/min 150 mg q24h(vii)
except: 150 mg q12h if co-administered  
with FPV/r
i  eGFR:  Use CKD-EPI formula; the abbreviated modification of diet in renal 
disease (aMDRD) or the Cockcroft-Gault (CG) equation may be used as 
an alternative; see http://www.hivpv.org/
ii  Dose reduction if combined with TDF 
iii  150 mg loading dose 
iv  After dialysis
v  TDF and (boosted) PIs are associated with nephrotoxicity; consider 
alternative ART if pre-existing CKD, risk factors for CKD and/or decreasing 
eGFR, see ARV-associated Nephrotoxicity and Kidney Disease: Definition, 
Diagnosis and Management
vi  Limited data available in persons with renal impairment; pharmacokinetic 
analysis suggests no dose adjustment required
vii  See summary of product characteristics for specific recommendations; use 
with caution if eGFR < 30 mL/min
viii In certain countries TDF is labelled as 245 mg rather than 300 mg to reflect 
the concentration of the active metabolite 
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Drug Formulation Crushtablets
Open 
capsules Comment
NRTIs
ABC tablet (300 mg)
solution 20 mg/mL
yes Bitter taste. Crushed tablets can be added to small amount of semi-solid 
food or liquid, all of which should be consumed immediately
d4T capsule (20, 30, 40 mg)
oral solution 1 mg/mL
no yes Take on empty stomach
FTC capsule (200 mg)
solution 10 mg/mL
no yes Dissolve in ≥ 30 mL of water, contains Na 460 µmol/mL
Bioequivalence: 240 mg solution = 200 mg capsule; adjust dosage 
accordingly
3TC tablet (150, 300 mg)
solution 10 mg/mL
yes Crushed tablets can be added to small amount of semi-solid food or liquid, 
all of which should be consumed immediately
TDF tablet (300(i) mg) yes Better: dissolve in ≥ 1 dL of water/orange or grape juice (bitter taste)
ZDV capsule (250 mg) no no Sticky, bitter taste
syrup 10 mg/mL Better: use syrup or iv 6 mg/kg per day in glucose 5%
TDF/FTC tablet (300(i)/200 mg) yes Better: dissolve in ≥ 1 dL of water/orange or grape juice (bitter taste)
ABC/3TC tablet (600/300 mg) no Use solution of individual compounds
ZDV/3TC tablet (300/150 mg) yes Disperse in ≥ 15 mL water, alternative: use solution of individual compounds
ABC/3TC/ZDV tablet (300/150/300 mg) no Use solution of individual compounds
NNRTIs
EFV tablet (600 mg) yes Difficult to dissolve; solution has lower bioavailability; if > 40 kg use 720 mg
capsule (50, 100, 200 mg) no yes
solution 30 mg/mL
ETV tablet (200 mg) no Disperse in ≥ 5 mL water. The glass should be rinsed with water several
times and each rinse completely swallowed to ensure the entire dose is 
consumed.
NVP tablet (200, 400 mg(ii)) 
suspension 10 mg/mL
yes(ii) Dissolve in water
TDF/FTC/EFV tablet (300(i)/200/600 mg) no
TDF/FTC/RPV tablet (300(i)/200/25 mg) no Crushing of tablets and dispersion into a liquid is not recommended. RPV is 
insoluble in water over a wide pH range.
PIs
ATV capsule (150, 200, 300 mg) no yes Difficult to open; take with food
DRV tablet (75,150, 400, 600, 
800 mg)
solution 100 mg/mL
yes Take with food. Crushed tablets can be added to small amount of semi-solid 
food or liquid, all of which should be consumed immediately
DRV/c tablet (800/150 mg) no
FPV tablet (700 mg)
suspension 50 mg/mL
Bitter taste; adults take suspension on empty stomach
LPV/r tablet (200/50 mg)
solution (80/20 mg/mL)
no 42% alcohol, do not dilute with water (risk of precipitation), rinse with milk
(no water); take with food, bitter taste: dilute with chocolate milk
RTV tablet (100 mg)
solution (80 mg/mL)
no 43% alcohol, do not dilute solution (risk of precipitation), rinse with milk (no
water); bitter taste; take with food
SQV tablet (500 mg) no
Others
DTG tablet (50 mg) Yes Tablets may be split or crushed and added to a small amount of semi-solid 
food or liquid, all of which should be consumed immediately
MVC tablet (150, 300 mg) yes While the company does not have any specific kinetic information, crushing 
the tablet is not expected to negatively affect the bioavailability
RAL(iii) tablet (400 mg)
chewable tablets (25, 100 
mg)
yes  The bioavailability of the chewable tablet is higher: 300 mg chewable tablet 
(= 400 mg film-coated tablet)
TDF/FTC
EVG/c
tablet (300(i)/200/150/150 
mg)
no Crushing of tablets and dispersion into a liquid is not recommended. EVG/c 
is practically insoluble in water
ABC/3TC/DTG tablet (600/300/50 mg) yes Tablets may be split or crushed and added to a small amount of semi-solid 
food or liquid, all of which should be consumed immediately
Administration of ARVs in Persons with Swallowing Difficulties
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Drug Formulation Crushtablets
Open 
capsules Comment
Prophylaxis/treatment of opportunistic infections
azithromycin tablet (250, 500 mg)
suspension 40 mg/mL
no
cotrimoxazole tablet (400/80 mg, forte
800/160 mg)
solution 40/8 mg per mL
yes; forte 
difficult
Dilute solution 3-5 times with water (high osmolality)
fluconazole capsule (50, 200 mg)
suspension 40 mg/mL
no yes
pyrimethamine tablet (25 mg) yes Take with food
valganciclovir tablet (450 mg)
solution 50 mg/mL
no no Difficult to dissolve
rifampicin tablet (450, 600 mg) yes Take on empty stomach
capsule (150, 300 mg) no yes
suspension 20 mg/mL
rifabutin capsule (150 mg) no yes Mix with apple sauce, syrup (insoluble in water)
isoniazid tablet (100, 150 mg) yes Take on empty stomach
pyrazinamide tablet (500 mg) yes
ethambutol tablet (100, 400 mg) yes Difficult to dissolve
Better: use iv solution
rifampicin/isoniazid tablet (150/100, 150/75 mg) yes Take on empty stomach
Rifater (rifampicin,
isoniazid,
pyrazinamide)
tablet (120/50/300 mg) yes Take on empty stomach
Rimstar (rifampicin,
isoniazid,
pyrazinamide,
ethambutol)
tablet (150/75/400/275 mg) yes Take on empty stomach
ribavirin capsule (200 mg) no yes Disperse in orange juice, take with food
       For recommendations on prophylaxis/treatment of opportunistic infec-
tions, see Part V Opportunistic Infections
i In certain countries TDF is labelled as 245 mg rather than 300 mg to 
reflect the concentration of the active metabolite
ii Extended release effect lost. Note: NVP 400 mg qd (immediate release) 
can lead to sub-therapeutic trough levels in individuals with higher body 
weight (≥ 90 kg) compared to NVP 200 mg bid. 
       Therefore, NVP bid administration should be preferred in individuals with 
higher body weight. 
iii     Crushing tablets is not recommended in the product information howev-
er absorption of RAL was not compromised when the drug was crushed, 
dissolved in 60 mL warm water and administered by gastrostomy tube 
[9]. In addition, RAL drug absorption has been shown to be higher in 
HIV-positive persons taking RAL 400 mg bid by chewing the tablets as 
compared to swallowing the intact tablets [10].
EACS   European
AIDS Clinical Society
30EACS Guidelines 8.0 PART III
Part III Prevention and Management of
Co-morbidities in HIV-positive Persons
The appropriate management of co-morbidities, which include cardiovascular, pulmonary, hepatic, metabolic, neoplastic, renal, bone, central nervous sys-
tem disorders as well as sexual dysfunction, has increasingly become an integral part of the overall management of individuals living with HIV. 
Potential contributors to co-morbidity pathogenesis include a higher prevalence of recognised risk factors, ART-exposure and toxicity, HIV itself as well as 
immune dysfunction/dysregulation and chronic immune activation/inflammation, associated with HIV or other co-infections (e.g. CMV, HCV).
Health care professionals other than HIV specialists, who are involved in the care of HIV-positive persons and who are not familiar with the use of ART, 
should consult their HIV specialist colleagues before introducing or modifying any type of medicines for co-morbidity. As intervals between visits to HIV-clin-
ics are increasingly extended, HIV-positive persons can be expected to seek care more frequently with their primary care physician. In these situations, it is 
important to ensure some level of shared-care arrangement.   
Conversely, many HIV physicians are not specialists in managing co-morbidities, and should seek expert advice where appropriate in the prevention and 
management of such conditions. Situations where consultation is generally recommended are indicated elsewhere in this document. 
As individuals with treated HIV age, complex multiple co-morbidities often co-exist in the same person and may be associated with frailty and disability. 
Such circumstances may require a comprehensive “geriatric-type” multidimensional, multidisciplinary assessment aimed at appropriately capturing the 
composite of medical, psychosocial and functional capabilities and limitations of elderly HIV-positive persons. 
Depending on future clinical research findings, these recommendations will be regularly updated as required. The online version at www.eacsociety.org and 
the EACS Guidelines App contain more detailed information and links to other relevant websites; these will be regularly updated. 
The current recommendations highlight co-morbidities that are seen frequently in the routine care of HIV-positive persons and those for which specific 
issues should be considered. 
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Drug Dependency and Drug Addiction
Characteristics of drugs used as opioid substitution therapy (OST)(i)
Feature Methadone Buprenorphine
Dose required to prevent withdrawal  
symptoms according to degree of opioid 
dependency
Linear relationship (from 10-300 mg per day) Linear relationship for persons with less opioid 
dependency only – ceiling effect (max daily dose 
24 mg)
Interaction with ARVs Methadone plasma concentrations are reduced if 
used together with NNRTIs or PIs:
• NVP & EFV: ↓ 50%
• ETV: ↓ < 10%(ii)
• LPV/r: ↓ 50%
• SQV/r, DRV/r, FPV/r: ↓ 15-25%
• ATV, IDV: ↓ < 10%
Buprenorphine (B) and active
metabolite norbuprenorphine (N)
plasma concentrations are reduced if
combined with NNRTIs and increased
if combined with some PIs 
• EFV: ↓ up to 50% (B) and 70% (N)
• ATV/r, IDV, SQV/r: ↑ 50-100% (B&N)
• DRV/r: ↑ 50% (N)
• CAVE: B reduces ATV; do not use without 
RTV or COBI boosting
CAVE: withdrawal symptoms if combined with ARV that decreases plasma concentration and risk of 
drug toxicity if such ARVs are interrupted – reverse if ARVs increase plasma concentration
Risk of overdose Yes No if used as a co-formulation with naloxone 
Causing QT prolongation on ECG Yes (dose-response relationship)(iii) No
Risk of obstipation High High
Type of administration Tablet or liquid Tablet applied sublingual
Risk of further impairment in persons with 
existing liver impairment
Yes Yes
i  See Drug-drug Interactions between Analgesics and ARVs 
ii  Note that despite ETV causes a decrease in the plasma concentration of 
methadone, the active methadone enantiomer is in fact increased 6% by 
ETV. 
iii  ECG recommended for daily methadone doses exceeding 50 mg; 
special caution with concomitant use of other drugs known to cause QT 
prolongation (e.g. certain PIs such as SQV/r as well as albuterol (USAN) 
or salbutamol (INN), amiodarone, amitriptyline, astemizole, chloroquine, 
clomipramine and moxifloxacin).
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Cancer: Screening Methods(i)
Problem Persons Procedure Evidence of benefit Screening interval Additional comments
Anal cancer MSM Digital rectal exam
± anal cytology 
Unknown; advocated by 
some experts
1-3 years If anal cytology abnor-
mal, anoscopy
Breast cancer Women 50-70 years Mammography ↓ Breast cancer mor-
tality 
1-3 years
Cervical cancer Sexually active women Liquid based cervical 
cytology test
↓ Cervical cancer 
mortality 
1-3 years Target age group should
include the 25 to 64 
years at least. HPV test-
ing may aid screening
Colorectal cancer Persons 50-75 years Faecal occult blood test ↓ Colorectal cancer 
mortality 
1-3 years Flexible sigmoidsco-
py at 55-years is an 
alternative
Hepatocellular  
carcinoma 
Persons with cirrhosis 
& Persons with HBV 
irrespective of fibrosis 
stage
Ultrasound and alpha-
foetoprotein
Earlier diagnosis allow-
ing for improved ability 
for surgical eradication
Every 6 months
Prostate cancer Men > 50 years Digital rectal exam
± prostate specific 
antigen (PSA)
Use of PSA is contro-
versial 
1-3 years Pros: ↑ early diagnosis. 
Cons: overtreatment; 
ambiguity about size 
of ↓ cancer-related 
mortality
i  Screening recommendations derived from the general population.
 These screenings should preferably be done as part of national general 
population-screening programmes. Although non-Hodgkin’s lymphoma 
has a higher incidence in HIV-positive persons than in the general popula-
tion, it is currently unknown whether it can be screened.
 Careful examination of skin should be performed regularly to detect 
cancers such as Kaposi’s sarcoma, basal cell carcinoma and malignant 
melanoma.
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Dietary  
counselling
• Dietary intervention should not interfere with the dietary 
requirements necessary for appropriate absorption of 
ART drugs
• Keep caloric intake balanced with energy expenditure
• Limit intake of saturated fat, cholesterol and refined 
carbohydrates
• Reduce total fat intake to < 30% and dietary cholesterol 
to < 300 mg/day
• Emphasise intake of vegetables, fruit and grain products 
with fibre
• Cut back on beverages and foods with added sugar 
• Choose and prepare foods with little or no salt. Aim to 
eat less than 1,500 mg of sodium per day 
• Emphasise consumption of fish, poultry (without skin) 
and lean meat
• Consider referral to dietician, one-week food and drink 
diary to discover ‘hidden’ calories
• Avoid binge eating (‘yo-yo dieting’)
• In persons with HIV-related wasting and dyslipidaemia, 
address wasting first and consider referral to dietician
• Persons who are obviously overweight should be motiva-
ted to lose weight. Starvation diets are not recommended 
(immune defence mechanisms potentially decreased). 
Malnutrition has to be addressed where observed. 
Normal BMI range: 18.5-24.9; Overweight: 25.0-29.9, 
Obesity: > 30.0 kg/m2
Lifestyle Interventions(i)
• The following questions are helpful to determine average 
alcohol intake 
1.  How often do you drink alcohol: never, ≤ 1/month, 
 2-4x/month, 2-3x/week, > 4x/week 
2. If you drink alcohol, how much typically at a time:  
 1-2, 3-4, 5-6, 7-9, > 10 drinks 
3. How many times do you have 6 or more alcoholic  
 drinks at one occasion: never, < 1/month, 1x/month,  
 1x/week, more or less daily.
• Intake of alcohol should be restricted to no more than 
one drink per day for women and two drinks per day for 
men (< 20-40 g/day).
• In particular, persons with hepatic disease, adherence 
problems, inadequate CD4 cell increase, tumours, past 
tuberculosis, diarrhoea and other conditions associated 
with high alcohol intake should be motivated to decrease 
or stop alcohol intake.    
Exercise 
promotion
• Promote active lifestyle to prevent and treat obesity, 
hypertension and diabetes
• Encourage self-directed moderate level physical activity 
(take the stairs, cycle or walk to work, cycling, swimming, 
hiking etc.) 
• Emphasise regular moderate-intensity exercise rather 
than vigorous exercise 
• Achieve cardiovascular fitness (e.g. 30 minutes brisk 
walking > 5 days a week) 
• Maintain muscular strength and joint flexibility 
i  Based on recommendations by the US Preventive Services Task Force 
 
Is the HIV-positive person an active smoker?
Yes No
Brief clear statement about the need to 
stop smoking
Explain the health consequences of smok-
ing and the benefits of quitting
Encourage contin-
ued abstinence
Is the person willing to quit?
Yes No
Pharmacotherapy(i) Cognitive-behav-ioural counselling(ii)
Motivational strat-
egy(iii). Encourage 
smoking reduction
Adapted from [6] and [7] 
i  Pharmacotherapy: Nicotine replacement therapy: Nicotine substitution (patch, chewing gum, spray), varenicline and bupropion are approved by the EMA. 
Buproprion is contraindicated with epilepsy and varenicline may induce depression. Bupropion may interact with PIs and NNRTIs, see Drug-drug Interac-
tions between ARVs and Non-ARVs 
ii  Cognitive-behavioral counselling: Use specific available resources. Either individual or group interventions to better suit and satisfy the HIV-positive per-
son. The programme should consist of four or more sessions lasting 30 minutes for 3-4 months. 
iii  Motivational strategy: Identify potential health risks of the smoker and to stratify both acute (e.g. exacerbations of COPD) and long-term (e.g. infertility, 
cancer) risks. Show the HIV-positive person the personal benefits of stopping smoking. Identify the barriers or obstacles that might impede the success 
of a quit attempt. Smoking cessation interventions should be delivered repeatedly, as long as the HIV-positive person is not willing/ready enough to quit 
smoking.
Smoking cessation 
HIV-positive tobacco users should be made aware of the substantial health benefits of smoking cessation which include reducing the risk of tobacco-related 
diseases, slowing the progression of existing tobacco related disease, and improving life expectancy by an average of 10 years.
Regularly consider the following algorithm with two major questions:
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Prevention of CVD
i Use the Framingham equation or whatever system local National Guid-
ance recommends; a risk equation developed from HIV populations is 
available: see http://www.hivpv.org. This assessment and the associated 
considerations outlined in this figure should be repeated annually in all 
persons under care, see page 4-5, to ensure that the various interven-
tions are initiated in a timely way. 
ii Options for ART modification include: 
(1) Replace with NNRTI, INSTI or another PI/r known to cause less 
metabolic disturbances, see page 16-17 
(2) Consider replacing ZDV or ABC with TDF or use an NRTI-sparing 
regimen 
iii Of the modifiable risk factors outlined, drug treatment is reserved for 
certain subgroups where benefits are considered to outweigh potential 
harm. Of note, there is a combined benefit of various interventions in tar-
get groups identified. Per 10 mmHg reduction in systolic blood pressure, 
per 1 mmol/L (39 mg/dL) reduction in TC and with use of acetylsalicylic 
acid, each reduces risk of IHD by 20-25%; the effect is additive. Obser-
vational studies suggest that smoking cessation results in about 50% 
less risk of IHD – and this is additive to other interventions.
Assess CVD risk in next 10 years(i)
Advise on diet and lifestyle in all 
persons
Consider ART modification if 10-
year CVD risk ≥ 20%(ii)
Smoking (see page 33) Identify key modifiable risk factors(iii)
Blood Pressure Coagulation Glucose Lipids
Drug treatment if: SBP ≥ 140 or 
DBP ≥ 90 mmHg (especially if 10-
year CVD risk ≥ 20%)
Drug treatment if: established CVD 
or age ≥ 50 and 10-year CVD risk 
≥ 20%
Confirm DM and treat with drugs
Drug treatment(iv) if: established 
CVD or type 2 diabetes or 10-year 
CVD risk ≥ 10%
Target Target - N/A
Consider treating with acetylsali-
cylic acid 75-150 mg(vi)
Target 
HbA1C  6.5-7.0%
Treatment (see page 39)
Target(v)
SBP < 140 Optimal Standard
DBP < 90 TC ≤ 4 (155) ≤ 5 (190)
LDL ≤ 2 (80) ≤ 3 (115)
Treatment (see page 35-37) 
Treatment (see page 40) 
Principles: The intensity of efforts to prevent CVD depends on the underly-
ing risk of CVD, which can be estimated(i). The preventive efforts are diverse 
in nature and require involvement of a relevant specialist, in particular if the 
risk of CVD is high and always in persons with a history of CVD.
iv See discussion on drug treatment of persons with lower CVD risk at  
www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm 
v Target levels are to be used as guidance and are not definitive – ex-
pressed as mmol/L with mg/dL in parenthesis. In case LDL cannot be 
calculated because of high triglyceride levels, the non-HDL-c (TC minus 
HDL-c) target should be used which is 0.8 mmol/L (30 mg/dL) higher 
than the corresponding LDL-c target. Target levels for TG are not listed 
because an independent contribution from TG to CVD risk is uncertain, 
and hence whether this condition should be treated, see page 40. 
vi Evidence for benefit when used in persons without a history of CVD (in-
cluding diabetics) is less compelling. BP should be reasonably controlled 
before Aspirin use in such a setting. 
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Other risk factors, asymp-
tomatic organ damage or 
disease
Blood pressure (mmHg) Blood pressure (mmHg) Blood pressure (mmHg) Blood pressure (mmHg)
High normal SBP  
130-139  
or DBP 85-89
Grade 1 hypertension
SBP 140-159
or DBP 90-99
Grade 2 hypertension
SBP 160-179
or DBP 100-109
Grade 3 hypertension
SBP ≥ 180  
or DBP ≥ 110
No other risk factors • No BP intervention • Lifestyle changes(i) for  
several months
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i)
• Immediate BP drugs 
targeting < 140/90
1-2 risk factors • Lifestyle changes(i)
• No BP Intervention
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90
≥ 3 risk factors • Lifestyle changes(i)
• No BP intervention
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90
Organ damage, CKD stage 
3 or diabetes
• Lifestyle changes(i)
• No BP intervention
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90
Symptomatic CVD, CKD 
stage ≥ 4 or diabetes with 
organ damage/risk factors
• Lifestyle changes(i)
• No BP intervention
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90
Hypertension: Diagnosis, Grading and Management
BP blood pressure
DBP   diastolic blood pressure:
SBP  systolic blood pressure
Repeated blood pressure measurements should be used for stratification
i  Recommended lifestyle interventions, see page 33
Table adapted from [1].
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Hypertension: Drug Sequencing Management
Choosing drugs(i) for persons newly diagnosed with hypertension
< 55 years ≥ 55 years or black(ii)
person of any age
A(iii) C(iii)
A + C(iii)
A + C + D(iii)
Add(iv) further diuretic therapy (e.g. spironolactone) or alpha-blocker (e.g.
doxazosin) or beta-blocker (e.g. atenolol). Refer to specialist
Abbreviations + details
A ACE inhibitor (e.g. perindopril, lisinopril or ramipril) or low cost  angioten-
sin receptor blockers (ARB) (e.g. losartan, candesartan) 
C Dihydropyridine calcium-channel blocker (e.g. amlodipine). If not 
tolerated or if deemed at high risk of heart failure, ’D’ drugs can be used 
instead. Where a C drug is preferred but not tolerated, verapamil or 
diltiazem may be used (note: dose with caution with PIs as these may 
increase plasma concentrations of these calcium-channel blockers, 
potentially leading to toxic reactions) 
D Thiazide-type diuretic* e.g. indapamide or chlorthalidone 
i Some calcium-channel blockers interact marginally with the pharmacoki-
netics of ARVs, see Drug-drug Interactions between Antihypertensives 
and ARVs 
ii Black persons are those of African or Caribbean descent, and not mixed 
race, Asian or Chinese persons 
iii Wait 4-6 weeks to assess whether target, see page 35, is achieved; if 
not, go to next step 
iv Requirement of 4-5 drugs to manage hypertension needs specialist 
training 
* This excludes thiazides (e.g. HCTZ, bendroflumethiazide etc.) 
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Drug-drug Interactions between Antihypertensives and ARVs
Legend
↑  potential elevated exposure of the antihypertensive     
↓  potential decreased exposure of the antihypertensive
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
a  [parent drug] decreased but [active metabolite] increased    
b  [parent drug] increased but [active metabolite] decreased
c  ECG monitoring recommended   
d  risk of PR interval prolongation
e use with caution as both LPV and calcium channel blockers prolong 
the PR interval. Clinical monitoring is recommended.
Numbers refer to decreased AUC of the antihypertensive as observed in 
drug-drug interactions studies.
Colour legend
 no clinically significant interaction expected.  
 these drugs should not be co-administered. 
 potential interaction, which may require a dosage adjustment or 
close monitoring.  
 potential interaction predicted to be of weak intensity (< 2 fold ↑AUC 
or < 50% ↓AUC).  A dosage adjustment is a priori not recommended.
 
Note: although some drug interactions are predicted to potentially require a 
dosage adjustment based on the drug's metabolic pathway, clinical 
experience with a particular antihypertensive and ARV drug may indicate 
that dosage adjustments are not an a priori requirement.    
Comment
The symbol (red, amber, green) used to rank the clinical significance of the 
drug interaction is based on www.hiv-druginteractions.org (University     
of Liverpool). For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, refer to the
above mentioned website.       
      
Antihypertensives ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL ABC FTC 3TC TDF ZDV
A
C
E 
in
hi
bi
to
rs
cilazapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
enalapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
lisinopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
perindopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
quinapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
ramipril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
trandolapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
A
ng
io
te
ns
in
 
an
ta
go
ni
st
s
candesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
irbesartan ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
losartan ↓a ↔ ↓a ↓a ↑b ↑b ↔ ↔ ↔ ↔ ↓a ↔ ↔ ↔ ↔ ↔ ↔
olmesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
telmisartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
valsartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
β 
bl
oc
ke
rs
atenolol ↔d ↔ ↔ ↔d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bisoprolol ↑d ↑ ↑ ↑d ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
carvedilol ↑↓d ↑ ↑↓ ↑↓d ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
metoprolol ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
propranolol ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
C
al
ci
um
 c
ha
nn
el
 b
lo
ck
er
s amlodipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
diltiazem ↑c ↑ ↑ ↑e ↓69% ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
felodipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lacidipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lercanidipine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nicardipine ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nifedipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nisoldipine ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
verapamil ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
D
iu
re
tic
s
amiloride ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bendroflumethiazide ? ? ? ? ? ? ? ↔ ↔ ↔ ? ↔ ↔ ↔ ↔ ↔ ↔
chlortalidone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
furosemide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E ↔
indapamide ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
torasemide ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
O
th
er
s doxazosin ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
spironolactone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
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Type 2 Diabetes: Diagnosis
Diagnostic criteria(i)
Fasting plasma 
glucose mmol/L 
(mg/dL)(ii)
Oral glucose 
tolerance test 
(OGTT) 2-h 
value mmol/L 
(mg/dL)(iii)
HbA1c(iv)  
(mmol/mol)
Diabetes ≥ 7.0 (126) OR→ ≥ 11.1 (200) ≥ 6.5%  (≥ 48)
Impaired  
glucose
tolerance (IGT) 
< 7.0 (126) AND→ 7.8 – 11.0  
(140-199) 
Prediabetes
5.7-6.4% (39-47)
Impaired fasting 
glucose (IFG)
5.7– 6.9 AND 
(100-125) 
< 7.8 (140) 
i  As defined by WHO and [2]
ii  An abnormal finding should be repeated before confirming the diagnosis
iii  Recommended in persons with fasting blood glucose of 5.7 - 6.9 mmol/L 
(100-125 mg/dL) as it may identify persons with overt diabetes
iv  Do not use HbA1c in presence of haemoglobinopathies, increased 
erythrocyte turnover and severe liver or kidney dysfunction. Falsely high 
values are measured under supplementation with iron, vitamin C and E 
as well as older age (age > 70: HbA1c + 0.4%). HbA1c values in treated 
HIV-positive persons, particularly when on ABC, tend to underestimate 
type 2 diabetes. Both IGT and IFG increase CVD morbidity and mortality, 
and increase the risk of developing diabetes by 4-6 fold. These persons 
should be targeted for lifestyle intervention, and their CVD risk factors 
must be evaluated and treated.
EACS   European
AIDS Clinical Society
39EACS Guidelines 8.0 PART III
Type 2 Diabetes(i): Management
If modification of lifestyle measures  
is insufficient
Metformin Sulfonylureas
• Always to be considered as the 
first oral agent(ii)
• Start dose (500-850 mg qd),  
increase to max tolerated dose of 
2(-3) g/day over 4-6 weeks(iii)
• May be considered for non-over-
weight if blood glucose is very high
• No clinical trial data in HIV-positive 
persons
HbA1C > 6.5-7% (> 48-53 mmol/mol)
Use a combination of 2 agents 
(metformin/sulfonylurea/others(ii))
HbA1C > 6.5-7% (> 48-53 mmol/mol)
Refer to specialist – use insulin
Treatment goals: 
Prevention of hyper-/hypoglycaemia, glucose control (HbA1c < 6.5-7% 
without hypoglycaemia, fasting plasma glucose 4-6 mmol/L (73-110 mg/dL), 
prevention of long-term complications
• Normal blood lipids, see page 34, and blood pressure < 130/80 mmHg, 
see page 35. 
• Acetylsalicylic acid (75-150 mg/qd) considered in diabetics with elevated 
underlying CVD risk, see page 34. 
• Nephropathy, polyneuropathy and retinopathy screening should be 
performed as in diabetic persons without HIV 
• Consultation with a specialist in diabetology is recommended 
i Type 1 diabetes should be treated according to national guidelines. 
ii Metformin may worsen lipoatrophy.Very limited data for any oral 
antidiabetic agents in terms of CVD prevention, and no data in HIV-
positive persons. Incretins (DDP4 inhibitors [e.g. saxagliptin, sitagliptin] 
and GLP-1 agonists [e.g. liraglutide & exenatide] are currently being 
evaluated in several major morbidity/mortality studies (neutral results to 
date); no clinically significant drug-drug interaction or adverse effects on 
CD4 counts expected; clinical use of pioglitazone questioned by its side 
effects; HbA1c targets up to 7.5% can be considered for older persons 
with long-standing type 2 diabetes and evidence of CVD.
iii    Consider lower dose in individuals with mild to moderate CKD or indivi-
duals receiving DTG.
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Dyslipidaemia
Principles: Higher LDL-c levels increase risk of CVD, hence reduction 
diminishes this risk (see table below for drugs used on this indication); the 
reverse is probably true for HDL-c but trial data are less compelling. The 
CVD risk implications from higher than normal TG levels are even less clear, 
as TG has not consistently been shown to independently predict the risk of 
CVD. Furthermore, the clinical benefit of treating moderate hypertriglycer-
idaemia is uncertain; very high TG (> 10 mmol/L or > 900 mg/dL) increase 
risk of pancreatitis.
Drugs used to lower LDL-c
Drug class Drug Dose Side effects Advise on use of statin together with ART
use with PI/r use with NNRTIs
Statin(i,ix) atorvastatin(ii) 10-80 mg qd Gastrointestinal
symptoms,
headache, insomnia,
rhabdomyolysis (rare)
and toxic hepatitis
Start with low dose(v) 
(max: 40 mg) 
Consider higher dose(vi) 
fluvastatin(iii) 20-80 mg qd Consider higher dose(vi) Consider higher dose(vi)
pravastatin(iii) 20-80 mg qd Consider higher 
dose(vi,vii)
Consider higher dose(vi)
rosuvastatin(ii) 5-40 mg qd Start with low dose(v) 
(max: 20 mg) 
Start with low dose(v) 
simvastatin(ii) 10-40 mg qd Contraindicated
Intestinal cholesterol 
absorption inhibitor↓(i,viii)
ezetimibe(iv) 10 mg qd Gastrointestinal
symptoms
No known drug-drug interactions with ART
i  A statin is preferred first-line therapy; different statins have variable 
intrinsic LDL-c lowering ability
ii, iii, iv  Target levels for LDL-c, see page 34. In persons where LDL-c 
targets are difficult to achieve, consult/refer to specialist
ii, iii, iv  Expected range of reductions of LDL-c: ii 1.5-2.5 mmol/L (60-100 
mg/dL), iii 0.8-1.5 mmol/L (35-60 mg/dL), iv 0.2-0.5 mmol/L (10-20 
mg/dL)
v, vi  The ARV may v inhibit (statin toxicity, ↓ dose) or vi induce (=less 
effect of statin, ↑ dose gradually to achieve expected benefit  ii, iii) 
the excretion of the statin
vii Exception: If used with DRV/r, start with lower dose of pravastatin
viii This agent can be used for HIV-positive persons intolerant of statins 
or added to a statin when LDL reduction is inadequate despite maxi-
mally tolerated statin
ix Pitavastatin has as yet no morbidity/mortality trial data to support its 
use but may have advantages of fewer drug-drug interactions, more 
HDL increase and less adverse glucose effect than other statins
Less calories, more exercise, reducing bodyweight, and stopping smoking 
tend to improve HDL. Eating fish, reducing calories, saturated fat and alcohol 
intake reduce triglyceride levels. Reducing dietary saturated fat intake 
improves LDL-levels; if not effective, consider change of ART, then consider 
lipid-lowering medication, see page 34. Statins should be used by all those 
with established vascular disease and among those with type 2 diabetes or 
at high risk of CVD, irrespective of lipid levels.
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Bone Disease: Screening and Diagnosis
Condition Characteristics Risk factors Diagnostic tests
Osteopenia 
• Postmenopausal women and men 
aged ≥ 50 years with BMD T-score 
-1 to -2.5 
Osteoporosis 
• Postmenopausal women and men 
aged ≥ 50 years with BMD T-score 
≤ -2.5 
• Premenopausal women and men 
aged < 50 years with BMD Z-score 
≤ -2 and fragility fracture 
• Reduced bone mass 
• Increased incidence of fractures in 
HIV-positive persons 
• Asymptomatic until fractures occur 
Common in HIV
• Up to 60% prevalence of osteo-
penia
• Up to 10-15% prevalence of 
osteoporosis 
• Aetiology multifactorial 
• Loss of BMD observed with  
antiretroviral initiation
• Greater loss of BMD with initiation 
of certain ARVs(i)
Consider classic risk factors(ii)
Consider DXA in any person  
with ≥ 1 of:(iii)                    
1. Postmenopausal women 
2. Men ≥ 50 years 
3. History of low impact fracture
4. High risk for falls(iv) 
5. Clinical hypogonadism (sympto-
matic, see Sexual  
Dysfunction)
6. Oral glucocorticoid use (minimum 
5 mg/qd prednisone equivalent for 
> 3 months) 
Preferably perform DXA in those 
with above risk factors prior to 
ART initiation. Assess effect of risk 
factors on fracture risk by including 
DXA results in the FRAX® score 
(www.shef.ac.uk/FRAX) 
• Only use if > 40 years 
• May underestimate risk in HIV- 
positive persons 
• Consider using HIV as a cause of 
secondary osteoporosis(v)
DXA scan 
Rule out causes of secondary 
osteoporosis if BMD low(vi) 
Lateral spine X-rays (lumbar and 
thoracic) if low spine BMD, osteopo-
rosis on DXA, or significant height 
loss or kyphosis develops. (DXA-
based vertebral fracture assessment 
[VFA] can be used as an alternative 
to lateral spine X-ray).
  
Osteomalacia • Defective bone mineralisation
• Increased risk of fractures and 
bone pain 
• Vitamin D deficiency may cause 
proximal muscle weakness 
• High prevalence (> 80%) of 
vitamin D insufficiency in some 
HIV cohorts and in the general 
population
• Dark skin
• Dietary deficiency
• Avoidance of sun exposure 
• Malabsorption
• Obesity 
• Renal phosphate wasting(vii)
Measure 25(OH) vitamin D 
in all persons at presentation
ng/mL nmol/L
Deficiency < 10 < 25
Insufficiency < 20 < 50
If deficient or insufficient, check PTH 
levels
Consider vitamin D replacement if 
clinically indicated, see page 42
Osteonecrosis • Infarct of epiphyseal plate of long 
bones resulting in acute bone pain 
• Rare but increased prevalence 
in HIV 
Risk factors: 
• Low CD4 count
• Glucocorticoid exposure 
• IVDU
MRI
i Greater loss of BMD observed with initiation of regimens containing TDF 
and some PIs. Additional loss and gains in BMD observed with switch 
to and away from TDF-containing ARV regimens, respectively. Clinical 
relevance to fracture risk not determined. 
ii Classic risk factors: older age, female gender, hypogonadism, family his-
tory of hip fracture, low BMI (≤ 19 kg/m2), vitamin D deficiency, smoking, 
physical inactivity, history of low trauma fracture, alcohol excess (> 3 
units/day), steroid exposure (minimum prednisone 5 mg/qd or equivalent 
for > 3 months) 
iii If T-score normal, repeat after 3-5 years in groups 1 and 2; no need for 
re-screening with DXA in groups 3 and 4 unless risk factors change and 
only rescreen group 5 if steroid use ongoing. 
iv Falls Risk Assessment Tool (FRAT) http://www.health.vic.gov.au/age-
dcare/maintaining/falls_dev/downloads/b2b_1a_frat.pdf
v If including BMD within FRAX, entering yes in the secondary cause box  
will not be considered in the FRAX algorithms, as it is assumed that se-
condary osteoporosis affects fracture risk solely through BMD. However, 
if the contribution of HIV infection to fracture risk is partially independent 
of BMD, fracture probability may be underestimated by FRAX.  
vi  Causes of secondary osteoporosis include hyperparathyroidism, 
hyperthyroidism, malabsorption, hypogonadism/amenorrhoea, diabetes 
mellitus, and chronic liver disease.
vii For diagnosis and management of renal phosphate wasting,  
see Indications and Tests for Proximal Renal Tubulopathy (PRT).
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Vitamin D Test Therapy(i)
Deficiency:
< 10 ng/mL (< 25 nmol/L)(ii)
Insufficiency:
< 20 ng/mL (< 50 nmol/L)
Serum 25 hydroxy vitamin D  
(25(OH) vitamin D)
If deficient, consider checking par-
athyroid hormone (PTH), calcium, 
phosphate(iii), alkaline phosphatase
If vitamin D deficient, replacement recommended. Various regimens 
suggested(iv)
Consider re-checking 25(OH) vitamin D levels 3 months after replacement.
After replacement, maintenance with 800-2000 IU vitamin D daily.
Vitamin D deficiency prevalent in 
both HIV+ and HIV- populations 
– may not be directly associated 
with HIV.
Factors associated with lower 
vitamin D:
• Dark skin
• Dietary deficiency
• Avoidance of sun exposure
• Malabsorption
• Obesity
• Chronic kidney disease
• Some ARVs(v)
Check vitamin D status in persons 
with history of:
• low bone mineral density and/or 
fracture
• high risk for fracture
Consider assessment of vitamin D 
status in persons with other factors 
associated with lower vitamin D 
levels (see left column)
Replacement and/or supplementation of 25(OH) vitamin D is  
recommended for persons with vitamin D insufficiency(vi) and:
• osteoporosis
• osteomalacia
• increased PTH (once the cause has been identified)
Consider re-testing after 6 months of vitamin D intake
Vitamin D Deficiency: Diagnosis and Management
i Can be provided according to national recommendations/availability of 
preparations (oral and parenteral formulations). Combine with calcium 
where there is insufficient dietary calcium intake. Consider that in some 
countries food is artificially fortified with vitamin D. 
ii Some experts consider a value of ≤ 30 ng/mL as vitamin D deficiency. 
Low vitamin D has a prevalence of up to 80% in HIV cohorts and was 
associated with increased risk for osteoporosis, type 2 diabetes, morta-
lity and AIDS events. Consider seasonal differences (in winter approxi-
mately 20% lower than in summer). 
iii Consider that hypophosphataemia can be associated with TDF therapy. 
This phosphate loss through proximal renal tubulopathy may be inde-
pendent of low vitamin D, see page 45. A combination of low calcium + 
low phosphate +/- high alkaline phosphatase may indicate osteomalacia 
and vitamin D deficiency. 
iv Expect that 100 IU vitamin D daily leads to an increase in serum 25(OH) 
vitamin D of approximately 1 ng/mL. Some experts prefer a loading dose 
of e.g. 10,000 IU vitamin D daily for 8-10 weeks in persons with vitamin 
D deficiency. The principal goal is to achieve a serum level > 20 ng/mL 
(50 nmol/L) and to maintain normal serum PTH levels. Combine with 
calcium where potential for insufficient dietary calcium intake. The thera-
peutic aim is to maintain skeletal health; vitamin D supplementation has 
not been proven to prevent other co-morbidities in HIV-positive persons. 
v The role of HIV-therapy or specific drugs remains unclear. Some studies 
suggest an association of EFV with reductions in 25(OH)D but not 
1.25(OH)D. PIs may also affect vitamin D status by inhibiting conversion 
of 25(OH)D to 1.25(OH)D. 
vi The implications of vitamin D levels that are below the physiological 
reference range but not markedly reduced and the value of supplemen-
tation are not completely understood. 
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Reducing risk  
of fractures 
• Aim to decrease falls by addressing fall risks(i)
• Ensure sufficient dietary calcium (1-1.2 g daily) and 
vitamin D (800-2,000 IU daily) intake(ii)
• Where appropriate, screen for osteoporosis(iii) and 
refer to national/regional guidelines on treatment of 
osteoporosis 
 – If no guidelines available, consider bisphosphonate(iv) 
treatment in all osteoporotic postmenopausal women 
and men > 50 years old (BMD T-score ≤ -2.5) and 
those with a history of fragility fracture. Consider 
treatment based on BMD alongside consideration of 
other risk factors for fracture, especially age.
 – Use bisphosphonate and ensure adequate calcium 
and vitamin D intake 
 – No significant interactions between bisphosphonates 
and antiretrovirals
 – If antiretroviral naïve, consider options for ART that 
preserve BMD(v)
 – If diagnosed with osteoporosis and requiring therapy, 
consider optimising ART to preserve or improve BMD
• In complicated cases (e.g. young men, premenopausal 
women, recurrent fracture despite bone protective thera-
py), refer to osteoporosis specialist
• If on bisphosphonate treatment, repeat DXA after 2 
years and reassess need for continued treatment after 
3-5 years
Approach to Fracture Reduction in HIV-positive Persons
i  Falls Risk Assessment Tool (FRAT), see http://www.health.vic.gov.au/
agedcare/maintaining/falls_dev/downloads/b2b_1a_frat.pdf  
ii  See page 42 for diagnosis and management of vitamin D deficiency.
iii  See page 41 for screening and diagnosis of bone disease in HIV.
iv  Bisphosphonate treatment with either of: alendronate 70 mg once  
weekly po; risedronate 35 mg once weekly po; ibandronate 150 mg  
oral monthly or 3 mg iv every 3 months; zoledronic acid 5 mg iv  
once yearly.
v BMD loss is greatest in the first year after ART initiation, with more BMD 
loss with ART regimens containing TDF and some PIs. Consider relative 
risk/benefit of using these agents in persons with high fracture risk. 
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Kidney Disease: Definition, Diagnosis and Management
Management of HIV-associated kidney disease(vi)
Prevention of progressive  
renal disease
Comment
1. ART Start ART immediately where 
HIV-associated nephropathy (HIVAN)
(vii) or HIV immune complex disease 
strongly suspected. Immunosup-
pressive therapy may have a role in 
immune complex diseases. Renal 
biopsy to confirm histological diag-
nosis recommended
2. Start ACE inhibitors or angio-
tensin-II receptor antagonists 
if:
a. Hypertension and/or
b. Proteinuria
Monitor eGFR and K+ level 
closely on starting treatment or 
increasing dose
a. Blood pressure target: < 130/80 
mmHg
3.  General measures:
a.  Avoid nephrotoxic drugs
b.  Lifestyle measures (smoking, 
weight, diet)
c.  Treat dyslipidaemia(viii) and diabe-
tes(ix)
d.  Adjust drug dosages where nec-
essary(v)
CKD and proteinuria are independ-
ent risk factors for CVD
i For eGFR: Use CKD-EPI formula based on serum creatinine, gender, 
age and ethnicity because eGFR quantification is validated >60 mL/
min. The abbreviated modification of diet in renal disease  (aMDRD) or 
the Cockcroft-Gault (CG) equation may be used as an alternative; see   
http://www.hivpv.org/. 
 Definition CKD: eGFR < 60 ml/min for > 3 months (see http://kdigo.org/
home/guidelines/ckd-evaluation-management). If not previously known 
to have CKD, confirm pathological eGFR within 2 weeks. Use of DTG, 
COBI and RTV boosted PIs is associated with an increase in serum 
creatinine/reduction of eGFR due to inhibition of proxi-mal tubular crea-
tinine transporters without impairing actual glomerular filtration: consider 
new set point after 1-2 months 
ii Urinalysis: use urine dipstick to screen for haematuria. To screen for 
proteinuria, use urine dipstick and if ≥ 1+ check urine protein/creatinine 
(UP/C), or screen with UP/C. Proteinuria defined as persistent if con-
firmed on ≥ 2 occasions > 2-3 weeks apart. If UP/C not available, use 
urine albumin/creatinine (UA/C), see (iii) 
iii UP/C in spot urine is preferred to UA/C as detects total urinary protein 
secondary to glomerular and tubular disease. UA/C largely detects glo-
merular disease and can be used for screening for HIV-associated renal 
disease where UP/C is not available, but is not appropriate for screening 
for tubular proteinuria secondary to drug nephrotoxicity (e.g. TDF). If 
both UP/C and UA/C are measured, UP/C > UA/C suggests tubular 
proteinuria. Screening values for UA/C are: < 30, 30-70 and > 70. UA/C 
should be monitored in persons with diabetes. UPC ratio is calculated as 
urine protein (mg/L) / urine creatinine (mmol/L); may also be expressed 
as mg/mg. Conversion factor for mg to mmol creatinine is x 0.000884 
iv Repeat eGFR and urinalysis as per screening table, see page 5 
v See Dose Adjustment of ARVs for Impaired Renal Function 
vi Joint management with a nephrologist 
vii HIVAN suspected if black ethnicity & UP/C > 100 mg/mmol & no haema-
turia 
viii See page 40 
ix See page 38-39 
x Different models have been developed for calculating a 5-years CKD 
risk score while using different nephrotoxic ARVs integrating HIV-inde-
pendent and HIV-related risk factors [4], [5]  
Diagnosis of kidney disease
eGFR(i)
≥ 60 mL/min 30-59 mL/min < 30 mL/min 
Pr
ot
ei
nu
ria
(ii
)
UP/C(iii) < 50 Regular follow-up • Check risk factors for CKD and nephrotoxic  
medicines including ART(iv)
• Discontinue or adjust drug dosages where appropriate(v) 
• Perform renal ultrasound 
• Urgent referral to nephrologist 
UP/C(iii) 50-100 • Check risk factors for CKD(x) and nephrotoxic 
medicines including ART(iv, x)
• Discontinue or adjust drug dosages where 
appropriate(v) 
• Perform renal ultrasound 
• If haematuria present with any level of proteinu-
ria refer to nephrologist
• Refer to nephrologist if new CKD or progressive 
decline in eGFR
UP/C(iii) > 100 
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ARV-associated Nephrotoxicity
Renal abnormality* ARV Management(vi)
Proximal tubulopathy with any combination of:
1. Proteinuria: urine dipstick ≥ 1, or confirmed increase in 
UP/C > 30 mg/mmol(i)
2. Progressive decline in eGFR and eGFR < 90 mL/min(ii)
3. Phosphaturia(iii): confirmed hypophosphataemia secon-
dary to increased urine phosphate leak
TDF Assessment:
• Tests for proximal renal tubulopathy/renal Fanconi syndrome(iii)
• Consider renal bone disease if hypophosphataemia of renal origin: mea-
sure 25(OH) vitamin D, PTH, DXA 
Consider stopping TDF if:
• Progressive decline in eGFR and no other cause
• Confirmed hypophosphataemia of renal origin and no other cause
• Osteopenia/osteoporosis in the presence of increased urine  
phosphate leak 
Nephrolithiasis:
1. Crystalluria
2. Haematuria(iv)
3. Leucocyturia
4. Loin pain
5. Acute renal insufficiency
IDV
ATV
(DRV)
Assessment:
• Urinalysis for crystalluria/stone analysis
• Exclude other cause for nephrolithiasis
• Renal tract imaging including CT scan
Consider stopping IDV/ATV if:
• Confirmed renal stones
• Recurrent loin pain +/- haematuria
Interstitial nephritis:
1. Progressive decline in eGFR(ii)
2. Tubular proteinuria(iii)/ haematuria
3. Eosinophiluria (if acute)
4.  Leucocyte casts
IDV
ATV
Assessment:
• Renal ultrasound
• Refer to nephrologist
Consider stopping IDV/ATV if:
• Progressive decline in eGFR and no other cause
Progressive decline in eGFR, but none of the above(v) TDF
PI/r
Complete assessment:
•   Risk factors for CKD(v) (see Kidney Disease: Definition, Diagnosis and 
Management)
•   PRT, UA/C, UP/C (see Kidney Disease: Definition, Diagnosis and Man-
gement and Indications and Tests for Proximal Renal Tubulopathy (PRT)
• Renal tract ultrasound
Consider stopping ARVs with potential nephrotoxicity if:
• Progressive decline in eGFR and no other cause(v)
* Use of COBI, DTG, RPV, but also PI/r is associated with an increase in 
serum creatinine/reduction of eGFR due to inhibition of proximal tubular 
creatinine transporters without impairing actual glomerular filtration: 
consider new set point after 1-2 months 
i UP/C in spot urine detects total urinary protein including protein of 
glomerular or tubular origin. The urine dipstick analysis primarily detects 
albuminuria as a marker of glomerular disease and is inadequate to 
detect tubular disease. 
ii For eGFR: use CKD-EPI formula. The abbreviated MDRD (Modification 
of Diet in Renal Disease) or the Cockcroft-Gault (CG) equation may be 
used as an alternative, see http://www.hivpv.org/ 
iii See Indications and Tests for Proximal Renal Tubulopathy (PRT) 
iv Microscopic haematuria is usually present. 
v Different models have been developed for calculating a 5-years CKD 
risk score while using different nephrotoxic ARVs integrating HIV-inde-
pendent and HIV-related risk factors [4], [5]  
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Indications and Tests for Proximal Renal Tubulopathy (PRT)
Indications for proximal renal tubulopathy tests Proximal renal tubulopathy tests(iv), including Consider stopping TDF if
• Progressive decline in eGFR(i) 
& eGFR < 90 mL/min & no other cause and/or
• Confirmed hypophosphataemia(ii) and/or
• Confirmed increase in UP/C(iii)
• Renal insufficiency even if stable (eGFR < 60 mL/min)
• Tubular proteinuria(v)
• Blood phosphate and urinary phosphate excretion(vi)
• Blood glucose and glucosuria
• Serum bicarbonate and urinary pH(vii)
• Blood uric acid level and urinary uric acid excretion(viii)
• Serum potassium and urinary potassium excretion
• Confirmed proximal renal tubulo-
pathy with no other cause
i For eGFR: use CKD-EPI formula. The abbreviated MDRD (Modification 
of Diet in Renal Disease) or the Cockcroft-Gault (CG) equation may be 
used as an alternative, see http://www.hivpv.org/
ii Serum phosphate < 0.8 mmol/L or according to local thresholds; con-
sider renal bone disease, particularly if alkaline phosphatase increased 
from baseline: measure 25(OH) vitamin D, PTH 
iii  UP/C in spot urine, detects total urinary protein, including protein of 
glomerular or tubular origin. The urine dipstick analysis primarily detects 
albuminuria as a marker of glomerular disease and is inadequate to 
detect tubular disease
iv  It is uncertain which tests discriminate best for TDF renal toxicity.  
Proximal tubulopathy is characterised by: proteinuria, hypophospha-
taemia, hypokalaemia, hypouricaemia, renal acidosis, glucosuria with 
normal blood glucose level. Renal insufficiency and polyuria may be 
associated. Most often, only some of these abnormalities are observed
v  Tests for tubular proteinuria include retinol binding protein, α1- or β2-mi-
croglobulinuria, urine cystatin C, aminoaciduria
vi  Quantified as fractional excretion of phosphate (FEPhos): (PO4(urine) 
/ PO4(serum) / (Creatinine(urine) / Creatinine(serum) in a spot urine 
sample collected in the morning in fasting state. Abnormal > 0.2 (> 0.1 
with serum phosphate < 0.8 mmol/L)
vii  S-bicarbonate < 21 mmol/L and urinary pH > 5.5 suggests renal tubular 
acidosis
viii  Fractional excretion of uric acid (FEUricAcid): (UricAcid(urine) / Uri-
cAcid(serum) / (Creatinine(urine) / Creatinine(serum) in a spot urine 
sample collected in the morning in fasting state; abnormal > 0.1
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Dose Adjustment of ARVs for Impaired Renal function
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
NRTIs
ABC  300 mg q12h
No dose adjustment required
 
 
ddI(ii) ≥ 60 kg 400 mg q24h 200 mg q24h 150 mg q24h 100 mg q24h 100 mg q24h(iv)
< 60 kg 250 mg q24h 125 mg q24h 100 mg q24h 75 mg q24h 75 mg q24h(iv)
d4T                   ≥ 60 kg 30 mg q12h 15 mg q12h 15 mg q24h 15 mg q24h 15 mg q24h(iv)
< 60 kg 40 mg q12h 20 mg q12h 20 mg q24h 20 mg q24h 20 mg q24h(iv)
FTC 200 mg q24h 200 mg q48h 200 mg q72h 200 mg q96h 200 mg q96h(iv)
3TC 300 mg q24h 150 mg q24h 100 mg q24h(iii) 50-25 mg q24h(iii) 50-25 mg q24h(iii), (iv)
TDF(v)
300(viii) mg q24h 300(viii) mg q48h
Not recommended Not recommended
300(viii) mg q7d(iv)(300(viii) mg q72-96h, 
if no alternative)
(300(viii) mg q7d, if 
no alternative)
ZDV 300 mg q12h No dose adjustment 
required
100 mg q8h 100 mg q8h(iv)
ABC/3TC 600/300 mg q24h
Use individual drugsZDV/3TC 300/150 mg q12h
ABC/3TC/ZDV 300/150/300 mg 
q12h
TDF/FTC 300(viii)/200 mg q24h 300(viii)/200 mg q48h Use individual drugs
NNRTIs
EFV 600 mg q24h              No dose adjustment required
ETV 200 mg q12h              No dose adjustment required
NVP 200 mg q12h              No dose adjustment required
TDF/FTC/RPV 300(viii)/200/25 mg 
q24h
Do not use
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
PIs(v)
ATV/r 300/100 mg q24h No dose adjustment required(vi)
DRV/r 800/100 mg q24h
600/100 mg q12h No dose adjustment required
(vi)
DRV/c 800/150 mg q24h No dose adjustment required(vi)
FPV/r 700/100 mg q12h No dose adjustment required(vi)
LPV/r 400/100 mg q12h No dose adjustment required(vi)
SQV/r 1000/100 mg q12h No dose adjustment required(vi)
TPV/r 500/200 mg q12h No dose adjustment required(vi)
Other ART
RAL 400 mg q12h No dose adjustment required(vi)
DTG 50 mg q24h No dose adjustment No clinical data; PK 
data suggest safety
ABC/3TC/DTG 600/300/50 mg q24h Use individual drugs
TDF/FTC/EVG/c Do not initiate if eGFR < 70 mL/min Discontinue if eGFR < 50 mL/min
MVC: co-administered
without CYP3A4
inhibitors(vii)
300 mg q12h No dose adjustment required
MVC: co-administered 
with CYP3A4 inhibitors(vii)
If eGFR < 80 mL/min 150 mg q24h(vii)
except: 150 mg q12h if co-administered  
with FPV/r
i  eGFR:  Use CKD-EPI formula; the abbreviated modification of diet in renal 
disease (aMDRD) or the Cockcroft-Gault (CG) equation may be used as 
an alternative; see http://www.hivpv.org/
ii  Dose reduction if combined with TDF 
iii  150 mg loading dose 
iv  After dialysis
v  TDF and (boosted) PIs are associated with nephrotoxicity; consider 
alternative ART if pre-existing CKD, risk factors for CKD and/or decreasing 
eGFR, see ARV-associated Nephrotoxicity and Kidney Disease: Definition, 
Diagnosis and Management
vi  Limited data available in persons with renal impairment; pharmacokinetic 
analysis suggests no dose adjustment required
vii  See summary of product characteristics for specific recommendations; use 
with caution if eGFR < 30 mL/min
viii In certain countries TDF is labelled as 245 mg rather than 300 mg to reflect 
the concentration of the active metabolite 
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Identify potential cause of increased liver enzymes, using the following steps:
ST
EP
 1
Does the person take any potentially hepatotoxic medication/
herbal products/illicit drugs? No
GO TO STEP 2
Yes
Stop the drug or replace if feasible; if ARV potentially involved,  
do not impair efficacy of the regimen 
Yes
Disappearance of liver abnormalities? No
Yes
Adapt treatment regimen accordingly
Can you identify recent/chronic alcohol intake? No
Yes
Recommend stopping alcohol intake and follow ALT/AST 
(4-8 weeks may be needed for improvement) 
ST
EP
 2
Exclude viral hepatitis test for:
• Hepatitis A (HAV IgM), if status unknown or person non-immune 
previously
Neg
GO TO STEP 3
Manage accordingly
• Acute/chronic HBV (HBsAg) or HCV (HCV-Ab, HCV-RNA),  
if status unknown or person non-immune/negative previously Neg
see page 67-78
ST
EP
 3
Identify other causes of increased ALT/AST Identify other causes of increased ALT/AST
Steatosis 
NASH(i) (metabolic 
syndrome, diabetes) 
HCV-associated 
steatosis
Nodular regenerative 
hyperplasia (more 
frequent in HIV-posi-
tive persons)
Other viral diseases 
(CMV, EBV, Hepa-
titis E)
Non-hepatic causes of  
increased ALT/AST
• Coeliac disease
• Myopathy
• Portal hypertension
• Heart failure
Rare disorders
• Autoimmune hepatitis
• Haemochromatosis
• Wilson’s disease 
• Alpha-1 anti-trypsine deficiency
IN ALL CASES PERFORM: • liver ultrasonography
• liver biopsy
If all causes of increased ALT/AST have been reasonably 
excluded, consider high HIV-VL as a potential explanation
See page 48-50                    Cirrhotic persons
i  Nonalcoholic steatohepatitis
Work-up and Management of HIV-positive Persons with Increased ALT/AST
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Liver Cirrhosis: Classification and Surveillance
Child-Pugh classification of the severity of cirrhosis
Point(i)
1 2 3
Total bilirubin, 
mg/dL (μmol/L)
< 2 (< 34) 2-3 (34-50) > 3 (> 50)
Serum albumin, 
g/L (μmol/L) 
> 35 (> 507) 28-35 (406-507) < 28 (< 406)
INR < 1.7 1.7-2.20 > 2.20
Ascites None Mild/Moderate 
(diuretic respon-
sive)
Severe
(diuretic refrac-
tory)
Hepatic enceph-
alopathy 
None Grade I-II
(or suppressed 
with medicine)
Grade III-IV
(or refractory)
i  5-6 points:    Class A
 7-9 points:    Class B
  10-15 points:  Class C
Algorithm for surveillance for varices and primary prophylaxis
Diagnosis of cirrhosis
Upper GI endoscopy
No varices Grade I varices Grade II/III varices
Re-endoscope
3-4 years
Re-endoscope
1 year
propranolol
80-160mg/day
or
carvedilol
6.25-50 mg/day
intolerant
Variceal band ligation
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Liver Cirrhosis: Management
Management of HIV-positive persons with cirrhosis should be done in collab-
oration with experts in liver diseases. More general management guidance is 
described below.
For dosage adjustment of antiretrovirals, see Dose Adjustment of ARVs for 
Impaired Hepatic Function.
In end-stage liver disease (ESLD), use of EFV may increase risk of  
CNS symptoms.
ART, if otherwise indicated, also provides net benefit to cirrhotic persons. 
See Diagnosis and Management of Hepatorenal Syndrome (HRS).
Management of hypervolaemic 
hyponatraemia
Management strategy of hepatic 
encephalopathy (HE)
1. Fluid restriction: 1000-1500 mL/
day (consumption of bouillon 
allowed ad libitum)
2. If fluid restriction is ineffective, 
consider use of oral tolvaptan
a. To be started in hospital at 
15 mg/day for 3-5 days, then 
titrated to 30-60 mg/day until 
normal s-Na; duration of treat-
ment unknown (efficacy/safety 
only established in short-term 
studies (1 month)
b. S-Na should be monitored 
closely, particularly after 
initiation, dose modification or if 
clinical status changes. 
c. Rapid increases in s-Na 
concentration (> 8 mmol/day) 
should be avoided to prevent 
osmotic demyelisation  
syndrome
d. Persons may be discharged 
after s-Na levels are stable and 
without need to further adjust 
dose
General management
1. Identify and treat precipitating 
factor (GI haemorrhage, infection, 
pre-renal azotaemia, constipation, 
sedatives)
2. Short-term (< 72 hours) protein 
restriction may be considered if 
HE is severe
Specific therapy
Lactulose 30 cm³ orally every 1-2h 
until bowel evacuation, then adjust 
to a dosage resulting in 2-3 formed 
bowel movements per day (usually 
15-30 cm³ orally bid)
Lactulose enemas (300 cm³ in 1L of 
water) in persons who are unable to 
take it orally. Lactulose can be
discontinued once the precipitating 
factor has resolved
Management strategy in uncomplicated ascites
General  
management
• Treat ascites once other complications have been 
treated
• Avoid NSAIDs
• Norfloxacin prophylaxis (400 mg orally, qd) in persons 
with 1) an ascites protein level of < 1.5 mg/dL,  
2) impaired renal function (serum creatinine level > 1.2 
mg/dL, BUN > 25 mg/dL), 3) s-Na level < 130mE g/L), 
or 4) severe liver failure (Child Pugh score > 9 points 
with s-bilirubin level > 3 mg/dL)
Specific  
management
• Salt restriction: 1-2 g/day. Liberalise if restriction results 
in poor food intake
• Large volume paracentesis as initial therapy only in 
persons with tense ascites
• Administer intravenous albumin (= 6-8 g per litre ascites 
removed)
Follow-up  
and goals
• Adjust diuretic dosage every 4-7 days
• Weigh the person at least weekly and BUN,  
s-creatinine, and electrolytes measured every  
1-2 weeks while adjusting dosage
• Double dosage of diuretics if: weight loss < 2 kg a week 
and BUN, creatinine and electrolytes are stable
• Halve the dosage of diuretics or discontinue if: weight 
loss ≥ 0.5 kg/day or if there are abnormalities in BUN, 
creatinine or electrolytes
• Maximum diuretic dosage: spironolactone (400 mg qd) 
and furosemide (160 mg qd)
Nutrition of cirrhotic persons
Caloric requirements
• 25-30 Kcal/Kg/day of normal body 
weight
Protein requirements
• Protein restriction is not recom-
mended (see above for exception 
if HE)
• Type: rich in branched chain (non-
aromatic) amino acids
• Some studies support that paren-
teral proteins carry less risk of en-
cephalopathy since not converted 
by colonic bacteria into NH3
Micronutrients
• Mg and Zn
Analgesia in persons with hepatic failure
• Acetaminophen can be used; 
caution on daily dose (max 2 g/day).
• NSAIDs generally avoided, 
predispose persons with cirrhosis 
to develop GI bleeding. Persons 
with decompensated cirrhosis are 
at risk for NSAID-induced renal 
insufficiency.
• Opiate analgesics are not contra-
indicated but must be used with 
caution in persons with pre-exis-
ting hepatic encephalopathy.
Screening for hepatocellular carcinoma
• Ultrasound (US) every 6 months 
Alpha-foetoprotein is a suboptimal surveillance tool because of low 
sensitivity and specificity
• In case of suspicious lesions on US, perform CT scan (+arterial phase) or 
dynamic contrast-enhanced MRI
• Confirm diagnosis by fine needle aspiration or biopsy should CT scan or 
MRI be inconclusive
 
When to refer for liver transplantation
Best to refer early as disease progresses rapidly
= MELD(ii) score 10-12 (listing at 15)
Decompensated cirrhosis (at least one of the following complications) 
• Ascites
• Hepatic encephalopathy
• Variceal bleeding
• Spontaneous bacterial peritonitis
• Hepatorenal syndrome
• Hepatopulmonary syndrome
• Hepatocellular carcinoma
 
i  Alpha-foetoprotein may also be expressed in μg/L (cut-off value of 400 is 
the same)
ii  Unit for both S-creatinine and S-bilirubin is mg/dL. 
 MELD score = 10 {0,957 Ln (serum creatinine (mg/dL)) + 0.378 Ln (total 
bilirubin (mg/dL)) + 1.12 Ln (INR) + 0.643}. See www.mdcalc.com/meld-
score-model-for-end-stage-liver-disease-12-and-older/
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Diagnosis Consider HRS in a person with cirrhosis and ascites and a creatinine level of > 1.5 mg/dL. It is a diagnosis of exclu-
sion. Before making the diagnosis, the following need to be ruled out and treated:
• Sepsis (person needs to be pancultured)
• Volume depletion (haemorrhage, diarrhoea, overdiuresis)
• Vasodilatators
• Organic renal failure (urine sediment; kidney ultrasound)
Diuretics should be discontinued and intravascular volume expanded with iv albumin.
If renal dysfunction persists despite above, diagnose HRS.
Recommended therapy Liver transplant (priority dependent on MELD score). If person is on transplant list, MELD score should be updated 
daily and communicated to transplant centre.
Alternative (bridging therapy) Vasoconstrictors octreotide 100-200 mcg subcutaneously tid
→ Goal to increase mean arterial 
pressure by 15 mm HG
+ midodrine 5-15 mg orally tid
or terlipressin 0.5-2.0 mg iv every 4-6 hours
and iv albumin  
(both for at least 7 days)
50-100 g iv qd
Diagnosis and Management of Hepatorenal Syndrome (HRS)
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Dose Adjustment of ARVs for Impaired Hepatic Function
NRTIs
ABC Child-Pugh Class A: 200 mg bid (use oral solution)
Child-Pugh Class B or C: Contraindicated
ddI Contraindicated
If used no dosage adjustment
d4T Contraindicated
If used no dosage adjustment
FTC No dosage adjustment
3TC No dosage adjustment
TDF No dosage adjustment
TDF/FTC No dosage adjustment
ZDV Reduce dose by 50% or double the interval between
doses if Child-Pugh Class C
NNRTIs
EFV No dosage adjustment; use with caution in persons 
with hepatic impairmentTDF/FTC/EFV
ETV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
NVP Child-Pugh Class B or C: contraindicated
RPV Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data
PIs
ATV Child-Pugh Class B: 300 mg qd
Child-Pugh Class C: not recommended
RTV boosting is not recommended in persons with
hepatic impairment (Child-Pugh Class B or C)
DRV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
FPV PI-naïve persons:
Child-Pugh Class A or B: 700 mg bid
Child-Pugh Class C: 350 mg bid
PI-experienced persons:
Child-Pugh Class A: 700 mg bid + RTV 100 mg qd
Child-Pugh Class B: 450 mg bid + RTV 100 mg qd
Child-Pugh Class C: 300 mg bid + RTV 100 mg qd
IDV Child-Pugh Class A or B: 600 mg q8h
Child-Pugh Class C: no data
LPV/r No dosage recommendation; use with caution in
persons with hepatic impairment
RTV Refer to recommendations for the primary PI
SQV Child-Pugh Class A or B: use with caution
Child-Pugh Class C: contraindicated
TPV Child-Pugh Class A: use with caution
Child-Pugh Class B or C: contraindicated
FI
ENF No dosage adjustment
CCR5 Inhibitor
MVC No dosage recommendations. Concentrations will
likely be increased in persons with hepatic impairment
INSTI
RAL No dosage adjustment
EVG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
DTG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TDF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
ABC/3TC/DTG Use separate compounds and refer to those adjust-
ments 
Note: Hepatic dysfunction is a good indication for TDM as clinical experience 
with these dose adjustments is very limited.
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Lipodystrophy: Prevention and Management
Lipoatrophy Lipohypertrophy(i)
Prevention
• Avoid d4T and ZDV or pre-emptively switch away from them. No evidence 
of benefit by switching other antiretrovirals.
• Avoid excessive weight loss due to diet and exercise.
• In ART-naïve persons, limb fat usually increases with initiation of ART not 
containing d4T or ZDV, reflecting “return-to-health” type of response
Prevention
• No proven strategy
• No current antiretroviral drug has been specifically associated with increa-
sed visceral adiposity
• An excess of visceral fat has been reported in HIV vs. non-HIV non-obese 
persons for the same body mass index
• Weight reduction or avoidance of weight gain may decrease visceral fat
• Avoid inhaled fluticasone (and potentially other inhaled corticosteroids)
with RTV or COBI-boosted PIs as it may cause Cushing syndrome or 
adrenal insufficiency (see Drug-Drug Interactions between ARVs and 
Corticosteroids)
Management
• Modification of ART
  –– Switch d4T or ZDV to ABC or TDF:
    –– Only ART modification proven to partially restore subcutaneous fat;
         increase in total limb fat ~400-500 g/year
    –– Risk of toxicity from new drug, see Adverse Effects of ARVs & Drug
         Classes
  –– Switch to regimen not including NRTIs
    –– Increase in total limb fat ~400-500 g/year
    –– May increase risk of dyslipidaemia
• Surgical intervention
  –– Offered for cosmetic relief of (facial) lipoatrophy only
Management
• Diet and exercise may reduce visceral adiposity;
  –– Limited data, but possible reduction in visceral adipose tissue and
       improvement in insulin sensitivity and blood lipids, especially in obesity
       associated with lipohypertrophy
  –– No prospective trials in HIV-positive persons to definitely indicate degree
       of diet and/or exercise needed to maintain reduction in visceral fat
  –– May worsen subcutaneous lipoatrophy
• Pharmacological interventions to treat lipohypertrophy have not been pro-
  ven to provide long-term effects and may introduce new complications;
• Growth hormone (not approved for this indication in Europe) 
  –– Decreases visceral adipose tissue
  –– May worsen subcutaneous lipoatrophy and insulin resistance
• Tesamorelin (not approved in Europe; approved for this indication by FDA)ii 
• Metformin (not approved for this indication in Europe)
  –– Decreases visceral adipose tissue in insulin resistant persons
  –– May worsen subcutaneous lipoatrophy
• Surgical therapy can be considered for localised lipomas/buffalo humps
  –– Duration of effect variable
i  Lipohypertrohy may occur as localised  lipomas in the subcutaneous 
region or as increased visceral adiposity, both intraabdominally and/or in 
the the epicardium 
ii  Tesamorelin (growth hormone releasing factor) was shown to reduce 
visceral adipose tissue volume but this effect was lost on discontinuation; 
the drug is not currently licensed in Europe
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Hyperlactataemia and Lactic Acidosis: Diagnosis, Prevention and Management
Risk factors Prevention/Diagnosis Symptoms
• Use of ddI > d4T > ZDV
• HCV/HBV co-infection
• Use of ribavirin
• Liver disease
• Low CD4 count
• Pregnancy
• Female sex
• Obesity
• Avoid d4T + ddI combination
• Routine monitoring of serum lactate levels not 
recommended - does not predict risk of lactic 
acidosis
• Measurement of serum lactate, bicarbonate & 
arterial blood gases + pH indicated in case of 
symptoms suggestive of hyperlactataemia
• Close monitoring for symptoms if > 1 risk factor
• Hyperlactataemia: unexplained nausea, abdo-
minal pain, hepatomegaly, elevated ALT and/or 
AST, weight loss
• Acidaemia: asthenia, dyspnoea, arrhythmias
• Guillain-Barré-like syndrome
Management
Serum lactate (mmol/L) Symptoms Action
> 5(i) Yes/No • Repeat test under standardised conditions to confirm & obtain arterial pH 
and bicarbonate(i)
• If confirmed, exclude other causes
 – Arterial pH ↓ and/or bicarbonate ↓(i): Stop NRTIs 
 – Arterial pH and/or bicarbonate normal: Consider switch from high to 
low-risk NRTI & monitor carefully OR stop NRTIs
2-5 Yes Exclude other causes; if none found: watchfully follow up OR consider 
switch from high to low-risk NRTI, OR stop NRTI 
2-5 No Repeat test 
If confirmed, watchfully follow up
< 2  None 
i Lactic acidosis is a rare but life-threatening situation usually associated 
with symptoms; high risk if serum lactate > 5 and especially > 10 mmol/L.
Management of lactic acidosis  
(irrespective of serum-lactate level)
Admit the person. Stop NRTIs. Provide iv fluids. Vitamin supplementation 
can be used (vitamin B complex forte 4 mL bid, riboflavin 20 mg bid, thia-
mine 100 mg  bid; L-carnitine 1000 mg  bid), although benefit is not proven.
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Travel
General precautions • Delay travel until clinically stable and treatment 
established
• Provide drug prescription and referral letter for 
emergencies
• Provide medical certificate for import of perso-
nal medicines/syringes
• Carry antiretrovirals split between suitcase and 
hand luggage
• Beware of fake drugs
ART • Maintain hours of medicines (e.g. 23.00 local 
time) when switching time zones, shortening 
the interval to the next dose when flying east
Acknowledge in-
creased susceptibili-
ty(i) of HIV-positive
1. Observe food hygiene
• Bacterial enterocolitis 
e.g. diarrhoeagenic E. coli, Salmonella, Shigel-
la, Campylobacter
• Opportunistic intestinal parasitosis
  Cryptosporidium, Cyclospora, Isospora, 
Microsporidia
2. Prevent insect bites
• Repellents (DEET ≥ 30%), spray clothing with 
insecticide (permethrin)
• Malaria chemoprophylaxis/emergency stand-
by treatment(ii) 
• Yellow fever, see page 58 
• Leishmaniasis 
    Beware of sand flies (dogs) 
Advice on travel restrictions – see www.hivtravel.org
i Higher susceptibility due to HIV-associated GALT destruction, low CD4 
count
ii According to malaria risk at travel destination and national guidelines; 
adherence counselling is particularly important in persons visiting friends 
and relatives. See Drug-drug Interactions between Antimalarial Drugs 
and ARVs 
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Drug-drug Interactions between Antimalarial Drugs and ARVs
Effect of ARVs on antimalarial drugs and key metabolite
Legend: 
Arrows indicate effect of antiretrovirals on antimalarial drug/key metabolite
Green no clinically significant interaction expected
Orange potential interaction (consider treatment ahead of travel and therapeutic drug monitoring)
Red clinically relevant interaction, do not use or use with caution
Mefloquine (M)
Metabolism CYP 3A4
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ No
RPV, RAL, MVC, DTG → No
PI, COBI ↑ M may reduce PI/c (RTV ca. 35%) Potential
Artemisinins (A)
Artemisinins and its key metabolite, dihydroartemisinin, are active compounds
Metabolism CYP 2B6, 3A4, 2C19
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ A & dihydroartemisinin; 
A & metabolites reduce NVP, but not EFV/ETR
Do not use or 
use with caution
RPV, RAL, MVC, DTG → A may reduce RPV, MVC Potential
PI, COBI ↑ Increase A: monitor toxicity (liver) Potential
Lumefantrin (L)
Metabolism CYP 3A4
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ Potential
RPV, RAL, MVC, DTG → No
PI, COBI ↑ LPV increases L 2-3x Do not use or
use with caution
Atovaquone (At), Proguanil (P)
• Atovaquone increases ZDV levels by 35%
• Synergy with atovaquone is related to proguanil, not its active metabolite; therefore presumably no net  
effect of induction/inhibition
Metabolism CYP 2C19
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ ETV is increased Potential  
RPV, RAL, MVC, DTG → No
PI, COBI ↓ At & P 
take with fat meal, consider dose increase
Potential
Doxycycline
Metabolism NA
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) possibly ↓ Potential
RPV, RAL, MVC, DTG → No
PI, COBI → No
Chloroquine
Metabolism CYP 3A4, 2D6
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) → No
RPV, RAL, MVC, DTG → No
PI, COBI → No
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Quinine (Q)
Metabolism CYP 3A4, 2D6
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) ↓ Consider dose increase Potential
RPV, RAL, MVC, DTG → No
PI, COBI ↑ RTV increases Q 4x: consider
dose reduction, monitor toxicity
(tinnitus). CAVE: PI & Q prolong QT
Potential
Primaquine
Metabolism CYP 1A2, 2D6, 3A4
ARVs Effect on antimalarial drugs and key metabolite Relevance
NNRTI (EFV, NVP, ETV) N/A Potential
RPV, RAL, MVC, DTG → No
PI, COBI N/A
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Vaccination
• Vaccinate according to national guidelines for healthy population
• Consider repeating vaccinations performed at CD4 count < 200 cells/μL 
(< 14%) following adequate immune reconstitution
• As vaccine responses may be significantly lower in HIV-positive per-
sons, consider antibody titers to assess their effectiveness
• Avoid polysaccharide vaccination
• For additional details, see www.bhiva.org/vaccination-guidelines.aspx
• For attenuated live vaccines(i) 
(in addition to restrictions for general population):
•  *Varicella, measles, mumps, rubella, yellow fever contraindicated 
if CD4 < 200 cells/μL (14%) and/or AIDS
• Oral live typhoid 
Contraindicated if CD4 < 200 cells/μL (14%): give inactivated parente-
ral polysaccharide vaccine. Preferred if CD4 > 200 cells/μL (14%).
Infection Vaccination rationale in HIV-positive 
persons
Comment
Influenza Virus Higher rate of pneumonia. Explicitly rec-
ommended in all HIV-positive persons 
Yearly
Human Papilloma Virus (HPV) Shared risk with HIV of contracting
infection. Higher rate of cervical and anal
cancer
If HPV infection is established, efficacy of vaccine is questionable
Hepatitis B Virus (HBV) Shared risk with HIV of contracting
infection. HIV accelerates liver disease
progression
Vaccinate if seronegative. Consider double dose (40 μg) and  
intradermal vaccination in non-responders, in particular with low CD4 cells 
count and high viraemia. Repeat doses until HBs antibodies ≥ 10 IU/L / ≥ 
100 IU/L according to national guidelines.
See page 67
Hepatitis A Virus (HAV) According to risk profile (travel, MSM,
IVDU, active hepatitis B or C infection)
Vaccinate if seronegative. Check antibody titres in individuals with  
risk profile
See page 67
Neisseria meningitidis As general population Use conjugated(ii) vaccine (2 doses 1-2 months apart) if available. Booster 
every five years if exposure continues. Polysaccharide vaccine not recom-
mended anymore.
Streptococcus pneumoniae Higher rate and severity of invasive
disease. Vaccine explicitly recommend-
ed for all HIV-positive persons
Use conjugated(ii) 13-valent vaccine instead of PPV-23 polysaccharide 
vaccine if available. No recommendations yet about the need for a booster 
dose.  
Varicella Zoster Virus (VZV) Higher rate and severity of both chicken-
pox and zoster
Perform serology if exposure history negative. Vaccinate if seronegative. 
For contraindications, see*
Yellow Fever Virus Mandatory for travel to selected coun-
tries (provide exemption letter if no true
risk of exposure)
Contraindicated if past or current haematological neoplasia or thymus 
affection (thymoma, resection/radiation) 
For other contraindications, see*
i Administer live vaccines simultaneously or with an interval of 4 weeks 
ii Conjugated vaccines are more immunogenic, induce memory cells, 
respond to boosting and reduce mucosal colonisation 
iii Repetitive boosting may attenuate immune response 
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Sexual and Reproductive Health of HIV-positive Women and Men
Screening questions about sexual and reproductive health and sexual func-
tioning should be routinely asked in every HIV consultation. 
Sexual transmission of HIV
Effective measures to reduce sexual transmission of HIV include:
Measure Comment
Male condom or 
female condom use
• Effective in treated and untreated HIV-positive 
persons
Post-exposure 
prophylaxis (PEP)
• Consider after situations of unprotected anal or
vaginal intercourse, if one partner has detectab-
le HIV-VL and the other partner is seronegative
• Start as soon as possible and within 72 hours
post sexual exposure
See Post-exposure prophylaxis (PEP)
Pre-exposure 
prophylaxis (PrEP)
• Effective in  HIV-negative persons with high risk 
sexual behavior, See Pre-exposure prophylaxis 
(PrEP)
ART for HIV-positive  
partner
• Considered effective from 6 months of fully 
suppressive ART if no active STIs
• Consider in e.g. serodifferent couples(i)
i  See page 7
Reproductive health 
Reproductive health issues should be preferentially discussed with both 
partners, particularly in serodifferent couples. See Drug-drug Interactions 
between Contraceptives/Hormone Therapy Replacement Treatment and 
ARVs  
Approaches for serodifferent couples who want to have children
Screening for STIs (and treatment, if required) of both partners is mandatory. 
For HIV-positive women wishing to conceive: (1) avoid using ddI, d4T or 
triple NRTIs, avoid EFV in first trimester; among PI/r, prefer LPV/r, SQV/r or 
ATV/r, already started NVP, RAL or DRV/r can be continued, see page 12;
(2) consider treating the HIV-positive partner to reduce risk of HIV transmis-
sion to the HIV-negative partner.
No single method is fully protective against transmission of HIV; the following 
list represents selected measures with increasing safety for serodifferent 
couples without active STIs:
• Unprotected intercourse during times of maximum fertility (determined by 
ovulation monitoring), if the HIV-positive partner has undetectable HIV-VL 
• Vaginal syringe injection of seminal fluid during times of maximum fertility, 
if the male partner is HIV-negative 
• Sperm washing, with or without intra-cytoplasmic sperm injection, if the 
male partner is HIV-positive 
Sexual dysfunction 
Guidelines for treatment of sexual dysfunction in the general population are 
available for men but not women. Refer to specialist where appropriate.
See Sexual Dysfunction and Treatment of Sexual Dysfunction in  
HIV-positive Men
Therapy Comment
Chlamydia infection Consider doxycycline (100 mg bid for 7-10 days) 
or ofloxacin (200 mg bid), erythromycin (500 mg 
qd for 7 days) or azithromycin (1 g once).
For Lymphogranuloma venereum consider doxy-
cycline (100 mg bid for at least 3 weeks)
• May cause therapy-resistant proctitis in HIV-positive MSM
• Consider co-infections with Neisseria gonorrhoeae
Gonorrhoea Therapy recommended according to geographi-
cal resistance profiles.
Ceftriaxone 500 mg im as a single dose together 
with azithromycin 2 g as a single dose po.
• Can cause proctitis, prostatitis and epididymitis
• In women often asymptomatic
• Fluroquinolone resistance is extensive
HBV infection
HCV infection
See table on HIV/HCV or HIV/HBV co-infections, 
page 67, 68-78
• Interruption of TDF, 3TC or FTC can lead to HBV reactivation
• Clusters of acute HCV infection in HIV-positive MSM across Europe
HPV infection Treatment of genital warts is challenging. Con-
sider operative removal by laser surgery, infrared 
coagulation, cryotherapy, etc.
Management of both pre-invasive cervical lesions 
as well as peri- and intra-anal lesions should 
follow local or national guidelines
• Infection is mostly asymptomatic; relapse of genital warts is frequent
• Cervical PAP smear test recommended in all HIV-positive women
• Anal HPV screening and cytology should be considered in all HIV-positi-
ve persons practising anal sex
• Consider high resolution anoscopy in case of suspicious cytological 
findings (rectal palpation or external inspection is not sufficient)
HSV2 infection Primary infection: aciclovir (400–800 mg po tid) 
or valaciclovir (500 mg bid) for 5 days, see page 
84
• Treatment of HSV2 alone does not prevent HIV-transmission and only 
modestly prevents HIV disease progression
Syphilis Primary/secondary syphilis: benzathine peni-
cillin G (2.4 million IU im as single dose).
Late latent syphilis and syphilis of unknown 
duration: benzathine penicillin (2.4 million IU im 
weekly on days 1, 8 and 15); alternatives such as 
doxycycline (100 mg bid), or erythromycin  
(2 g/day) for 2 weeks are considered less effective.
Neurosyphilis: penicillin G (6 x 3 - 4 million IU iv 
for at least 2 weeks)
• Expect atypical serology and clinical courses
• Consider cerebral spinal fluid (CSF) testing in persons with neurologi-
cal symptoms (evidence for intrathecally-produced specific antibodies, 
pleocytosis, etc.)
• Successful therapy clears clinical symptoms and/or decreases VDRL test 
by at least 2 titre levels
• Serology cannot distinguish re-infection from re-activation
STI screening and treatment
STI screening should be offered to all sexually active HIV-positive persons at 
the time of HIV diagnosis, annually thereafter or at any time STI symptoms 
are reported. Diagnosis procedures should follow local or national guide-
lines. More comprehensive advice can be found at  
www.iusti.org/regions/Europe/euroguidelines.htm
The following STIs should be universally considered in HIV-positive persons 
and their sexual partner(s):
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When sexual 
complaints exist:
What is the exact nature of the 
problem? In which phase(s) of 
the sexual response cycle does 
the problem occur?
1. Desire (lack of sexual desire or libido; desire discrepancy with partner; aversion to sexual activi-
ty)
2.  Arousal (difficulties with physical and/or subjective sexual arousal; difficulties or inability to achie-
ve or sustain an erection of sufficient rigidity for sexual intercourse (M)–i.e. erectile dysfunction; 
lack or impaired nocturnal erections (M); difficulties lubricating (W); difficulties sustaining arousal)
3. Orgasm (difficulties experiencing orgasm) 
4. Pain (pain with sexual activity; difficulties with vaginal/anal penetration–anxiety, muscle tension; 
lack of sexual satisfaction and pleasure)
Identify the 
causes:
Psychological or sociological 
problems?
Stigma, body image alteration, depression, fear of infecting an 
HIV-negative partner? 
Refer to clinical psychologist
Relevant co-morbidity? CVD (note: if complete sexual response possible - e.g. with 
another partner, with masturbation or nocturnal - then no major 
somatic factors are involved)
Refer to urologist, andrologist, 
cardiologist
Relevant medicines, drugs, 
lifestyle factors? 
Drugs associated with sexual dysfunction: 1) psychotropics 
(antidepressants, antiepileptics, antipsychotics, benzodiazepines), 
2) lipid-lowering drugs (statins, fibrates), 3) antihypertensives 
(ACE-inhibitors, betablockers, alfablockers), 4) others (omepra-
zole, spironolactone, metoclopramide, finasteride, cimetidine); 5) 
contribution from ARVs is controversial and benefit from switching 
studies is not proven.
Refer to clinical pharmacologist
Signs of hypogonadism in men? Signs of testosterone insufficiency (reduced sexual arousal and 
libido; decreased frequency of sexual thoughts and fantasies; 
decreased or absent nocturnal erections; decreased genital sensi-
tivity; loss of vitality; fatigue; loss of muscle mass and muscle 
strength and decreased body hair)
Refer to endocrinologist
Sexual Dysfunction
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Treatment of Sexual Dysfunction in HIV-positive Men
Treatment of erectile dysfunction Treatment of premature ejaculation
Primarily oral PDE5-Is (sildenafil, tadalafil, vardenafil).
• All at least 30 minutes before initiation of sexual activity
• Use lower dose if on PI/r
  –– sildenafil (25 mg every 48 hours)
  –– tadalafil 5 mg initial dose with maximum dose 10 mg in 72 hours
  –– vardenafil 2.5 mg maximum dose in 72 hours
• Tadalafil also licensed for use as an everyday ongoing therapy
Consider behavioural interventions and/or psychosexual counselling,
SSRIs, tricylclic antidepressants, clomipramine and topical anaesthetics.
• Use lower dose of clomipramine and other tricyclic antidepressants if on 
PI/r 
• Dapoxetine, a short-acting SSRI, is the only drug approved for on-demand 
treatment of premature ejaculation in Europe.
• Treatment must be maintained as recurrence is highly likely following 
withdrawal of medicine
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Depression: Screening and Diagnosis
Significance
• Higher prevalence of depression reported in HIV-positive persons (20-40% 
versus 7% in general population) 
• Significant disability and poorer treatment outcomes associated with 
depression
Screening and diagnosis
Who? How to screen? How to diagnose?
Screening of all HIV-positive per-
sons recommended in view of the 
high prevalence of depression
Populations at particular high risk
• Positive history of depression in 
family
• Depressive episode in personal 
history
• Older age
• Adolescence
• Persons with history of drug ad-
diction, psychiatric, neurologic or
severe somatic co-morbidity
• Use of EFV
• Use of neurotropic and recreatio-
nal drugs
• As part of investigation of neuro-
cognitive impairment see page 64
• Screen every 1-2 years
• Two main questions: 
1. Have you often felt depressed, 
sad or without hope in the last few 
months? 
2. Have you lost interest in activi-
ties that you usually enjoy?
• Specific symptoms in men:
 – Stressed, burn out, angry 
outbursts, coping through work 
or alcohol
• Rule out organic cause (such as 
hypothyroidism, hypogonadism, 
Addison’s disease, non-HIV drugs, 
vitamin B12 deficiency)
Symptoms – evaluate regularly
A.  At least 2 weeks of depressed mood
OR
B.  Loss of interest 
OR
C.  Diminished sense of pleasure
PLUS 4 out of 7 of the following:
1.  Weight change of ≥ 5% in one month or a persistent change of appetite
2.  Insomnia or hypersomnia on most days
3.  Changes in speed of thought and movement
4.  Fatigue
5.  Feelings of guilt and worthlessness
6.  Diminished concentration and decisiveness
7.  Suicidal ideation or a suicide attempt(i)
i  EFV has been associated with a higher risk of suicidal ideation
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Depression: Management
Degree of  
depression
Number of 
symptoms                  
(see page 62:   
A,B or C + 4/7)
Treatment Consultation with expert
No < 4 No
Mild 4 • Problem-focused consultation
• Consider antidepressant 
treatment(i)   
• Recommend physical activity
• Always if treating physician is unfamiliar with use of antidepressants
• If depression not responding to treatment
• If person has suicidal ideation
• In case of complex situations such as drug addiction, anxiety disorders, 
personality disorders, dementia, acute severe life eventsIntermediate 5-6 Start antidepressant treatment(i)  
Severe > 6 Refer to expert (essential)   
i See Drug-drug Interactions between Antidepressants and ARVs
 
If a person is diagnosed with depression switching off EFV to another third 
ARV drug according to switch rules is recommended
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Classification, Doses, Safety and Adverse Effects of Antidepressants
Mechanisms & 
classification
Start dose Standard dose Lethality in 
overdose
Insomnia  
and agitation
Sedation Nausea or 
GI effects
Sexual  
dysfunction
Weight gain
mg/day
Selective serotonin-reuptake inhibitors (SSRIs)(i)
paroxetine 10-20 20-40 Low + - / + + ++ ++
sertraline 25-50 50-150 Low + - / + + + +
citalopram 10-20 20-40 Low + - / + + + +
escitalopram 5-10 10-20 Low + - / + + + +
Mixed or dual-action reuptake inhibitors
venlafaxine 37.5-75 75-225 Moderate ++ - / + + + - / +
Mixed-action newer agents
mirtazapine 30 30-60 Low - / + ++ - / + - / + ++
-  none
+  moderate
++ severe
i For many persons, SSRI induction may be associated with adverse 
effects (GI tract, dizziness, anxiety, panic attacks). Commencing at lower 
doses (i.e. 10, 25 & 10 mg for paroxetine, sertraline and citalopram, 
respectively) and increasing to the above starting doses after 4 to 7 days 
if tolerated may reduce such effects.
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Drug-drug Interactions between Antidepressants and ARVs
Legend
↑  potential elevated exposure of the antidepressant       
↓  potential decreased exposure of the antidepressant
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
a  ECG monitoring is recommended       
b  the US Prescribing Information recommends that co-administration 
should be avoided as there are insufficient data to make dosing 
recommendations.
 Numbers refer to decreased AUC of the antidepressant as observed 
in drug-drug interactions studies.
SSRI  selective serotonin reuptake inhibitors 
SNRI serotonin and norepinephrine reuptake inhibitors
TCA  tricyclic antidepressants    
TeCA  tetracyclic antidepressants
Colour legend
 no clinically significant interaction expected.  
 these drugs should not be co-administered. 
 potential interaction, which may require a dosage adjustment or 
close monitoring.  
 potential interaction predicted to be of weak intensity (< 2 fold ↑AUC 
or < 50% ↓AUC).  A dosage adjustment is a priori not recommended. 
Comment
The symbol (red, amber, green) used to rank the clinical significance of the 
drug interaction is based on www.hiv-druginteractions.org (University of 
Liverpool). For additional drug-drug interactions and for more detailed 
pharmacokinetic interaction data and dosage adjustments, refer to the above 
mentioned website.       
    
Antidepressants ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL
SSRI citalopram ↑ a ↑ ↑ ↑ a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
escitalopram ↑ a ↑ ↑ ↑ a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
fluvoxamine ↑ ↑ ↑ ↑ ↔ ↔ E ↔ ↔ ↔ ↑ ↔
fluoxetine ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
paroxetine ↑↓? ↑↓? ↓39% ↑↓? ↔ ↔ ↔ ↔ ↔ ↔ ↑↓? ↔
sertraline ↓ ↑ ↓49% ↓ ↓39% ↓ ↓ ↔ ↔ ↔ ↑ ↔
SNRI duloxetine ↑↓ ↑ ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
venlafaxine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ D ↔ ↑ ↔
TCA amitriptyline ↑a ↑ ↑ ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
clomipramine ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
desipramine ↑a ↑ ↑ ↑5%a ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
doxepin ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
imipramine ↑ a ↑ ↑ ↑ a ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
nortriptyline ↑ a ↑ ↑ ↑ a ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
trimipramine ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
TeCA maprotiline ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
mianserine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
mirtazapine ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
Others bupropion ↓ ↔ ↓ ↓57% ↓55% ↔ ↓ ↔ ↔ ↔ ↑? ↔
lamotrigine ↓32% ↔ ↓ ↓50% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔
nefazodone ↑ ↑ ↑ ↑ ↓E ↓ E ↓E E E ↔ ↑ ↔
St John's wort D D D D D D D D D Db D ↔
trazodone ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↑ ↔
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Algorithm for Diagnosis and Management of HIV-Associated Neurocognitive  
Impairment (NCI) in Persons without Obvious Confounding Conditions
Abbreviations
CSF cerebrospinal fluid
GDR genotypic drug resistance test
HAD HIV-associated dementia
MND mild neurocognitive disorder
MRI brain magnetic resonance imaging
NP neuropsychological
HIV-positive person-
self or their relatives 
complaining of, or 
care giver noting 
cognitive problems 
- without obvious 
confounding condi-
tions(i)
Initial assesments(ii)
Problems confirmed
Evaluation for 
depression and pos-
sible treatment(iii)
Problems persisting but 
depression excluded or 
optimally managed
NP examination(iv)
Abnormal
Neurological  
examination
Brain MRI
CSF examination(v)
Additional causes of NCI 
other than HIV excluded
Diagnosis:
HIV-associated 
NCI(vi)
Off ART On ART
CSF viral escape(vii) Other situations(viii)
Start ART (refer to
general guidelines)
Consider inclusion of
potentially CNS-ac-
tive drugs(ix)
Optimise ART by CSF
and plasma GDR
testing
Include potentially 
CNS-active drugs(ix)
Continue or switch
ART (refer to general
guidelines)
Reconsider other
causes of NCI
Repeat CSF exam-
ination and other 
evaluations after  
≥ 4 weeks
 
i  Obvious confounding conditions: 
1. Severe psychiatric conditions 
2. Abuse of psychotropic drugs 
3. Alcohol abuse 
4. Sequelae from previous CNS-OIs or other neurological diseases 
5. Current CNS-OIs or other neurological diseases 
ii  The following 3 questions may be used to guide physician assess-
ment 
1. Do you experience frequent memory loss (e.g. do you forget the oc-
currence of special events even the more recent ones, appointments, 
etc.)? 
2. Do you feel that you are slower when reasoning, planning activities, or 
solving problems? 
3. Do you have difficulties paying attention (e.g. to a conversation, book 
or movie)? 
For each question, answers could be: a) never, b) hardly ever, or c) yes, 
definitely. HIV-positive persons are considered to have an “abnormal” 
result when answering “yes, definitely” on at least one question. 
iii See Depression: Screening and Diagnosis 
iv NP examination will have to include tests exploring the following cognitive 
domains: fluency, executive functions, speed of information processing, 
attention/working memory, verbal and visual learning, verbal and visual 
memory, motor skills plus assessment of daily functioning 
v  Neurological examination, brain MRI and CSF examination are 
required to exclude other pathologies and to further characterise HIV-
associated NCI, by including assessment of CSF HIV-VL level and, where 
appropriate, evidence for genotypic drug resistance (GDR) in a paired 
CSF and plasma sample.  
vi NCI includes 
1) marked acquired impairment in cognitive functioning involving at least 
2 cognitive domains, as documented by performance of at least 1 SD 
below the mean for age-education appropriate norms on NP tests 
2) interference in daily functioning; 
3) no evidence of another pre-existing cause for the dementia 
vii CSF escape definition: either CSF VL > 50 and plasma HIV-VL < 50 
copies/mL- or both CSF and plasma HIV-VL > 50 copies/mL, with CSF 
HIV-VL > 0.5 log10 higher than plasma HIV-VL. 
viii Including all situations that do not fulfill the CSF escape definition 
ix Definition of potentially CNS-active drug
    ARV drugs with either: 
1. demonstrated clear CSF penetration when studied in healthy 
HIV-positive populations (concentration above the IC90 in > 90% 
examined persons) 
2. proven short-term (3-6 months) efficacy on cognitive function or 
CSF HIV-VL decay when evaluated as single agents or in cont-
rolled studies in peer-reviewed papers
    • Drugs with demonstrated clear CSF penetration: 
       ––NRTIs: ZDV, ABC* 
       ––NNRTIs: EFV**, NVP 
       ––PI/r: IDV/r, LPV/r, DRV/r* 
       ––INSTI: DTG
       ––Other classes: MVC 
   • Drugs with proven clinical efficacy: 
       ––NRTIs: ZDV, ABC 
       ––PI/r: LPV/r 
*  When administered bid. Once-daily administration of these drugs, although 
common in clinical practice, has not been studied extensively with regard 
to CNS effects/CSF penetration and may have different CNS activity.
** EFV should be used cautiously in HIV-positive persons with NCI because 
of its detrimental effects on neurocognitive function in a RCT and potenti-
ally confounding CNS effects.
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Part IV   Clinical Management and Treatment  
 of HBV and HCV Co-infection in  
 HIV-positive Persons               
General Recommendations for Persons with Viral Hepatitis/HIV Co-infection
Screening
1. All HIV-positive persons should be screened for HCV at time of HIV 
diagnosis and annually hereafter. Screening should use an anti-HCV 
antibody test. A positive result should be followed by HCV-RNA and 
genotype determination. Persons with risk factors (ongoing IVDU, 
mucosal traumatic sex, ongoing unprotected anal intercourse, recent 
sexually transmitted infection) with unexplained increase in hepatic 
transaminases and a negative anti-HCV antibody test should be tested 
for HCV-RNA for early detection of a recent infection. 
2. HIV-positive persons should be screened for HAV and HBV. Persons 
who are anti-HBc positive and HBsAg negative, in particular those with 
elevated liver transaminases, should be screened for HBV-DNA in additi-
on to HBsAg to rule out occult HBV infection. 
3. Hepatitis Delta antibodies should be screened for in all HBsAg positive 
persons. 
4. HCV co-infected persons with liver cirrhosis and HBV co-infected 
persons with high risk for HCC (Asian, black, family history of HCC, 
liver cirrhosis, NAFLD, replicating HBV infection) should be screened 
at 6-monthly intervals with hepatic ultrasound (CT in case of nodules– 
alpha-foetoprotein may also be used, but value controversial) for the 
occurrence of hepatocellular carcinoma (HCC). Routine screening is 
also advised for oesophageal varices at the time of diagnosis mainly 
when there is evidence of portal hypertension and at 3-4-year intervals 
thereafter if not present initially, see page 49. Regarding HCC screening, 
see page 50. In the presence of a liver nodule or a liver mass, recall 
policy of EASL/EORTC guidelines should be followed. Management 
of HCC should be defined for each case with a multidisciplinary team 
including transplant surgeon, interventional radiologist and hepatologist. 
In persons treated with sorafenib, toxicity of ARVs and sorafenib should 
be strictly monitored. 
Vaccination see page 58
5. Persons lacking anti-HAV IgG antibodies or anti-HBs antibodies should 
be offered vaccination for the respective virus to prevent infection 
regardless of their CD4 count. The response to the HBV vaccine is 
influenced by the CD4 count and level of HIV-VL. In persons with low 
CD4 count (< 200 cells/μL) and ongoing HIV replication, ART should be 
initiated first prior to respective vaccination. Because of the lack of data 
on the impact of immunisation in isolated anti-HBc IgG positive persons 
(HBsAg negative, anti-HBc positive and anti-HBs negative profile), vac-
cination is not presently recommended in this population. This guideline 
might be revised when more data are available from current trials. 
6. In HIV-positive persons vaccinated for HBV with insufficient response 
(anti-HBs < 10 IU/L), re-vaccination should be considered. Double-dose 
(40 μg) at 3-4 time points (months 0, 1, 6 and 12) may help to improve 
response rates to the HBV vaccine. Persons who fail to seroconvert 
after HBV vaccination and remain at risk for HBV should have annual 
serological tests for evidence of HBV infection. TDF based cART has 
been associated with prevention of HBV infection in these persons. 
ART
7.   HIV-positive persons with HBV and/or HCV co-infection benefit from 
early ART because liver fibrosis progression is reduced with immune 
reconstitution and suppression of HIV-VL. Thus, ART initiation with a 
TDF-based regimen is recommended in all persons with HBV co-
infection (HBsAg-positive) irrespective of CD4 count. In persons with 
chronic HCV, ART initiation is also recommended irrespective of CD4  
count. Stopping ART has been associated with enhanced risk for AIDS 
and non-AIDS related events; indeed, the risk for non-AIDS events was 
particularly increased for persons with hepatitis co-infection. Stopping 
anti-HBV containing ART should be avoided in persons with HIV/HBV 
co-infection because of the high risk of severe hepatitis flares and de-
compensation following HBV reactivation hepatitis.
End Stage Liver Disease (ESLD)
8. HIV-positive persons require the same measures for the treatment of 
oesophageal varices, hepatorenal syndrome, hepatic encephalopathy 
or ascites as HIV-negative persons, see page 49-50 and Diagnosis and 
Management of Hepatorenal Syndrome (HRS). 
9. Persons with viral hepatitis/HIV co-infection suffering from ESLD warrant 
particular attention in the management of liver insufficiency; see Dose 
Adjustment of ARVs for Impaired Hepatic Function. Nevertheless, it is 
important to highlight that ART initiation in cirrhotic persons generally im-
proves overall survival and is therefore strongly recommended in these 
persons. 
10. Renal complications are frequent, see page 50 and Diagnosis and 
Management of Hepatorenal Syndrome (HRS) 
11. Persons with HCC or a MELD-score > 15*, CD4 count > 100 cells/ μL 
and options for efficacious and durable ART should be evaluated for 
liver transplantation (OLTX). OLTX outcomes in persons with HIV/HBV 
co-infection are particularly promising, whereas post-transplant survival 
in persons with HIV/HCV co-infection has been somewhat lower than in 
persons with HCV mono-infection mainly due to the complicated course 
of HCV re-infection after transplantation. An improvement in survival in 
HIV/HCV co-infected persons is expected in the next years due to the 
possibility to eradicate HCV pre- or post- transplant with direct acting 
antiviral drug (DAA)-based therapy. 
* MELD calculation, see page 50.
Prevention/Support
12. Psychiatric, psychological, social and medical support should be made 
available to persons with alcohol intake to stop drinking. 
13. Substitution therapy (opioid replacement therapy) in persons with active 
drug use as a step towards cessation of active drug use should be 
encouraged. Help provided (e.g. through needle and syringe exchange 
programme) reduces the risk of re-infection including parenteral viral 
transmission (harm reduction strategy). See Drug Dependency and Drug 
Addiction 
14. Since HBV and HIV, and occasionally HCV, are transmitted sexually, 
adequate counselling including the use of condoms is advisable. Infor-
mation on the risk of HCV transmission due to mucosal traumatic sexual 
practices associated with a high likelihood of blood contact or iv adminis-
tration of recreational drugs (“chem sex”) should be provided and risk 
reduction should be discussed. 
Delta Virus 
15. In persons with Delta virus co-infection and significant liver fibrosis (≥ 
F2), long-term (> 18 months) treatment with PEG-IFN might be conside-
red in association with TDF-based ART. Because of its anti-HBV activity, 
TDF should be added to PEG-IFN in order to reduce HBV-DNA load. 
Treatment efficacy should be monitored with HBV-DNA and HDV-RNA 
measurements, when available, and with follow-up of biochemical and 
liver fibrosis estimates. Persons with anti-HCV antibodies and detectable 
HCV-RNA should be offered anti-HCV treatment in order to induce a 
sustained virologic response for HCV co-infection. Persistent off-treat-
ment HDV-RNA negativity and anti-HBs seroconversion are the ideal 
goals of antiviral treatment for hepatitis Delta even if they can only be 
obtained in a minority of persons. Histological remission of liver disease 
is a less ambitious but more likely to be achieved goal. In persons with 
Delta virus and ESLD or HCC, liver transplantation from HBsAg negative 
donor should be strongly considered especially in the absence of active 
HCV co-infection. Transplant with anti-HBV post-OLTX prophylaxis 
cures HBV and Delta virus infection. 
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Treatment of Chronic HBV in Persons with HBV/HIV Co-infection
          HIV/HBV Co-infection
Any CD4 count or cirrhosis(i-iii)
3TC
experienced
3TC
naïve
Add or substi-
tute one NRTI 
with TDF as 
part of ART(ii)
ART(iii) 
including TDF 
+ 3TC or FTC
i For management of cirrhotic persons, see page 49-52. Persons with 
liver cirrhosis and low CD4 count require careful surveillance in the first 
months after starting ART in order not to overlook immune reconstitution 
syndrome and subsequent liver decompensation due to flares of liver 
enzymes. 
ii All persons with HBV/HIV co-infection should receive ART including TDF 
+ 3TC or FTC unless history of TDF intolerance. In HBV/HIV co-infected 
persons with chronic kidney disease, see recommendations for Dose 
Adjustment of ARVs for Impaired Renal Function and page 45. If TDF 
is strictly contra-indicated, entecavir + adefovir may be tried. However, 
efficacy and renal toxicity need to be closely monitored, because of the 
proven renal toxicity of adefovir. In persons with no prior 3TC exposure, 
entecavir may be used alone. NRTI substitution should only be perfor-
med if feasible and appropriate from the perspective of maintaining HIV 
suppression. Caution is warranted to switch from a TDF-based regimen 
to drugs with a lower genetic barrier, e.g. FTC or 3TC, in particular in 
3TC-pretreated cirrhotic persons as viral breakthrough due to archived 
YMDD mutations is likely to happen. This has also been described in 
individuals with previous 3TC HBV-resistance who have been switched 
from TDF to entecavir. The addition of entecavir to TDF in persons with 
low persistent HBV-replication has not statistically proved to be efficient 
and should therefore be avoided. Results of trials are awaited. 
iii The optimal treatment duration for nucleos(t)ide analogues with anti-
HBV activity has not yet been determined and experts recommend 
life-long therapy if anti-HBV nucleos(t)ides are given as part of ART. In 
those on ART where the nucleoside backbone needs changing, anti-
HBV therapy may be stopped cautiously in HBeAg positive persons 
who have achieved HBe-seroconversion for at least six months or after 
confirmed HBs-seroconversion in those who are HBeAg negative. In 
persons with liver cirrhosis, stopping of effective anti-HBV treatment is 
not recommended in order to avoid liver decompensation due to flares of 
liver enzymes. 
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Diagnostic Procedures for HCV in Persons with HCV/HIV Co-infection
Diagnosis of HCV 
HCV-Ab (turn positive 1-6 months after infection as late seroconversions 
have been described, may rarely be lost due to immunosuppression) 
HCV-RNA levels(i) (in particular important for the prediction of response to 
IFN treatment) 
Status of liver damage 
Staging of fibrosis (e.g. FibroScan, liver biopsy, serum fibrosis markers(ii)) 
Hepatic synthetic function (e.g. coagulation, albumin, cholinesterase) 
Ultrasound every 6 months if cirrhosis (gastroscopy upon diagnosis of cir-
rhosis and every 2-3 years thereafter if negative for oesophageal varices), 
see page 49
Before HCV treatment 
HCV genotype (GT), HCV-RNA, renal and liver function tests
Autoantibodies (ANA, LKM1)(iii)
TSH, thyroid autoantibodies (risk of hyperthyroidism under IFN-based 
therapy)
Monitoring of HCV treatment 
Differential blood count, creatinine, liver enzymes and, in persons with 
advanced fibrosis, bilirubin, albumin and INR every 2-4 weeks.
In persons treated with IFN-free regimens HCV-RNA at 2-4 weeks and 
whenever needed in order to assess compliance and or breakthrough in 
persons experienced to oral DAAs.
HCV-RNA at week 4 (to evaluate rapid virological response (RVR) under 
IFN-based HCV regimens) and under all treatments at end-of-treatment 
and at week 12 and 24 after treatment cessation (to assess SVR). In 
persons receiving all oral DAA therapy no association between viral load at 
any given time-point under therapy and SVR has yet been found.
CD4 count and HIV-VL every 12 weeks
TSH and non-organ specific autoantibodies every 12 weeks under IFN-
based therapy
i Low HCV-RNA defined as < 400,000-600,000 IU/mL when using PEG-
IFN+RBV. There is no standard conversion formula for converting the 
amount of HCV-RNA reported in copies/mL to the amount reported in 
IU/mL. The conversion factor ranges from about one to five HCV-RNA 
copies per IU/mL.
ii Serum fibrosis markers include APRI, FIB-4, Hyaluronic acid, Fibro-
meter, Fibrotest, Forns, Hepascore and other indices; recently more 
complex tests such as Fibrometer, Fibrotest and Hepascore have shown 
to more accurately predict liver fibrosis than simple biochemical tests 
such as APRI, FIB-4 or Forns.
iii  Persons with positive anti LKM or ANA with homogeneous pattern 
should be evaluated for concurrent autoimmune hepatitis especially in 
the presence of ALT elevation during IFN-based treatment. Other con-
current causes of liver disease should be identified by blood tests and 
liver biopsy if needed. 
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Treatment indication
1. HCV treatment offers the possibility of eradicating HCV within a defined 
treatment period which translates into HCV cure. This is potentially 
advantageous for the subsequent management of the person with HIV, 
and every person with co-infection should therefore be considered for 
treatment when the benefits of therapy outweigh the risks including pre- 
or post-liver transplantation. This also needs to be seen in the context 
of faster liver fibrosis progression in persons with HCV/HIV co-infection 
(particularly in persons with low CD4 counts (< 200 cells/µL)) and with 
better HCV-treatment outcome with the use of DAAs in these persons. 
Furthermore, achieving SVR has also been associated with an improved 
survival even in lower fibrosis stages (F2) suggesting benefits of HCV 
therapy beyond cure of HCV and prevention of further liver disease 
progression. Thus HIV co-infection gives a high priority to anti-HCV 
treatment already at lower liver fibrosis stages (F0/F1). Similar HCV 
cure rates and tolerability in HCV/HIV co-infected persons as in HCV 
mono-infected persons under DAA therapy have further questioned the 
separation of HIV co-infected persons as a separate patient group and 
have claimed treatment indication and regimens to be the same as in 
HCV mono-infection. 
2. If chronic HCV and HIV infection are newly diagnosed at the same time 
with a CD4 count > 500 cells/µL treatment of HCV in presence of imme-
diate HCV treatment indication (≥ F2 fibrosis) can be considered prior to 
ART initiation to avoid potential drug-drug interactions between ART and 
HCV DAAs, see Drug-drug Interactions between DAAs and ARVs.
3. Information on liver fibrosis staging is important for making therapeutic 
decisions in persons with co-infection. However, a liver biopsy is no 
longer mandatory for considering treatment of chronic HCV. 
4. In case of the availability of a liver biopsy or FibroScan® demonstrating 
lack of or minimal liver fibrosis (F0-1), regardless of HCV GT, treatment 
can be deferred in countries where no or only limited DAAs have become 
available so far or where cost reimbursement issues still have not been 
clarified. In these cases, fibrosis assessment should be carried out every 
12 months to monitor for fibrosis progression (see page 71). 
Treatment of chronic HCV in persons with HCV/HIV-co-infection
 
5. With multiple studies in HCV treatment-naïve and treatment experienced 
persons with HCV/HIV co-infection demonstrating significantly higher 
SVR 12-24 rates with DAA based therapy, IFN-free DAA combinations 
should be considered standard of care for chronic HCV, in particular in 
advanced fibrosis. IFN-containing HCV regimens are no longer recom-
mended with the exception of HCV GT 3 infected persons experienced 
to IFN. For IFN-containing HCV regimens see IFN-containing Treatment 
of HCV Co-infection in HIV-positive Persons
6. The combination of sofosbuvir 400 mg qd and a weight-adapted dose of 
RBV of 1000 (wt < 75 Kg) -1200 (wt > 75Kg) mg/day (administered bid) 
for 12 weeks has become the new gold standard therapy for all HCV 
GT2 persons promising HCV cure in > 90% of persons. Persons with 
cirrhosis can be treated for an extended duration of 16 weeks. The ap-
proval of further DAAs have offered the opportunity of IFN- and partially 
also RBV-free DAA combination regimens which because of significantly 
improved tolerability and higher HCV cure rates should now be consi-
dered as new gold standard in HCV therapy. In particular, combination 
of sofosbuvir and simeprevir (GT1 and 4), a fixed-dose combination of 
sofosbuvir/ledipasvir (GT 1 and 4), sofosbuvir and daclatasvir (GT1, 
2, 3 and 4) or a combination of ombitasvir/paritaprevir/r and dasabuvir 
(GT 1 and 4 without dasabuvir) are recommended, see HCV Treatment 
Options in HCV/HIV Co-infected Persons. Addition of RBV may be con-
sidered to reduce relapse rate and shorten treatment duration for some 
of the DAA combinations. Also RBV should be added to the ombitasvir/
paritaprevir/r and dasabuvir combination when treating GT1a and ombi-
tasvir/paritaprevir/r when treating GT 4.
7. Use of older, first generation HCV PIs (boceprevir and telaprevir; only 
indicated in GT1) are no longer recommended because of increased 
toxicities. Simeprevir can cause hyperbilirubinaemia and skin reactions/
photosensibility. 
8. Due to drug-drug interactions in particular HIV and HCV PIs careful 
checking for interactions is urgently recommended prior to starting HCV 
therapy, see Drug-drug Interactions between DAAs and ARVs or www.
hep-druginteractions.org. During PEG-IFN-RBV therapy, ddI is contrain-
dicated in persons with cirrhosis and should be avoided in persons with 
less severe liver disease. Use of d4T and ZDV should also be avoided if 
possible. 
Treatment goal
9. The primary aim of HCV treatment is SVR defined as undetectable HCV-
RNA 12-24 weeks after the end of therapy (evaluated using sensitive 
molecular tests). 
Treatment of acute HCV
10. In the absence of randomised, controlled data on the use of DAAs in 
the setting of acute HCV co-infection treatment with PEG-IFN and RBV 
should be based on an individual decision weighing the known toxicities 
and longer treatment duration under dual therapy against a potentially 
strong patient wish from the co-infected person for early HCV cure, 
particularly in HIV-positive MSM with a higher risk of HCV transmis-
sion and in countries where DAAs will only be reimbursed in chronic 
HCV with ≥F3 fibrosis. After diagnosis of acute HCV, HCV-RNA should 
be measured 4 weeks later. Treatment can be discussed in persons 
without a decrease of 2*log10 of HCV-RNA at 4 weeks compared with 
initial HCV-RNA and in persons with persistent serum HCV-RNA 12 
weeks after diagnosis of acute HCV, see Algorithm for Management of 
Acute HCV in Persons with HCV/HIV Co-infection. Early discontinua-
tion of dual therapy is justified in persons experiencing significant side 
effects of PEG-IFN and/or RBV. Enrollment of persons with acute HCV 
co-infection in ongoing trials using IFN-free DAA combination therapy is 
strongly encouraged. 
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*  Metavir fibrosis score: F0=no fibrosis; F1= portal fibrosis, no septae; F2= 
portal fibrosis, few septae, F3=bridging fibrosis, F4=cirrhosis. FibroS-
can®: F0-F1 < 7.1 KPa; F2 7-10 KPa; F3/F4 > 10 Kpa
**  Treatment must be considered independently from liver fibrosis in per-
sons with low CD4 count (<200 cells/µL), ongoing HIV replication, HBV 
co-infection, debilitating fatigue, extrahepatic manifestations, high risk of 
HCV transmission (IVDU, prisoners, MSM with high risk behavior, fertile 
women who want to be pregnant).
 
Chronic HCV/HIV
Perform FibroScan and/or serum 
marker and/or liver biopsy
F0/F1* F2-F4*
HCV treatment 
can be 
considered
HCV treatment 
is 
recommended
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HCV Treatment Options in HCV/HIV Co-infected Persons
IFN-free HCV Treatment Options
HCV GT Treatment regimen
                               Treatment duration & ribavirin usage
                  Non-cirrhotic Compensated
cirrhotic
Decompensated
cirrhotics CTP 
class B/C
1 & 4 SOF + SMP + RBV 12 weeks without RBV 12 weeks with RBV 
or 24 weeks without 
RBV(i)
Not recommended
SOF/LDV + RBV 12 weeks without RBV 12 weeks with RBV or 24 weeks without 
RBV in cirrhotics or pre-/post-transplant(i)
SOF + DCV + RBV 12 weeks without RBV 12 weeks with RBV or 24 weeks without 
RBV in cirrhotics or pre-/post-transplant(i)
OBV/PTV/r + DSV 12 weeks in GT 1b                  Not Recommended
OBV/PTV/r + DSV + RBV 12 weeks in GT 1a 12 weeks in GT 1b
24 weeks in GT 1a
Not recommended
OBV/PTV/r + RBV 12 weeks in GT 4 24 weeks in GT 4 Not recommended
2 SOF + DCV + RBV 12 weeks without RBV 12 weeks without RBV 12 weeks with RBV
SOF + RBV 12 weeks                       16-20 weeks(ii)
3 SOF + PEG-IFN/RBV Not recommended(iv) 12 weeks in persons 
eligible for PEG-IFN
Not recommended
SOF + RBV 24 weeks                    Not recommended
SOF + DCV + RBV(iii) 12 weeks without RBV                    24 weeks with RBV
5 SOF/LDV 12 weeks without RBV                    12 weeks without RBV
6 In the absence of clinical data on DAAs in HCV GT 6 infection
persons should be treated similarly to HCV GT 1 and 4 infection
RBV =   ribavirin
SOF =   sofosbuvir
SMP =   simeprevir
DCV =  daclatasvir
LDV =    ledipasvir
OBV =   ombitasvir
PTV/r =  paritaprevir/RTV
DSV  =  dasabuvir
i Cirrhotic persons with negative predictors of response can be treated 24 weeks with RBV (negative predictors: treatment-experienced, 
     platelet count < 75x103/uL) 
ii Possible extension up to 16 weeks in treatment-naïve cirrhotics or relapsers; up to 20 weeks in treatment-experienced cirrhotics
iii Based on expert opinion and preliminary data from studies in persons on pre-marketing expanded access programmes
iv See IFN-containing Treatment of HCV in Persons with HCV/HIV Co-infection
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Drug-drug Interactions between DAAs and ARVs
HCV drugs ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC DTG EVG/c RAL ABC FTC 3TC TDF ZDV
D
A
A
s
boceprevir D35% ↓D ↓32%D44% ↓45%D34% ↓19%E20% ↑10%D23% ↓E ↓6%E39% E ↔ ↓D ↔ ↔ ↔ ↔ ↔ ↔(i)
daclatasvir ↑110%(ii) ↑ ↑40% ↑15% ↓32%(iii) ↓ ↓ ↔ ↔ ↔ ↑(ii) ↔ ↔ ↔ ↔ ↑10%E10% ↔
ombitasvir/parita-
previr/r/dasabuvir
↑94%(iv) ↑ D(v) ↑ vii ↓E? ↓E? E(viii) E E38% ↑ E134% ↔ ↔ ↔ ↔ ↔
ombitasvir/parita-
previr/r
↑(iv) ↑ ↑(vi) ↑ vii ↓E? ↓E? E(viii) E ↔ ↑ E20% ↔ ↔ ↔ ↔ ↔
simeprevir ↑ ↑ ↑ ↑ ↓71% ↓ ↓ ↑6%E12% ↔ ↔ ↑ ↓11%E8% ↔ ↔ ↔ ↓14%E18% ↔
sofosbuvir/ledi-
pasvir
↑8/113%(ix) ↑E(ix) ↑34/39%(ix) ↔(ix) ↓-/34%(ix) ↔ ↔ ↔(ix) E? ↔ ↑36/78E(ix) D≈20% ↔ ↔ ↔ E(ix) ↔
sofosbuvir ↔ ↑ ↑34% ↔ ↓6%D4% ↔ ↔ ↑9%E6% ↔ ↔ ↔ ↓5%D27% ↔ ↓6% ↔ ↓6% ↔
telaprevir ↓20%E17% ↓D ↓35%D40% ↓54% ↓26%D7% ↓16% ↓? ↓5%E E E25% ↑13%D16% E31% ↔ ↔ ↔ E30%(ix) ↔(i)
Legend
↑  potential elevated exposure of DAA      
↓  potential decreased exposure of DAA
↔  no significant effect    
D  potential decreased exposure of ARV
E  potential elevated exposure of ARV
Numbers refer to decreased/increased AUC of DAAs and ARVs as observed in 
drug interactions studies. Sofosbuvir/ledipasvir: first/second numbers refer to 
changes AUC sofosbuvir/ledipasvir.
i    Potential hematological toxicity 
ii   Daclatasvir should be reduced to 30 mg qd with ATV/r or EVG/c. 
 No dose reduction with unboosted ATV
iii   Daclatasvir should be increased to 90 mg qd  
iv   Use only with unboosted ATV and in persons without significant HIV PI 
 mutations (ATV increased paritaprevir exposure due to CYP3A4 and 
 OATP1B1/3 inhibition, not recommended without dasabuvir)  
v   Co-administration decreased DRV trough concentration by approximately 
50%. Although co-administration of DRV with ombitasvir/paritaprevir/r + dasa-
buvir is not recommended in the US Prescribing Information, the European 
SPC advises that DRV (dosed at 800 mg qd and administered at the same 
time as ombitasvir/paritaprevir/r + dasabuvir) can be used in the absence of 
extensive HIV PI resistance and should be taken without additional RTV
vi   Increase in paritepravir exposure when co-administered with DRV 800 
 mg given with Viekirax 
vii   Severe tolerability issues
viii  Not recommended unless benefit outweights the risk due to potential for 
 QT interval prolongation with higher concentrations of rilpivirine, co-adminis-
tration should only be considered in persons without known QT prolongation 
and without other QT prolongation co-medications 
ix   Frequent monitoring of kidney function due to increase of TDF if contained in 
the regimen              
               
Colour legend
 no clinically significant interaction expected. 
 these drugs should not be co-administered. 
 potential interaction which may require a dosage adjustment or close 
monitoring. 
Note: the symbol (green, amber, red) used to rank the clinical significance of the 
drug interaction is based on www.hep-druginteractions.org.     
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Algorithm for Management of Acute HCV in Persons with Chronic HCV/HIV Co-in-
fection
Initial
presentation
Acute HCV
Week 4
Decay HCV-RNA
≥ 2*log10 Week 12
HCV-RNA level
Negative
Serial HCV-RNA measurements
throughout week 48 to confirm
resolution
< 2*log10
Treatment with
PEG-IFN + RBV
Positive
Week 4
HCV-RNA level
Negative Positive
Stop treatment 
after 24 weeks
Treatment for 
48 weeks, stop 
treatment if  
< 2*log10 
decrease in 
HCV-RNA level 
at week 12  
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IFN-containing treatment of chronic HCV in persons with HCV/HIV 
co-infection
1. In countries where no sofosbuvir is available PEG-IFN and RBV combi-
nation treatment for 24 weeks (if RVR i.e. negative HCV-RNA at week 
4 after starting HCV therapy) or 48 weeks represents an alternative 
treatment choice for HCV GT2. The standard dose for PEG-IFN 2a is 
180 μg once weekly, and for PEG-IFN 2b 1.5 μg/kg body weight once 
weekly. 
2. In case of limited DAA availability or reimbursement issues sofosbuvir in 
combination with PEG-IFN and RBV would be the next best treatment 
option (for GT1, 3-6), see IFN-containing HCV Treatment Options For 
Fibrosis Stages up to CHILD A. Simeprevir in combination with PEG-
INF and RBV can also be an alternative (for GT1 or 4; but with longer 
treatment duration for IFN), however absence of the Q80K mutation 
should be demonstrated prior to treatment initiation. 
3. Use of older, first generation HCV PIs (boceprevir and telaprevir; only 
indicated in GT1) are only recommended where other DAAs are not 
currently available and for some future time. 
4. Use of HCV PIs is associated with additional toxicities: boceprevir cau-
ses anaemia, teleprevir skin rash and simeprevir hyperbilirubinaemia 
and skin reactions/photosensibility. 
5. Due to drug-drug interactions in particular HIV and HCV PIs, careful 
checking for interactions is urgently recommended prior to starting HCV 
therapy, see www.hep-druginteractions.org or Drug-drug Interactions 
Between ARVs and DAAs. During PEG-IFN-RBV therapy, ddI is con-
traindicated in persons with cirrhosis and should be avoided in persons 
with less severe liver disease. d4T and ZDV should also be avoided if 
possible. 
Treatment goal
 
6. The primary aim of HCV treatment is SVR defined as undetectable HCV- 
RNA 12-24 weeks after the end of therapy, evaluated using sensitive 
molecular tests.
Stopping rules
7. If an early virological response (decline of at least 2*log10 reduction 
in HCV-RNA at week 12 compared to baseline) is not achieved when 
treating HCV infection with PEG-IFN and RBV, treatment should be 
stopped, see page 76. Different stopping rules apply when DAAs are 
being used in combination with PEG-IFN and RBV and are summarised, 
see page 77. Futility rules with simeprevir in combination with PEG-IFN 
and RBV are that HCV-RNA> 25 IU/mL after 4,12 or 24 weeks of HCV 
therapy should be discontinued. In case of successful telaprevir-based 
HCV therapy at week 4 (HCV-RNA < 1000 IU/mL), telaprevir should be 
continued until week 12, see page 77. If HCV-RNA at week 12 is still 
< 1000 IU/mL, dual therapy with PEG-IFN-RBV should be continued 
until week 24. If HCV-RNA is undetectable at week 24, dual therapy 
with PEG-IFN-RBV should be continued for another 24 weeks resulting 
in total treatment duration of 48 weeks. Futility rules for boceprevir-
containing HCV therapy are that in case of HCV-RNA > 100 IU/mL at 
week 12 or detectable HCV-RNA at week 24, all HCV therapy needs to 
be discontinued and interpreted as lack of response and high risk for 
boceprevir resistance selection. In PEG-IFN and sofosbuvir or IFN-free 
based therapies reasons to stop treatment may be non-adherence or 
toxicities on an individual basis. 
IFN-containing Treatment of HCV in Persons with HCV/HIV Co-infection
IFN-containing HCV treatment options  
(For fibrosis stages up to CHILD A)
HCV GT Treatment Treatment duration
1 & 4 SOF + PEG-IFN/RBV 12 weeks (possible ex-
tension up to 24 weeks in 
cirrhotics)
SMP* + PEG-IFN/RBV 24 weeks** (48 weeks in 
cirrhotics and treatment-ex-
perienced)
DCV + PEG-IFN/RBV*** 24 weeks if RVR, 48 weeks 
if non-RVR
2 PEG-IFN/RBV IFN-free treatment recom-
mended. If SOF not avail-
able: PR 24 weeks if RVR, 
48 weeks if non-RVR
3 SOF + PEG-IFN/RBV 12 weeks (possible ex-
tension up to 24 weeks in 
cirrhotics)
5 & 6 In the absence of clinical data on DAAs in HCV GT 5 and 
6 infection persons should be treated similar to HCV GT 1 
and 4 infection
PEG-IFN/RBV pegylated-interferon + ribavirin
RBV ribavirin
SOF sofosbuvir
SMP simeprevir
DCV daclatasvir
* SMP for 12 weeks only
** also in relapsers
*** GT4 only, DCV for 24 weeks only
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Proposed Optimal Duration of Dual HCV Therapy in Persons with Chronic HCV/HIV 
Co-infection Not Eligible for Triple Therapy Including DAAs against HCV
i Where no access to DAAs available or high chances of cure even with dual 
therapy (favourable IL28B GT, low HCV-RNA and no advanced fibrosis)
Week 4 Week 12 Week 24 Week 48 Week 72
HCV-RNA neg
GT2/3 Stop treatment after 24 weeks
GT1(i)/4 Stop treatment after 48 weeks
HCV-RNA neg GT2/3
≥ 2*log10 drop in 
HCV-RNA GT1/4
Stop treatment after 
72 weeks
HCV-RNA pos HCV-RNA pos Stop treatment when criteria are met
< 2*log10 drop in 
HCV-RNA
Stop treatment when 
criteria are met
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Use of Boceprevir, Telaprevir, Simeprevir or Sofosbuvir with PEG-IFN + RBV  
in Persons with HIV/HCV Co-infection
0 4 12 24 48
PEG-IFN  
+ RBV boceprevir 800 mg tid + PEG-IFN + RBV
If ≥ 100 IU/mL, stop all therapy If detectable, stop all therapy
HCV-RNA
0 4 12 24 48
telaprevir 750 mg tid
+ PEG-IFN + RBV PEG-IFN + RBV
If > 1000 IU/mL, stop all therapy If detectable, stop PEG-IFN/RBV
HCV-RNA
0 4 12 24 48
simeprevir 150 mg qd
+ PEG-IFN + RBV PEG-IFN + RBV Only in prior non responders
If > 25 IU/mL, stop all therapy
HCV-RNA
Therapy should be stopped if there is a confirmed increase in HCV-RNA by 1*log10 following a decline at any stage.
0 4 12
sofosbuvir 400 mg qd
+ PEG-IFN + RBV
HCV-RNA
No stopping rules apply: Fixed duration of 12 weeks regardless of HCV-RNA decline.
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Definition of Treatment Response of PEG-IFN and RBV
Time HCV-RNA
Rapid Virological Response (RVR) Week 4 on treatment Undetectable (< 50 IU/mL)
Early Virological Response (EVR) Week 12 on treatment Undetectable (< 50 IU/mL)
Delayed Virological Response 
(DVR)
Week 12 on treatment > 2*log10 decrease from baseline, but not undetectable
Null Response (NR) Week 12 on treatment < 2*log10 decrease from baseline
Partial Non-Response (PR) Week 12 and week 24 on treatment > 2*log10 decrease at week 12, but detectable at week 12 and 24
Sustained Virological Response 
(SVR)
24 weeks post treatment Undetectable (< 50 IU/mL)
Breakthrough Any time during treatment Reappearance of HCV-RNA at any time during treatment after virological 
response
Relapse (RR) End of treatment and week 24  
post treatment
Undetectable HCV-RNA at end of therapy, detectable by week 24  
post treatment
Adapted from [1]
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CD4 count threshold/indication
CD4 count < 200 cells/µL, CD4 percentage < 14%, recurrent oral thrush, or relevant concomitant immunosuppression*
Prophylaxis against Pneumocystis jirovecii Pneumonia (PcP) & Toxoplasma gondii
Stop: if CD4 count > 200 cells/µL over 3 months or CD4 count 100-200 cells/μL and HIV-VL undetectable for 3 months
* e.g. use of corticosteroids > 20 mg prednisone equivalent per day for > 2 weeks, cancer chemotherapy, biological agents such as rituximab and others. 
Decisions on installation and discontinuation in these situations have to be taken individually.
Drug Dose Comments
Positive or negative serology for  
toxoplasmosis
TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x/week po or
1 single-strength tablet (ss)
(400/80 mg) 1 x/day po or
1 ds tablet 1 x/day po
Negative serology for toxoplasmosis pentamidine 300 mg in 6 mL aqua
1 x inhalation/month
Does not prevent the rare extrapulmo-
nary manifestations of P. jirovecii
Negative serology for toxoplasmosis dapsone 1 x 100 mg/day po Check for G6PD-deficiency 
Positive or negative serology for  
toxoplasmosis
atovaquone suspension 1 x 1500 mg/day po (with food)
Positive serology for toxoplasmosis dapsone 200 mg 1 x/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg 1 x/week po
+ folinic acid 25-30 mg 1 x/week po
Positive serology for toxoplasmosis atovaquone suspension
+ pyrimethamine
+ folinic acid
1 x1500 mg/day po (with food)
75 mg 1 x/week po
25-30 mg 1 x/week po
CD4 count < 50 cells/µL
Prophylaxis against Non-Tuberculous Mycobacteria (NTM) (M. avium complex, M. genavense, M. kansasii)
Only consider prophylaxis if no clinical suspicion of disseminated NTM. Prophylaxis can be withheld if cART started within four weeks.
Stop: if CD4 count > 100 cells/µL over 3 months
Regimens listed are alternatives azithromycin 1 x 1200-1250 mg/week po Check for interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVs
or
clarithromycin 2 x 500 mg/day po
or
rifabutin 1 x 300 mg/day po Check for interactions with ARVs, see Drug-drug Interactions between ARVs 
and Non-ARVs
Part V  Opportunistic Infections
Primary Prophylaxis of Opportunistic Infections (OIs) according to stage of 
immunodeficiency
Prevention and Treatment of Opportunistic Infections in HIV-positive Persons
This chapter provides an overview of the most important aspects in management of the most frequent OIs occurring in HIV-posi-
tive persons in Europe. For more detailed discussion, we refer to national guidelines [1-6]
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Pneumocystis jirovecii Pneumonia (PcP)
Primary prophylaxis
Start: if CD4 count < 200 cells/µL, CD4 percentage < 14%, oral thrush or relevant concomitant immunosuppression (see above)
Stop: if CD4 count > 200 cells/µL over 3 months or CD4 count 100-200 cells/µL and HIV-VL undetectable for 3 months
Drug Dose Comments
Negative or positive serology for  
toxoplasmosis
TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x/week po or
1 single-strength tablet (ss)
(400/80 mg) 1 x/day po or
1 ds tablet /1 x/day po
Negative serology for toxoplasmosis pentamidine 300 mg in 6 mL aqua
1 x inhalation/month
Does not prevent the rare extrapulmo-
nary manifestations of P. jirovecii
Negative serology for toxoplasmosis dapsone 1 x 100 mg/day po Check for G6PD-deficiency
Negative or positive serology for  
toxoplasmosis
atovaquone suspension 1 x 1500 mg/day po (with food)
Positive serology for toxoplasmosis dapsone 200 mg 1 x/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg 1 x/week po
+ folinic acid 25-30 mg 1 x/week po
Positive serology for toxoplasmosis atovaquone suspension
+ pyrimethamine
+ folinic acid
1 x 1500 mg/day po (with food)
75 mg 1 x/week po
25-30 mg 1 x/week po
Treatment
Treat at least 21 days, then secondary prophylaxis until CD4 count > 200 cells/µL for > 3 months.
Diagnosis: 
-   Definitive diagnosis: Cough and dyspnea on exertion AND diagnosis by cytology / histopathology of induced sputum (sensitivity up to 80%), BAL (sen-
sitivity > 95%) or bronchoscopic tissue biopsy (sensitivity > 95%)
-   Presumptive diagnosis: CD4 count < 200 cells/ µL AND dyspnea / desaturation on exertion and cough AND radiology compatible with PcP AND no 
evidence for bacterial pneumonia AND response to PcP treatment
Drug Dose Comments
Preferred therapy TMP-SMX  3 x 5 mg/kg/day TMP iv/po + 
3 x 25 mg/kg/day SMX iv/po
+ prednisone 
if PaO2 <10 kPa or <70 mmHg 
or alveolar/arterial O2 gradient> 
35 mmHg. Start prednisone 
preferentially 15-30 min before 
TMP/SMX
2 x 40 mg/day po 5 days
1 x 40 mg/day po 5 days
1 x 20 mg/day po 10 days
Benefit of corticosteroids if started 
before 72 hours
Alternative therapy for moderate to severe 
PcP
primaquine 1 x 30 mg (base)/day po Check for G6PD deficiency
+ clindamycin 3 x 600-900 mg/day iv/po
or
pentamidine 1 x 4 mg/kg/day iv (infused over
60 min.)
For each regimen:
+ prednisone, if PaO2 <10 kPa 
or <70 mmHg, or alveolar/arteri-
al O2 gradient > 35 mmHg. Start 
Prednisone preferentially 15-30 
min before TMP/SMX
Preliminary data point towards 
adding caspofungin in persons 
non responding to standard 
treatment
2 x 40 mg/day po 5 days
1 x 40 mg/day po 5 days
1 x 20 mg/day po 10 days
Benefit of corticosteroids if started within 
72 hours after start of treatment
Alternative Therapy for mild to moderate 
PcP 
primaquine 1 x 30 mg (base)/day po Check for G6PD deficiency 
+ clindamycin  3 x 600-900 mg/day po
or
atovaquone suspension 2 x 750 mg/day po (with food)
or
dapsone 1 x 100 mg/day po Check for G6PD deficiency
In case of rash: reduce dose of TMP
(50%), antihistamines
+ trimethoprim 3 x 5 mg/kg/day po
Primary Prophylaxis, Treatment and Secondary Prophylaxis/Maintenance Treat-
ment of Individual OIs
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Secondary prophylaxis / Maintenance treatment
Stop: if CD4 count > 200 cells/µL over 3 months 
Drug Dose Comments
Negative or positive serology for  
toxoplasmosis
TMP-SMX 1 ds tablet (800/160 mg) 
3 x/week po or 1 ss tablet 
(400/80) mg 1x/ day po or 1 ds 
tablet 1x/day po
Negative serology for toxoplasmosis pentamidine 300 mg in 6 mL aqua 1 x
inhalation/month
Not to use in the rare case of extrapul-
monary manifestations of P. jirovecii
Negative serology for toxoplasmosis dapsone 1 x 100 mg/day po Check for G6PD-deficiency
Negative or positive serology for  
toxoplasmosis
atovaquone suspension 1 x 1500 mg/day po (with food)
Positive serology for toxoplasmosis dapsone 1 x 200 mg/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg/week po
+ folinic acid 25-30 mg/week po
Positive serology for toxoplasmosis atovaquone suspension
+ pyrimethamine
+ folinic acid
1 x 1500 mg/day po (with food)
75 mg/week po
25-30 mg/week po
Toxoplasma gondii Encephalitis
Primary prophylaxis
Start: if CD4 count < 200 cells/µL, or CD4 percentage < 14%, oral thrush, or relevant concomitant immunosuppression (see above)
Stop: if CD4 count > 200 cells/µL over 3 months or CD4 count 100-200 cells/µL and HIV-VL undetectable for 3 months
Drug Dose Comments
TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x/week po or
1 single-strength tablet (ss)
(400/80 mg) 1 x/day po or
1 ds tablet 1 x/day po
atovaquone suspension 1 x 1500 mg/day po (with food)
dapsone 200 mg 1 x/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg 1 x/week po
+ folinic acid 25-30 mg 1 x/week po
atovaquone suspension
+ pyrimethamine
+ folinic acid
1 x 1500 mg/day po (with food)
75 mg/week po
25-30 mg/week po
Treatment
Treat 6 weeks, then secondary prophylaxis until CD4 count > 200 cells/µL over 6 months
Diagnosis: 
-   Definitive diagnosis: clinical symptoms, typical radiology of the cerebrum AND cytological / histological detection of organism 
-   Presumptive diagnosis: clinical symptoms, typical radiology AND response to empirical treatment. It is the standard in most clinical settings.
Drug Dose Comments
Preferred therapy pyrimethamine Day 1: 200 mg po, then 
• If ≥ 60 kg; 1 x 75 mg/day po
• If < 60 kg: 1 x 50 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia
+ sulfadiazine • If ≥ 60 kg: 2 x 3000 mg/day
po/iv
• If < 60 kg: 2 x 2000 mg/day
po/iv
Sulfadiazine is associated with crys-
talluria and may lead to renal failure 
and urolithiasis. Good hydratation is 
essential. Check renal function and 
urine sediment for microhematuria and 
crystalluria
+ folinic acid 1 x 10-15 mg/day po
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Alternative therapy pyrimethamine
+ clindamycin 
+ folinic acid
Day 1: 200 mg/day po, then
• If ≥ 60 kg: 1 x 75 mg/day po
• If < 60 kg: 1 x 50 mg/day po
4 x 600-900 mg/day po/iv
1x 10-15 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia 
Additional PcP prophylaxis is necessary
or
TMP-SMX
2 x 5 mg TMP/kg/day po/iv
2 x 25 mg SMX/kg/day po
or
pyrimethamine
+ atovaquone
+ folinic acid
Day 1: 200 mg po, then
If ≥ 60 kg; 1 x 75 mg/day po
If < 60 kg: 1 x 50 mg/day po
2 x 1500 mg/day po (with food)
1 x 10-15 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia
or
sulfadiazine
+ atovaquone
• If ≥ 60 kg: 4 x 1500 mg/day
po/iv
• If < 60 kg: 4 x 1000 mg/day
po/iv
2 x 1500 mg/day po (with food)
or
pyrimethamine
+ azithromycin
+ folinic acid
Day 1: 200 mg po, then
• If ≥ 60 kg; 1 x 75 mg/day po
• If < 60 kg: 1 x 50 mg/day po
1 x 900-1200 mg/day po
1 x 10-15 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia
Secondary prophylaxis / Maintenance therapy
Stop: if CD4 count > 200 cells/µL over 6 months 
Drug Dose Comments
Regimens listed are alternatives sulfadiazine
+ pyrimethamine
+ folinic acid
2-3 g/day po (in 2-4 doses)
1 x 25-50 mg/day po
1 x 10-15 mg/day po
or
clindamycin
+ pyrimethamine
+ folinic acid
3 x 600 mg/day po
1 x 25-50 mg/day po
1 x 10-15 mg/day po
Additional PCP prophylaxis is necessary
or
atovaquone suspension
+ pyrimethamine
+ folinic acid
2 x 750-1500 mg/day po
(with food)
1 x 25-50 mg/day po
1 x 10-15 mg/day po
or
atovaquone suspension
2 x 750-1500 mg/day po (with
food)
or
TMP-SMX 2 x 800 mg/day po
Cryptococcal meningitis
Treatment
14 days induction therapy, then 8 weeks consolidation therapy, then secondary prophylaxis for at least 12 months. Stop, if CD4 count > 100 
cells/µL for more than 3 months
Diagnosis: positive microscopy OR detection of antigen, OR culture from CSF
Other organ manifestations: Cryptococcal infection can also cause a pneumonitis which may be difficult to distinguish from Pneumocystis pneumonia and 
also involve other organs.
Pre-emptive therapy: Early stages of disseminated cryptocccal infections may be oligosymptomatic. Newer data from mainly resource limited settings 
support determination of serum cryptococcal antigen in all persons. If cryptococcal antigen is detected, CSF should be examined to rule out cryptococcal 
meningitis. If meningitis is ruled out, pre-emptive therapy with fluconazole 800mg/day po for two weeks is recommended before starting cART to reduce the 
risk of unmasking IRIS.
Drug Dose Comments
Pre-emptive therapy flucanozole 800 mg/day po for 2 weeks
followed by 
400 mg/day po for 8 weeks
In case of: 
-  positive cryptococcal serum antigen
-  asymptomatic individual
-  cryptococcal meningitis ruled out by 
CSF examination
Induction therapy liposomal amphotericin B     
+ flucytosine
3 mg/kg/day iv                            
4 x 25 mg/kg/day po
14 days
- Then perform LP: if CSF culture sterile 
switch to oral regimen
- Opening pressure should always be 
measured, when LP is performed 
- Repeated LPs or CSF shunting are 
essential to effectively manage in-
creased intracranial pressure which is 
associated with better survival 
- Flucytosine dosage must be adapted to 
renal function
- Defer start of cART for at least 4 weeks
- Amphotericin B deoxycholate may not 
be available in all European countries
or
amphotericin B deoxycholate 
+ flucytosine
0.7 mg/kg/day iv
4 x 25 mg/kg/day po
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Consolidation therapy fluconazole 1 x 400 mg/day po
(loading dose 1 x 800 mg 1st 
day)
8 weeks. Repeated LP until opening 
pressure < 20 cm H20 or 50% of initial 
value
Secondary prophylaxis / Maintenance therapy
At least 12 months
Consider to stop: if CD4 count >100 cells/µL for at least 3months
Drug Dose Comments
fluconazole 1 x 200 mg/day po
 Candidiasis
Oropharyngeal Candidiasis
Diagnosis: typical clinical appearance
Drug Dose Comments
fluconazole 1 x 150-200 mg/day po Once or until improvement (5-7 days)
or
itraconazole
1-2 x 100-200 mg/day po
(oral solution fasting)
7-14 days. Be aware of interactions with
ARVs, see Drug-drug Interactions
Between ARVs and Non-ARVs
or
amphotericin B
3-6 lozenges at 10 mg/day or
oral suspension 1-2 g/day
(in 2-4 doses)
7-14 days
Oesophagitis
Definitive diagnosis: macroscopic inspection at endoscopy, OR histology of biopsy, OR cytology of specimen from the mucosal surface 
Presumptive diagnosis: if 1.Recent onset of dysphagia AND 2. Oropharyngeal candidiasis
Drug Dose Comments
fluconazole 1 x 400 mg/day
or
400 mg loading dose, then 200 
mg/day po 
3 days
10-14 days
or
itraconazole 1-2 x 100-200 mg/day po
(oral solution fasting)
10-14 days. Be aware of interactions 
with ARVs, see Drug-drug Interactions
Between ARVs and Non-ARVs
Histoplasmosis (Histoplasma capsulatum)
Treatment
Diagnosis: antigen detection in blood, urine or broncho-alveolar fluid OR by positive microscopy OR mycological culture of blood, urine, broncho-alveolar 
fluid, CSF or tissue biopsy
Note: CSF, which shows typically a lymphatic pleocytosis, is usually microscopic and culture negative. Detection of Histoplasma antigen or antibody is 
more sensitive. Though, a clinical diagnosis is possible in case of negative Histoplasma antigen or antibody in CSF, if dissiminated histoplasmosis is pres-
ent and CNS infection is not explained by another cause
 
Seek expert advice for the use of fluconazole, voriconazole or posaconazole, if itraconazole is not tolerated. Be aware of interactions of azoles with 
ARVs, see Drug-drug Interactions Between ARVs and Non-ARVs. Measurement of plasma concentration of itraconazole and voriconazole is advised to 
guide optimal treatment. 
Drug Dose Comments
Severe disseminated histoplasmosis Induction therapy:
liposomal amphotericin B   
Consolidation therapy:
itraconazole
3 mg/kg/day iv             
3 x 200 mg/day po for 3 days, 
then 2 x 200 mg/day po       
For 2 weeks or until clinical improvement
For at least 12 months
Moderate disseminated histoplamosis itraconazole 3 x 200 mg/day po for 3 days, 
then 2 x 200mg/day po 
For at least 12 months
Histoplasma meningitis Induction therapy:
liposomal amphotericin B
Consolidation therapy:
itraconazole
5 mg/kg/day iv    
2 x or 3 x 200 mg/day po                 
For 4-6 weeks
For at least 12 months and until resolu-
tion of abnormal CSF findings. Measure 
plasma concentration.
Secondary prophylaxis / Maintenance therapy
Stop: if CD4 count > 150/µL and cART > 6 months, negative fungal blood cultures, Histoplasma antigen < 2µg/L and > 1 year treatment
Consider long-term suppressive therapy in severe cases of meningitis and in cases of relapse despite adequate treatment
itraconazole 1 x 200 mg/day po 
or
fluconazole 1 x 400 mg/day po 
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Herpes simplex virus (HSV) infections
Treatment
Diagnosis: antigen testing / PCR / culture of swab / CSF / biopsy. Clinical appearance of skin lesions not reliable
Drug Dose Comments
Initial genital / mucocutaneous HSV valaciclovir 2 x 1000 mg/day po 7-10 days or until lesions healed
or
famciclovir
2 x 500 mg/day po 7-10 days or until lesions healed
or
aciclovir
3 x 400-800 mg/day po 7-10 days or until lesions healed
Recurrent genital / mucocutaneous HSV
(> 6 episodes/year)
valaciclovir 2 x 500 mg/day po Chronic suppressive therapy. Alterna-
tively start early treatment if recur-
rences as above
Severe mucocutaneous lesions aciclovir 3 x 5 mg/kg/day iv After lesions begin to regress, switch to
oral treatment or until lesions healed
Encephalitis aciclovir 3 x 10 mg/kg/day iv 14-21 days
Aciclovir resistant mucocutaneous HSV 
infection
foscarnet 2-3 x 80-120 mg/kg/day iv Until clinical response
 Varicella zoster virus (VZV) infections
Treatment
Diagnosis: typical clinical appearance with/without antibody testing OR antigen testing / PCR / culture of swab / CSF / biopsy
Drug Dose Comments
Primary Varicella infection (Chickenpox) valaciclovir 3 x 1000 mg/day po 5-7 days
Herpes Zoster (Shingles):
Not disseminated
valaciclovir 3 x 1000 mg/day po 10 days
or
famciclovir
3 x 500 mg/day po 10 days
or
aciclovir
3 x 5 mg/kg/day iv 10 days
Herpes Zoster: Disseminated aciclovir 3 x 10 mg/kg/day iv 10-14 days
Encephalitis (including vasculitis) aciclovir 3 x 10-15mg/kg/day 14-21 days
 Cytomegalovirus (CMV) infections
Treatment
Diagnosis of retinitis: clinical appearance of typical retinal lesions AND response to therapy. PCR of aqueous and vitreous humor optional
Diagnosis of esophagitis / colitis: endoscopic presence of ulcerations AND typical histopathological picture (cellular / nuclear inclusion bodies)
Diagnosis of encephalitis / myelitis: clinical appearance AND positive PCR in CSF
Antibody testing and PCR in blood not useful for diagnosis of end-organ disease
Drug Dose Comments
Retinitis, Immediate sight-threatening le-
sions
ganciclovir 2 x 5 mg/kg/day iv 21 days, then secondary prophylaxis
or
foscarnet
2 x 90 mg/kg/day iv 21 days, then secondary prophylaxis
Retinitis, small peripheral retinal lesions valganciclovir 2 x 900 mg/day po (with food)
or
foscarnet
2 x 90 mg/kg/day iv
or
cidofovir
+ probenecid+ NaCl 0.9% 
hydration
1 x 5 mg/kg/week iv 2 weeks then every 2 weeks. Cidofovir 
may not be available in all European 
countries
Oesophagitis/Colitis ganciclovir 2 x 5 mg/kg/day iv Treat 3-6 weeks, respectively until symp-
toms resolved
or
foscarnet
2 x 90 mg/kg/day iv
or
valganciclovir
2 x 900 mg/day po (with food) In milder disease if oral treatment 
tolerated
Encephalitis/Myelitis ganciclovir and / or  
foscarnet 
2 x 5 mg/kg/day iv
2 x 90 mg/kg/day iv
Treat until symptoms resolved and 
cleared CMV replication in by negative 
PCR in CSF 
Treatment is individualised according 
to clinical symptoms and response to 
treatment  
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Secondary prophylaxis / Maintenance therapy: Cytomegalovirus (CMV) Retinitis
Stop: if CD4 count > 200 cells/µL over 3 months
Regimens listed are alternatives valganciclovir 1 x 900 mg/day po (with food)
or
ganciclovir
1 x 5 mg/kg/day  (x 5 days/
week) iv
or
foscarnet
1 x 90-120 mg/kg/day (x 5 days/ 
week) iv
or
cidofovir
+ probenecid + NaCL 9% 
hydration  
1 x 5 mg/kg every 2 weeks iv Cidofovir may not be available in all 
European countries
 Progressive Multifocal Leukoencephalopathy (PML)
Treatment PML
Definitive diagnosis (laboratory): evidence of JCV-DNA in CSF AND presence of compatible clinical-radiological picture 
Definitive diagnosis (histology): typical histological findings with in situ evidence of JCV-DNA antigen or JCV-DNA AND presence of compatible clini-
cal-radiological picture
Presumptive diagnosis: compatible clinical-radiological picture if JCV-DNA in CSF negative or not performed
Person off-ART Initiate cART immediately (following general guidelines for treatment, see Initial Combination Regimen for 
ART-naïve Adult HIV-positive Persons 
Person on-ART, HIV-VL failure Optimise cART (following general guidelines for treatment, see Virological Failure)
Person on-ART, treated for weeks-
months or on effective cART
Continue current cART
Note: There is no specific treatment for JCV infection that proved to be effective in PML outside of anecdotal 
case reports, therefore there is no recommendation to use the following drugs which previously or occasion-
ally were used in PML: Alpha-IFN, cidofovir, corticosteroids (except for treatment of IRIS-PML, see below), 
cytarabine, iv immunoglobulins, mefloquine, mirtazapine and topotecan
Treatment Immune Reconstitution Syndrome (IRIS) – PML
Diagnosis:
- Paradoxical IRIS-PML: paradoxical worsening of PML symptoms in the context of cART-induced immune-reconstitution, AND in association with inflam-
mation at MRI (oedema, mass effect or contrast enhancement) or at brain biopsy
- Unmasking IRIS-PML: onset of PML in the context of cART-induced immune-reconstitution, AND in association with inflammation at MRI (oedema, mass 
effect, and/or 'contrast enhancement') or at brain biopsy
Treatment: 
-  Corticosteroids, e.g., high dose iv methylprednisolone (e.g.1 g/day for 3-5 days) or iv dexamethasone (e.g.0.3 mg/kg/day for 3-5 days), followed by oral 
tapering (e.g starting with 1 mg/kg/day and taper over 1-6 weeks)
Note: Use of corticosteroids is not justified in persons without signs of inflammation. There are no other treatments that proved to be effective in IRIS-PML 
outside of anecdotal case reports
 Bacillary Angiomatosis (Bartonella henselae, Bartonella quintana)
Treatment
Diagnosis: typical histology
Drug Dose Comments
doxycycline 2 x 100 mg/day po Until improvement (until 2 months)
Possible interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVs
or
clarithromycin 2 x 500 mg/day po
Infections with Non-Tuberculous Mycobacteria (NTM) (M. avium complex, M. genavense, M. kansasii)
Primary prophylaxis
Only consider prophylaxis if no clinical suspicion of disseminated NTM. Prophylaxis can be withheld if cART started within four weeks
Stop: if CD4 count > 100 cells/µL over 3 months
Regimens listed are alternatives azithromycin 1 x 1200-1250 mg/week po Check for interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVsorclarithromycin
2 x 500 mg/day po
or 
rifabutin 1 x 300 mg/day po Check for interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVs 
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Treatment
Diagnosis: clinical appearance and cultures of blood, lymph nodes, bone marrow or other usually sterile specimen. For any treatment regimen, check 
interactions with ARVs, see Drug-drug Interactions between ARVs and Non-ARVs
Mycobacterium avium-intracellulare complex (MAC)
clarithromycin
+ ethambutol
Ev. + rifabutin
Ev. + levofloxacin
Ev. + amikacin
2 x 500 mg/day po
1 x 15 mg/kg/day po
1 x 300 mg/day po
1 x 500 mg/day po
1 x 10-15 mg/kg/day iv
12 months, then secondary prophylaxis
Consider rifabutin if resistance to
macrolides or ethambutol is suspected,
severe immunodeficiency (CD4 count < 
50 cells/µL), high bacterial load (> 2 L of
CFU/mL of blood), no cART
4th drug to consider for disseminated
disease
4th drug to consider for disseminated 
disease
or
azithromycin
+ ethambutol
1 x 500 mg/day po
1 x 15 mg/kg/day po
Consider additional drugs as above
Mycobacterium kansasii
rifampicin
+ isoniazid
+ ethambutol
1 x 600 mg/day po (or rifabutin
300 mg/day po)
1 x 300 mg/day po
1 x 20 mg/kg/day po
12 months after negative culture 
or
rifampicin
+ clarithromycin
+ ethambutol
1 x 600 mg/day po (or rifabutin
300 mg/day po)
2 x 500 mg po
1 x 15-20 mg/day po
12 months after negative culture 
Secondary prophylaxis / Maintenance therapy
Stop: if CD4 count > 100 cells/µL over 6 months and MAC treatment for at least 12 months
Mycobacterium avium (MAC) infection
Regimens listed are alternatives
clarithromycin
+ ethambutol
2 x 500 mg/day po
1 x 15 mg/kg/day po
or
azithromycin
+ ethambutol
1 x 500 mg/day po
1 x 15 mg/kg/day po
 Cryptosporidiosis (C. parvum, C. hominis)
Treatment
Diagnosis of AIDS-defining cryptosporidiosis can be made only in cases of severe immunodeficiency (CD4 count < 100 cells/µL) AND chronic diarrhoea (> 
4 weeks) by immunofluorescence or acid fast stain of stools or tissue.
Mainstay of therapy is the induction of ART to restore immune competence with CD4 count > 100 cells/µL. 
Additionally, measurements are symptomatic treatment, rehydration and electrolyte management.
All antiprotozoal therapies can be used additively to cART in severe cases, but are not sufficient to achieve protozoal eradication without immune restora-
tion.
Drug Dose Comments
nitazoxanide 2 x 500-1000 mg/day po 14 days
or
paromomycin 4 x 500 mg/day po 14-21 days
Cystoisosporiasis (Cystoisospora belli, formerly Isospora belli)
Treatment
Diagnosis of AIDS-defining cystoisosporiasis can be made only in cases of chronic diarrhoea (> 4 weeks) by UV fluorescence or microscopy of stools, 
duodenal aspirates or intestinal tissue biopsy.
Besides antiprotozoal treatment, additional measurements are symptomatic treatment, rehydration and electrolyte management.
Drug Dose Comments
Preferred therapy
TMP-SMX 2 x 2 double-strength tablet (ds) 
(800/160 mg)/day po
or
2 x 1 double-strength tablet (ds) 
(800/160 mg) /day po
Treat minimally 10 days, increase dura-
tion to 3-4 weeks if symptoms worsen 
or persist
Treat minimally 10 days, increase dose 
to 2 x 2 ds tablet/day, if symptoms wors-
en or persist
Alternative therapy, if TMP-SMX is not 
tolerated
pyrimethamin
+ leucovorin
or
ciprofloxacin
1 x 50-75 mg//day po
1 x 10-15 mg//day po
2 x 500 mg/day po 
10 days
7 days
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Secondary prophylaxis / Maintenance therapy
Stop: if CD4 count > 200 cells/µLfor 6 months and no signs of persistent cystoisosporiasis
Preferred therapy TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x /week po or 
1 ds tablet/day po or 
2 ds tablet 3 x/week po
Alternative therapy, if TMP-SMX is not 
tolerated
pyrimethamin
+ leucovorin
1 x 25 mg/day po 
1 x 10-15 mg/day po 
Leishmaniasis
Treatment
Diagnosis: microscopy or PCR in smears, body fluids or tissue
Drug Dose Comments
Preferred treatment liposomal amphotericin B 1 x 2-4 mg/kg/day iv for
10 consecutive days
Then secondary prophylaxis
or
liposomal amphotericin B 1 x 4 mg/kg/day iv on day 1-5,
10, 17, 24, 31 and 38
Alternative therapy lipidcomplex amphotericin B 1 x 3 mg/kg/day iv 10 days
or
amphotericin B deoxycholate 1 x 0.5-1 mg/kg/day iv
(total dose 1.5-2 g)
amphotericin B deoxycholate may not be
available in all European countries
or
pentavalent antimonium salt
(Glucantine®)
1 x 20 mg/kg/day iv or im 4 weeks
or
miltefosine 1 x 100 mg/kg/day po 4 weeks
Secondary prophylaxis / Maintenance therapy
Consider stopping: if CD4 count > 200-350 cells/µL over 3 months, no relapse for at least 6 months and negative PCR in blood or negative urinary anti-
gen
Preferred treatment liposomal amphotericin B 4 mg/kg every 2-4 weeks iv
or
lipidcomplex amphotericin B
3 mg/kg every 3 weeks iv
Alternative therapy pentavalent antimonium salts
(Glucantine®)
20 mg/kg every 4 weeks iv/im
or
miltefosine
1 x 100 mg/day po
or
pentamidine
300 mg every 3 to 4 weeks iv
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Diagnosis and Treatment of TB in HIV-positive Persons
Disease Drug Dose Comments
Susceptible Mycobacterium tuberculosis
Initial phase rifampicin     Weight based Initial phase (rifampicin+isoniazid+pyr-
izinamide+ethambutol) for 2 months, then 
Continuation phase (rifampicin+isoniazid) 
according to TB type (see below)
Possibility to omit ethambutol, if M. tubercu-
losis is known to be fully drug sensitive
+ isoniazid 
+ pyrizinamide 
+ ethambutol 
Alternative rifabutin Weight based Initial phase (rifabutin+isoniazid+ 
pyrizinamide+ethambutol) for 2 months,
then Continuation phase (rifabutin +
isoniazid) according to TB type (see below)
Possibility to omit ethambutol, if M. tubercu-
losis is known to be fully drug sensitive
+ isoniazid 
+ pyrizinamide 
+ ethambutol 
Continuation phase rifampicin/rifabutin
+ isoniazid
according to TB type
Total duration of therapy: 
1. Pulmonary, drug susceptible TB: 6 months
2. Pulmonary TB & positive culture at 8 
weeks of TB treatment: 9 months 
3. Extrapulmonary TB with CNS involvement 
or disseminated TB: 9-12 months
4. Extrapulmonary TB with bone/joint in-
volvement: 9 months
5. Extrapulmonary TB in other sites: 6-9 
months
Treatment of TB in HIV-positive persons
For standard treatment of TB in HIV-positive persons, including appropriate 
choice of ARVs, see below table and ART in TB/HIV Co-infection
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Diagnosis of Multi-drug Resistant TB (MDRTB) /  
Extended-Drug Resistant TB (XDRTB)
MDRTB/XDRTB should be suspected in case of:
• Previous TB treatment
• Contact with MDR/XDR TB index case 
• Birth, travel or work in an area endemic for MDRTB 
• History of poor adherence
• No clinical improvement on standard therapy and/or sputum smear  
positive after 2 months of TB therapy or culture positive at 3 months
• Homelessness/hostel living and in some countries recent/current  
incarceration
• In areas with very high MDRTB/XDRTB prevalence
MDRTB: Resistance to isoniazid and rifampicin.
XDRTB: Resistance to isoniazid and rifampicin and quinolones and at last 
one at the following injectable drugs: kanamycin, capreomycin or amikacin
Rapid detection
Gene Xpert or similar technology has the advantage of rapid detection  
of drug resistance. Drug susceptibility testing is important in optimising 
treatment.
Some countries/regions have neither of the above and have to use an  
empirical approach.
Treatment of resistant TB
INH-resistant TB
• RIF or RFB + EMB + PZA for 7 months
Each dose of MDR/XDR TB regimen should be given as DOT throughout 
the whole treatment. 
Treatment regimens should consist of at least four active drugs based on:
• Susceptibility testing for isoniazid, rifampicin, rifabutin, floroquinolones, 
injectable agents and other drugs if available
• Treatment history
• Local surveillance data 
• Drug not been part of regimens used in the area
More than four drugs should be started if the susceptibility pattern is
unknown or the effectiveness of one or more agents is questionable.
Drug choices 
Regimens often contain five to seven drugs
Include drugs from groups 1-5 (see below) in hierarchical order based  
on potency
1. Use any of the first-line oral agents (group 1) that are likely to be  
effective
2. Use an effective aminoglycoside or polypeptide by injection (group 2)
3. Use a fluoroquinolone (group 3)
4. Use the remaining group 4 drugs to complete a regimen of at least four 
effective drugs
5. For regimens with fewer than four effective drugs, consider adding two 
group 5 drugs 
6. Consider bedaquiline and seek expert advice therefore, 
a. when an effective treatment regimen containing four second-line 
drugs in addition to pyrazinamide cannot be designed
b. when there is documented evidence of resistance to any fluoroquino-
lone 
The regimen should be reassessed and modified if needed once drug 
sensitivity results become available.
Group 1:                                          
First-line oral agents 
• pyrazinamide (Z)
• ethambutol (E)
• rifabutin (RFB)
Group 2:
Injectable agents
• kanamycin (Km)
• amikacin (Am)
• capreomycin (CM)
• streptomycin (S) 
Group 3:
Fluoroquinolones
• levofloxacin (LFX)
• moxifloxacin (MFX)
• ofloxacin (OFX)
• gatifloxacin (G)
Group 4:
Oral bacteriostatic sec-
ond-line agents
• para-aminosalicylic acid (PAS)
• cycloserine (CS)
• terizidone (TRD)
• ethionamide (ETO)
• protionamide (PTO)
Group 5:
Agents with unclear role in 
treatment of drug resistant-TB
• clofazimine (CFZ)
• linezolid (LZD) /tedizolid (TZD)
• amoxicillin/clavulanate (Amx/CLV)
• thioacetazone (THZ)
• imipenem/cilastatin (IPM/CLN)
• high-dose isoniazid (high-dose 
H-16–20 mg/kg/day )
• clarithromycin (CLR)
• consider bedaquiline, delamanid  and 
new anti-TB agents for MDR/XDR TB
Duration of MDR/XDR treatment
8 months of intensive phase using 5 or more drugs, followed by 12 months 
of 3 drugs depending on response.
E.g . 8 months of Z, Km, OFX, PTO and CS, followed by 12 months of 
OFX, PTO and CS
Drug interactions with ART and MDR/XDR regimens
Unless RFB is being used, use normal doses but with caution as few data 
available on potential drug interactions, see ART in TB/HIV Co-infection
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Latent tuberculosis  
Indication: TST > 5 mm or positive IGRA or close contacts to persons with 
sputum smear positive tuberculosis 
Regimen Comments
isoniazid (INH) 5 mg/kg/day (max 
300 mg) po 
+
pyridoxin (Vit B6) 25 mg/day po
6-9 months
rifampicin 600 mg/day po 
or rifabutin po (dose according to 
current cART)
4 months, check interactions with 
ARVs, see Drug-drug Interactions 
between ARVs and Non-ARVs
rifampicin 600 mg/day po
or rifabutin po (dose according to 
current cART) 
+
isoniazid (INH) 5 mg/kg/day (max 
300 mg) po
+
pyridoxin (Vit B6) 25 mg/day po
3 months, check interactions with 
ARVs, see Drug-drug Interactions 
between ARVs and Non-ARVs
rifampicin 600mg 2x/week po
+
INH 900 mg 2x/week po
+
pyridoxin (Vit B6) 300mg 1x/week 
po 
3 months, check interactions with 
ARVs, see Drug-drug Interactions 
between ARVs and Non-ARVs
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